Role of Platelet-Derived Growth Factor Receptor signalling in microglia-mediated neuroinflammation by Taiwo, Moyinoluwa Temitope
  
   
 
 
 
Role of Platelet-Derived Growth Factor Receptor signalling 
in microglia-mediated neuroinflammation 
 
 
Inaugural Dissertation 
 
zur 
 
Erlangung des Doktorgrades 
Dr.nat.med. 
 
der Medizinischen Fakultät 
und 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Universität zu Köln 
 
vorgelegt von 
 
Moyinoluwa Temitope Taiwo 
aus Lagos, Nigeria 
 
 
 
Digital Express 24 GmbH & Co. KG, Köln 
 
 
2020 
 
 
 
 
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Betreuer:    Prof. Dr. Thomas Langmann 
 
Referenten:    Prof. Dr. Hamid Kashkar  
     Prof. Dr. Manolis Pasparakis   
 
 
Datum der mündlichen Prüfung: 02.10.2020       
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Printed with the support of the German Academic Exchange Service 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
DEDICATION 
To my parents, HRH Oba and Olori C.A Taiwo 
  
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The use of thesis-writing is to train the mind, or to prove that the mind has been 
trained; the former purpose is, I trust, promoted, the evidences of the latter are scanty 
and occasional” 
          Thomas Albutt 
 
 
 
 
v 
ABSTRACT 
Neuroinflammation, associated with the onset and progression of neurodegenerative 
events, is predominantly orchestrated by microglia, the resident immune cells of the 
central nervous system. Microglia-mediated neuroinflammation, thus, results from 
dysregulation of its physiological functions, which are tightly controlled by several 
signalling pathways, including growth factor signalling. Despite the involvement of 
Platelet-Derived Growth Factor Receptor (PDGFR) signalling and microglia in 
physiologic and pathologic angiogenesis, this signalling remains uncharacterised in 
microglia. Thus, the role of PDGFR signalling in microglia-mediated 
neuroinflammatory responses have been investigated using BV-2 microglial cell line. 
The expression of PDGFs and their receptors were first characterised in microglia 
using quantitative polymerase chain reaction, immunocytochemistry, and western blot. 
Microglia functions, PDGF receptor’s role and intracellular signal transduction 
pathways were investigated using recombinant human PDGF ligands. 
Resting BV-2 cells expressed Pdgfa, Pdgfb, Pdgfc, Pdgfrα and Pdgfrβ genes. In 
Lipopolysaccharide (LPS) activated cells, Pdgfb and Pdgfrβ were significantly 
upregulated and sustained at protein levels, Pdgfa and Pdgfrα were not significantly 
altered, while Pdgfc was significantly downregulated. PDGF induced an amoeboid-like 
phenotype with concomitant downregulation of the homeostatic gene, P2Y 
purinoceptor-12 (P2ry12); however, migratory and phagocytic capacities were not 
significantly affected. Also, reactive oxygen species (ROS) levels were significantly 
decreased with an upregulation of the anti-oxidant genes, glutathione reductase (Gsr) 
and superoxide dismutase 2 (Sod2), though, the main ROS generating enzymes, 
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, Nox1 and Nox2, 
were significantly upregulated. PDGF induced an inflammatory response in BV-2 cells; 
however, decreasing neurotoxicity effects on 661W photoreceptor cells cultured in 
microglia conditioned medium. Pharmacological inhibition and RNAi mediated 
silencing of Pdgfrβ gene reduced both LPS and PDGF-induced inflammatory 
responses while variable results were seen for Pdgfrα gene. Using small-molecule 
kinase inhibitors, a role for phosphatidylinositol-3-kinase/Akt (PI3K/Akt), extracellular-
signal-regulated kinase -1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK) pathways 
were defined in PDGF-induced inflammatory response in BV-2 cells.  
These results demonstrate a fundamental regulatory role of autocrine PDGFR 
signalling in microglia-mediated responses in resting and activated state. 
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ZUSAMMENFASSUNG 
Neuroinflammation, die mit dem Beginn und Fortschreiten neurodegenerativer 
Ereignisse verbunden ist, wird überwiegend von Mikrogliazellen, den lokalen 
Immunzellen des Zentralnervensystems, gesteuert. Eine durch Mikrogliazellen 
vermittelte Neuroinflammation resultiert aus einer Fehlregulation der physiologischen 
Zellfunktionen, welche durch mehrere Signalwege, einschließlich die der 
Wachstumsfaktoren, streng überwacht und gesteuert werden. Es ist bekannt, dass 
sowohl der PDGFR-Signalweg (Platelet-Derived Growth Factor Receptor) als auch die 
Mikrogliazellen bei der physiologischen und pathologischen Angiogenese eine Rolle 
spielen. Bisher ist allerding unbekannt, welche Rolle der PDGFR-Signalweg in 
Mikrogliazellen spielt. Daher wurde die Rolle des PDGFR-Signalwegs in der 
Miikroglia-vermittelten neuroinflammatorischen Reaktionen unter Verwendung der 
BV-2-Mikroglia-Zelllinie untersucht. 
Zunächst wurde die Expression von PDGFs und ihren Rezeptoren in Mikrogliazellen 
mittels quantitativer Polymerasekettenreaktion, der Immunhistochemie und dem 
Western Blot Analyseverfahren charakterisiert. Sowohl die Mikrogliazellfunktion, als 
auch die Rolle von PDGF-Rezeptoren und der intrazelluläre Signalwege wurden unter 
Verwendung rekombinanter menschlicher PDGF-Liganden untersucht. 
Ruhende BV-2-Zellen exprimierten die Gene Pdgfa, Pdgfb, Pdgfc, Pdgfrα und Pdgfrβ. 
In Lipopolysaccharid (LPS) -aktivierten Zellen waren die Gene, welche für Pdgfb und 
Pdgfrβ codieren, signifikant hochreguliert, blieben auf Proteinebene allerdings 
konstant. Expression von Pdgfa and Pdgfrα waren nicht signifikant verändert, während 
Pdgfc signifikant herunterreguliert war. PDGF Stimulation induzierte einen amöboid 
ähnlichen Mikrogliaphänotypen bei gleichzeitiger Herunterregulierung des 
homöostatischen Gens P2Y Purinoceptor-12 (P2ry12). Die Migrations- und 
Phagozytenkapazitäten wurden jedoch nicht signifikant beeinflusst. Auch die 
Konzentrationen an reaktiven Sauerstoffspezies (ROS) wurden durch eine 
Hochregulation der antioxidativem Genes Glutathionreduktase (Gsr) und Superoxid-
Dismutase 2 (Sod2) signifikant verringert, obwohl die Expression der wichtigsten 
ROS-generierenden Enzyme, Nicotinamidadenindinukleotidphosphat (NADPH) 
Oxidasen - Nox1 und Nox2 - signifikant hochreguliert waren. PDGF induzierte eine 
Entzündungsreaktion in BV-2-Zellen, verringerte jedoch die neurotoxischen Effekte in 
661W-Photorezeptorzellen, die in Mikrogliazellen-konditioniertem Medium kultiviert 
wurden. Die pharmakologische Hemmung und RNAi-vermittelte Stummschaltung des 
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Pdgfrβ-Gens reduzierte sowohl die LPS- als auch PDGF-induzierte 
Entzündungsreaktionen in Mikrogliazellen, während gleiche Versuche für das Pdgfrα-
Gen zu variablen Ergebnissen führten. Mittels der Verwendung von 
niedermolekularen Kinase-Inhibitoren konnte festgestellt werden, dass 
Phosphoinositid-3-Kinasen/AKT (PI3K/Akt), extrazelluläre signalregulierte Kinase 1/2 
(ERK1/2) und C-Jun-N-terminale Kinasen (JNK) eine Rolle in der PDGF-induzierten 
Entzündungsreaktion in BV-2-Zellen spielen. 
Diese Ergebnisse zeigen eine grundlegende regulatorische Rolle der autokrinen 
PDGFR-Signalübertragung bei Mikroglia-vermittelten Reaktionen im Ruhezustand 
und im reaktivem Zustand. 
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CHAPTER ONE: INTRODUCTION 
1.1 Role of microglia in central nervous system (CNS) vascular development 
Microglia are the only resident immune cells of the CNS parenchyma under 
homeostatic conditions (Ransohoff and Cardona 2010; Mrdjen et al. 2018). Derived 
from yolk-sac macrophages, microglial cells, function in immune regulation, 
maintenance of homeostasis, tissue development, and wound repair (Arnold and 
Betsholtz 2013).  
During embryonic development, they migrate into the CNS and retinal neuro-
epithelium before the emergence of blood vessels (Arnold and Betsholtz 2013). 
However, soon after colonising the neuro-epithelium, they start to interact with the 
growing blood vessels in the brain and retina (Cuadros et al. 1993; Kurz and Christ 
1998; Herbomel et al. 2001; Chen et al. 2002) at approximately E10.5 (Ginhoux et al. 
2010; Schulz et al. 2012) where they tend to affect each other’s development as seen 
from the ex-vivo study of Rymo et al., 2011. Since the developing CNS is devoid of an 
intrinsic vascular system, the development of blood vessels herein is entirely via 
angiogenesis (Risau 1997; Lee et al. 2009; Eilken and Adams 2010; Vallon et al. 2014) 
where new capillaries, via pro-angiogenic signals sprout from perineural vessels 
(Arnold and Betsholtz 2013). Angiogenesis, thus, involves the co-ordinated responses 
of two primary cells, endothelial cells (ECs) and mural cells [composed of vascular 
smooth muscle cells (VSMCs) and pericytes] which must undergo migration, 
proliferation, polarisation for lumen formation and basement membrane deposition 
(Rymo et al. 2011). During angiogenesis, an endothelial tip-cell (reacting to pro- and 
anti-angiogenic signals from the surrounding tissue), thus leads each sprout.  
Vascular endothelial growth factor-A (VEGFA), the primary pro-angiogenic factor, 
signals through VEGF receptor- 2 present on tip-cells promoting filopodia formation 
and extension in the direction of the VEGFA source (Rymo et al. 2011). In addition to 
VEGFA/VEGFR2 signalling, the PDGFB/PDGFRβ signalling is also critically involved 
in recruiting mural cells to newly formed vessels during which time their proliferation is 
enhanced (Hellstrom et al. 1999; Hoch and Soriano 2003). During the angiogenic 
process, PDGFB is expressed by the sprouting ECs, and it signals through PDGFRβ 
expressed specifically by mural cells which surrounds the blood vessels to provide 
stability (Lindahl et al. 1997; Annika et al. 2005; Adams and Alitalo 2007).  Thus, 
disruption of the PDGFB/PDGFRβ signalling results in the diminished capacity to 
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recruit mural cells thereby contributing to pathologic angiogenesis (Ucuzian et al. 
2010). As earlier mentioned that microglia migrate into the CNS and retinal neuro-
epithelium before the emergence of blood vessels, this positions them to guide the 
initial sprouting, migration, connection and refinement of the developing CNS and 
retina vasculature (Arnold and Betsholtz 2013). This concept of microglia’s 
involvement in CNS vascular development is however strongly supported by 
angiogenic studies following microglia depletion, or in studies of mice devoid of 
microglia (Checchin et al. 2006; Kubota et al. 2009).  
In line with microglia’s important role in retinal angiogenesis (Rathnasamy et al. 2019), 
blood vessel disruption and blood-brain/retina barrier (BBB/BRB) breakdown in 
pathological conditions such as in neurodegenerative diseases have been seen to 
correlate with microgliosis (Matsumoto et al. 2012; Barkauskas et al. 2015). 
Additionally, in the retina of patients with Age-related Macular Degeneration (AMD), 
accumulation of microglial cells were seen in the sub-retinal space especially at 
locations of retinal degeneration and choroidal neovascularization (CNV) (Combadière 
et al. 2007). Also, in the laser-induced CNV animal model, microglia have been seen 
at future CNV sites before angiogenesis commenced (Liu et al. 2013) and these cells 
expressed some pro-angiogenic factors including VEGF and PDGFB (Krause et al. 
2014; Li et al. 2017) establishing their role in the induction of pathological angiogenesis 
(Rathnasamy et al. 2019).  
1.2 Study aim and objectives  
In light of the involvement of microglia and the PDGFR system in physiologic and 
pathologic angiogenesis, this study sought to understand the direct association and 
interaction between microglia and the PDGF/PDGFR system as this remains largely 
uncharacterised. As such, the aim of this study was to investigate the role of PDGFR 
signalling in microglia-mediated neuroinflammatory responses in-vitro. To achieve this 
aim, three specific objectives were set: 
i. To characterise the microglia-specific expression of PDGF ligands and their 
receptors in resting and activated state. 
ii. To study the effect of ligand-mediated PDGFR activation on microglia functional 
properties. 
iii. To determine the role of each PDGFR in microglia inflammatory responses and 
to investigate the signalling pathways involved therein.  
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CHAPTER TWO: LITERATURE REVIEW 
2.1 Microglia 
Microglial cells were first identified and reported as ‘rod cells’ (‘Staebchenzellen’ in 
German) in 1899 and 1900 by Nissl and Robertson respectively on the basis of their 
rod-like nuclei shape describing these cells as reactive neuroglia while also noticing 
that they accumulate at the surroundings of inflammation-induced lesions in the CNS 
(Gomez-Nicola and Perry 2015; Waisman et al. 2015). These cells were later 
characterised and distinguished from all other glial cells and was called “microglia” by 
Pio del Rio-Hortega who also highlighted that these cells had the potential to acquire 
an amoeboid morphology from a ramified one during  pathological conditions 
(Kettenmann et al. 2011; Gomez-Nicola and Perry 2015). 
The glial cells are the third main cells in the CNS asides neurons and vascular cells 
and they account for more than 90% of these three population of cells (Ransohoff and 
Cardona 2010; Greter and Merad 2013). Microglia derived from two words ‘micro’ 
meaning small and ‘glia’ meaning glue, are now the third population of glial cells 
present in the CNS apart from the macroglia which is made up of astrocytes and 
oligodendrocytes (Greter and Merad 2013; ElAli and Rivest 2016). Therefore, 
microglial cells are the only cell type in the CNS parenchyma that is neither vascular 
nor neuronal, instead, they are the resident CNS inflammatory cells (Ransohoff and 
Cardona 2010).  
They are also a member of the mononuclear phagocyte series of cells (comprising of 
CNS-associated macrophages, peripheral tissue macrophages, monocyte-derived, 
and dendritic cells) (Prinz et al. 2011; Gomez Perdiguero et al. 2013) but of myeloid 
lineage (McKercher et al. 1996; Chan et al. 2007; Ransohoff and Perry 2009; Perry et 
al. 2010; Ginhoux et al. 2010). This makes microglia a special and distinct type of cells 
in that they are CNS glial cells as well as a unique type of mononuclear phagocyte.  
These cells are distributed uniformly all through the brain and spinal cord with higher 
neuronal nuclei densities, including the substantia nigra in the midbrain (Lawson et al. 
1990). Their densities also vary between humans and rodents with minute 
morphological differences in different cytoarchitectural regions (Lawson et al. 1990). 
However, depending on the region anatomically, various methods used, health or 
pathology, microglia account for somewhere between 0.5 and 16.6% of the human 
brain total cell population (Mittelbronn et al. 2001; Pelvig et al. 2008; Lyck et al. 2009; 
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Lull and Block 2010) while also varying, depending on the region, at somewhere 
between 5% in the corpus callosum and 12% in the substantia nigra in the normal 
adult mouse brain (Lawson et al. 1990). 
Morphologically, in the healthy adult mammalian CNS, microglia has a small cell soma, 
a small perinuclear cytoplasm, and a host of fine, extremely mobile, branched 
processes covered by fine protrusions (Ransohoff and Perry 2009; Boche et al. 2013; 
Patro et al. 2016; Salter and Stevens 2017). This morphological state is habitually 
termed ‘ramified’, which for a long time has been assumed to reflect a relatively 
inactive or ‘resting’ state (Boche et al. 2013). However, with time-lapse in-vivo two-
photon video microscopy, microglia processes were seen to be constantly in motion 
(highly mobile), actively surveying their immediate environment (Davalos et al. 2005; 
Nimmerjahn et al. 2005). This surveillance activity does support the theory of microglia 
being CNS first line of defense  (Kreutzberg 1996; van Rossum and Hanisch 2004).  
2.1.1 Origin, development and maintenance of microglia 
Prior to the works of Ginhoux et al. 2010 and Schulz et al. 2012, the origin of microglia, 
has been a controversial subject over years, however the general consensus now is 
that microglia stem from primitive hematopoietic progenitors (erythromyeloid 
precursors - EMP) that originate from the extra embryonic yolk sac (Fig. 2.1), a 
structure believed to be present from a previous  stage of embryogenesis (Alliot et al. 
1999; Ginhoux et al. 2010; Schulz et al. 2012; Kierdorf et al. 2013; Prinz and Priller 
2014). The yolk sac origin of microglia was confirmed in sophisticated genetic fate-
mapping experiments in mice (Ginhoux et al. 2010; Schulz et al. 2012). By either 
inducing Cre recombinase activity from the Runx locus (Ginhoux et al. 2010) or from 
the colony stimulating factor 1 (Csf1) receptor locus (Schulz et al. 2012) through 
tamoxifen injections into pregnant mice between E7.0 and E8.5 (when embryonic 
hematopoiesis is confined in the yolk sac), these authors discovered that the principal 
source of microglia were the early yolk sac cells. 
Further characterisation of these early yolk sac precursors that gave rise to the brain 
microglia showed c-kit+ lineage- progenitor cells within the yolk sac with the potential 
to differentiate into CX3CR1+ microglia both in-vitro and in-vivo (Kierdorf et al. 2013). 
These cells were also shown to give rise to Ter119+ erythrocytes representing a 
common EMP in the yolk sac. Subsequently, there is the disappearance of these 
uncommitted EMPs and immature F4/80+CX3CR1- and F4/80+CX3CR1+ 
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macrophages develop, populating the developing brain surface at around E9.0 
(Kierdorf et al. 2013). Starting at E8.5, these EMPs journey through the bloodstream 
to the developing CNS, continuing until the BBB is formed (Alliot et al. 1999; Ginhoux 
et al. 2010; Schulz et al. 2012; Gomez Perdiguero et al. 2015). These early cells 
differentiate under the control of transcription factors Pu.1 and interferon regulatory 
factor-8 (Irf8), where they predominate the developing brain giving rise to embryonic 
microglia at E9.0 - 9.5 (Ginhoux et al. 2010; Schulz et al. 2012; Kierdorf et al. 2013). 
Another transcription factor, Runt-related transcription factor 1 (RUNX1) is important 
in regulating microglia during embryonic development (Ginhoux et al. 2010) (Fig 2.1).  
An interesting finding was that myeloid precursors from the blood did not substantially 
contribute to the pool of adult microglial cell after birth, substantiating that the wide 
majority of adult microglia originate from the yolk sac (Prinz and Priller 2014). After 
predominating the brain, they are said to be present as a closed, long-lived population 
under homeostatic conditions segregated from other bone marrow-derived precursors 
or circulating monocytes by the BBB (Ajami et al. 2007).  
 
Figure 2.1  Microglia development. 
The respective symbols (highlighted on the right) as expressed by each population of 
cell. Microglia derive from immature, uncommitted KIT+ EMPs originating from the 
extra embryonic yolk sac at around E7.5 - E8.0 (Kierdorf et al. 2013). A1 cells: 
upregulation of the CD45 antigen without expression of myeloid markers, A2 cells: 
expression of myeloid cell markers - CX3C chemokine receptor 1 (CX3CR1), F4/80, 
and CSF1 receptor (CSF1R). Migrating A2 cells colonise the brain mesenchyme. 
Image modified and adapted from Prinz and Priller, 2014. 
Three main developmental stages of microglia have been identified in mice from yolk 
sac to adult. Using RNA sequencing and epigenomic analysis to study the 
transcriptional repertoire dynamics, the stages identified were: early stage (less than 
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E14), pre-microglia stage (E14 to a few weeks postnatal - P9), and adult microglia 
stage (more than a few weeks) (Matcovitch-Natan et al. 2016). Similarly, in humans, 
the same developmental pattern seems to exist where microglia-like cells with diverse 
morphologies can already be spotted in human fetuses as early as 13 weeks of 
estimated gestational age (Hutchins et al. 1990). At this period, the cells are denoted 
‘fetal macrophages’ (Lull and Block 2010). These cells have been seen to colonise the 
spinal cord sometime around 9 weeks where the main microglia entry and distribution 
begins at around 16 weeks while the distribution of ramified microglia within the 
intermediate zone take up to 22 weeks (Rezaie and Male 1999, 2002; Rezaie 2003). 
Actually, it is at 35 weeks (close to term), that well-differentiated microglia populations 
(with ramified morphology) can be seen in the developing human brain (Esiri et al. 
1991; Rezaie and Male 1999; Rezaie et al. 2004; Verney et al. 2010). 
Following the establishment of microglia populations, they are said to be maintained 
within the CNS solely by self-renewal (local proliferation) without the dependence or 
contribution of blood-monocyte (Ajami et al. 2007; Ginhoux et al. 2010) (Fig 2.2). 
Thereafter, Schulz et al., 2012, showed that microglia together with other tissue 
macrophages did not require the transcription factor, Myb, for development finally 
establishing that the maintenance of microglia is not reliant on hematopoietic stem 
cells but are continually self-renewed. In the healthy adult mouse brain, individual 
microglial cells usually live for long periods with a turn-over rate of 0.05% cells per 
hour (Lawson et al. 1992). However, human microglia averagely live for 4.2 years with 
a yearly median turn-over rate of 28% meaning that the majority of the microglial cell 
population is renewed many times during lifetime (Réu et al. 2017).  
Thus, microglia maintenance is dependent on CSF1R activation which is also vital for 
its development as well as for macrophage development (Ginhoux et al. 2010; Erblich 
et al. 2011). CSF-1 and IL-34, the endogenous ligands for CSFR1, produced by 
neurons within the CNS during development (Greter et al. 2012; Wang et al. 2012) 
must therefore be released constantly as the pharmacological blockade of CSF1R has 
been shown to rapidly deplete microglial cells (Elmore et al. 2014). 
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Figure 2.2  Microglia maintenance and renewal. 
(a) Microglia is autonomously maintained via TGFβ1, signalling through TGFR1 or 2. 
TGFβ1 controls the transcriptional regulation of genes that encodes the TFs: EGR1, 
MEF2A, SALL1, and MAFB via PU.1 and or SMAD3 TFs. Microglia are identified by 
distinct surface receptors such as SIGLECH, ENTPD1, FCRLS, TMEM119, and 
P2RY12. (b) Microglia self-renew through local clonal expansion (Tay et al. 2017). 
However, peripherally derived macrophages recruited to the CNS can also replace 
lost microglia under certain conditions. TGFβ1 (Transforming growth factor-β1), 
TGFR1/2 (TGF receptor 1/2), EGR1 (early growth response protein -1), MEF2A 
(myocyte-specific enhancer factor 2A), SALL1 (Sal-like protein-1), SMAD3 (mothers 
against decapentaplegic homologue 3), SIGLECH (sialic acid binding Ig-like lectin H, 
isoform CRA_a), ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1), 
FCRLS (Fc receptor-like S, scavenger receptor), TMEM119 (transmembrane protein-
119), P2RY12 (P2Y purinoceptor-12) (Butovsky and Weiner 2018). 
2.1.2 Physiological functions of microglia 
Microglia participate in a number of physiological roles, but in general, their 
transcriptomes permit them to carry out three important functions: (i) survey their 
microenvironment, (ii) perform physiological housekeeping, and (iii) host defense. 
These physiological functions are essential in the different developmental stages from 
embryonic stage to adulthood to aging. Thus, any functional irregularity causes an 
imbalance initiating the onset of neurodegeneration (Hickman et al. 2018). 
Microglia surveillance and monitoring/Sensing: 
As earlier mentioned, with in-vivo two-photon video microscopy in mice specifically 
expressing green fluorescent protein (GFP) in microglia, it was seen that microglial 
cells have highly dynamic processes, that forms a network which spans the CNS and 
is constantly and actively surveying the microenvironment (Lawson et al. 1990; 
Davalos et al. 2005; Nimmerjahn et al. 2005). On estimate, resident microglia scan 
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and survey the whole brain region within a space of few hours and rapidly migrate 
towards the injurious site or external danger cues (Davalos et al. 2005; Nimmerjahn 
et al. 2005; Hickman et al. 2018) such as pathogens that invade the brain, or internal 
danger cues from locally impaired or dying cells (Bessis et al. 2007; Hanisch and 
Kettenmann 2007). These processes are also in constant contact with axons, neurons 
and dendritic spines (Salter and Stevens 2017). Approximately about 100 gene 
products including AXL, P2yr12, and MER are used by microglia processes to sense 
changes within their immediate environment (their sensome) (Haynes et al. 2006; 
Hickman et al. 2013; Fourgeaud et al. 2016) (Fig. 2.3). Sensome mRNAs are 
expressed consistently by microglia in several brain regions, an indication that all 
microglia have the capability to perform their sensing function. Hence, sensing is 
necessary for microglia to carry out their function of housekeeping and host defense 
(Hickman et al. 2018). 
 
Figure 2.3  Ontology of the sensome. 
Three-dimensional image of a mouse microglia with an overview of the sensome 
gene ontology (Hickman et al. 2018). 
Housekeeping: 
Microglia are involved in a number of physiological housekeeping functions including; 
synaptic monitoring and remodeling (Zhan et al. 2014; Lui et al. 2016; Vasek et al. 
2016); migration to sites of neuronal death in order to phagocytose dying or dead cells 
or other forms of debris, including foreign matter and plaques (Fuhrmann et al. 2010; 
Lull and Block 2010; Krasemann et al. 2017) and myelin homeostasis maintenance 
(Healy et al. 2016). Microglial cells are also known to engage with astrocytes, an 
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essential function that is necessary: for homeostasis maintenance, in inflammation, 
and perhaps neurodegeneration (Liddelow et al. 2017). Several genes are involved in 
these housekeeping functions, amongst them are phagocytosis related genes 
(scavenger receptors and Trem2), genes encoded by chemokine and chemoattractant 
receptors, and the ones involved in synaptic pruning and remodeling (C1q and Cx3cr1) 
(Hickman et al. 2013). Thus, any anomaly with these housekeeping functions can 
result to neurodegeneration (Krasemann et al. 2017). 
Host defense: 
Microglia regulate host defense against pathogens, harmful self-proteins like 
aggregated α-synuclein, amyloid beta (Aβ), prions, mutant or oxidised superoxide 
dismutase (SOD), mutant huntingtin, as well as primary or metastatic CNS tumors. 
Thus, to carry out host defense function, microglia express antimicrobial peptides, 
viral, Toll-like, and Fc receptors (Hickman et al. 2013). In turn, a neuro-inflammatory 
response is initiated by microglia in response to these stimuli and in a similar vein to 
peripheral inflammation, this response involves production of cytokines like IL-1, TNF 
(El Khoury et al. 2003; Hickman et al. 2008), and chemokines like Ccl2 (El Khoury et 
al. 2007), to attract additional cells inducing them to get rid of harmful substances and 
maintain brain homeostasis (Hickman et al. 2018). For instance, monocytes are 
recruited to the brain by microglia in a Ccl2-dependent manner where they play 
essential roles in neuro-inflammatory responses, however, they are not part of the 
resident microglial pool (Ajami et al. 2011).  
Thus, when there is a change in microglia homeostasis, tending towards disease-
associated phenotype, expression levels of these chemokines including Ccl2 are at 
their highest. Unlike peripheral inflammation, neuroinflammation can be microglia 
restricted without attracting other circulating leukocytes. However, unresolved 
neuroinflammation subsequently induces neurotoxicity, which can lead to 
neurodegeneration (Hickman et al. 2018). 
Other physiological functions of microglia have been extensively reviewed in Boche 
et al. 2013; Nayak et al. 2014 and Butovsky and Weiner 2018. 
2.1.3 Microglia activation in neuroinflammation and neurodegeneration 
Microglial cells are dynamic in nature, constantly responding either slightly or greatly 
to various signals. In maintaining CNS homeostasis, these cells notably express a 
category of receptors called the pathogen recognition receptors (PRRs). Examples of 
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PRRs include; Toll-like receptors (TLRs), Scavenger receptors (SRs), C-type lectin 
receptors (CLRs), Nucleotide-binding Oligomerization Domain (NOD)-like receptors 
(NLRs), RIG-I-like receptors (RLRs), and macrophage antigen complex 1 receptor 
(MAC1R, also called complement receptor 3, CR3) functioning as both a PRR and an 
adhesion molecule (Block et al. 2007; Rubartelli and Lotze 2007; Colton 2009; Brown 
and Neher 2010; Figuera-Losada et al. 2014). PRRs are able to recognise molecules 
released by injured or dying cells known as pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs)  capable of activating 
microglia (Rubartelli and Lotze 2007; Colton 2009; Varnum and Ikezu 2012).  
Further, microglia has very minimal activation threshold, with activation being very 
rapid, within a few tens of minutes (Davalos et al. 2005). Thus, their capability to swiftly 
react to a variety of noxious stimuli and or other potential threats has been referred to 
as ‘‘microglial activation’’ (Hanisch 2013a). Microglia activation can be induced by 
PAMPs such as; bacterial, viral, fungal, and parasitic molecules like O-linked mannan, 
α- and β-glucan, flagellin, viral RNA and DNA, chitin, and microbial cell wall 
components. DAMPs capable of inducing microglial activation also include molecules 
that are not usually present in healthy CNS, such as DNA and RNA released by 
necrotic cells, blood coagulation factors, antigen-antibody complexes, 
phosphatidylserine externalised on apoptotic cells, mis-folded proteins or aggregates, 
and opsonizing complement (Block et al. 2007; Hanisch 2013b).  
Microglia activation can also be triggered in-vivo by an underlying pathological 
condition or both in-vivo and in-vitro by stimulating with cytokines, and other chemical 
agents (Figuera-Losada et al. 2014) (Fig. 2.4). However, the common method of 
inducing microglia activation has been with lipopolysaccharide (LPS) (Figuera-Losada 
et al. 2014) (Fig. 2.4) which has also been used in this study to understand the 
expression of PDGFRs and their ligands during microglia activation. LPS is a major 
component of almost all gram-negative bacteria cell wall structure and a well 
characterised endotoxin which is made of a polysaccharide chain (varying from one 
gram-negative bacteria to the other) and lipid A (Alexander and Rietschel 2001). LPS 
recognises and binds TLR4 expressed on microglial cells (Alexander and Rietschel 
2001), this association activates the formation of a myddosome, a macromolecular 
complex, consisting of myeloid differentiation primary response gene 88 (MyD88) and 
TIR domain-containing adaptor protein (TIRAP) and several members of the 
interleukin-1 receptor-associated kinase 1 (IRAK) family (Rosadini and Kagan 2017). 
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Subsequently, this myddosome complex, promotes the activation of downstream 
kinases including IkB (inhibitor of kB) and mitogen activated protein kinase (MAPK) 
which subsequently activates several transcription factors including NF-kB (Nuclear 
Factor kappa-light-chain-enhancer of activated B cells), AP-1 (Activator protein 1), and 
the interferon regulator factor (IRF) families. These transcription factors in turn 
regulate the expression of several genes including those involved in inflammation 
(Takeuchi and Akira 2010; Rosadini and Kagan 2017). 
In general, the extent of  microglia activation is dependent on a number of factors like; 
the nature of insult (or stimuli), duration of the stimuli, factors present within the 
immediate environment (Stout 2010; Luo and Chen 2012) and microglia “primed” 
(sensitised) state which renders it more susceptible to a second inflammatory stimulus, 
thus magnifying the inflammatory response (Perry and Holmes 2014).  
A hallmark of microglia responsiveness is therefore the ability of the cells to change 
their morphology, with or without proliferation (Salter and Stevens 2017). While 
microglia morphological changes, cell proliferation, migration towards the site of injury 
or towards dying or damaged cells (to phagocytose) and the expression and or 
secretion of pro- and anti-inflammatory cytokines have been used to describe 
microglia activation states (Kraft and Harry 2011; Bazan 2012; Perry and Holmes 
2014; Patro et al. 2016), Salter and Stevens, 2017, opined that these changes seen 
in morphology are only an indication that microglia have detected a homeostatic 
change; and that they do not define a specific response state neither do they define 
an activity during any given CNS disease. 
During activation, not only do these cells release neurotrophic factors for 
neuroprotection, they also secrete pro-inflammatory mediators and neurotoxic factors. 
Secreted neurotrophic factors include brain derived neurotrophic factor (BDNF), nerve 
growth factor (NGF), glial cell-derived neurotrophic factor (GDNF), and insulin-like 
growth factor-1 (IGF-1) (Kim and de Vellis 2005; Lu et al. 2005; Block et al. 2007; 
Thored et al. 2009). Pro-inflammatory mediators include; pro-inflammatory enzymes 
(e.g., COX-2, iNOS, glutaminase), cytokines (IL-18, IL-1β, IL-6, TNFα etc), 
chemokines (CCL2, CCL3, CCL4, CCL5, CXCL10 and/or CCL12) while neurotoxic 
factors include reactive oxygen [superoxide (O2-)] and nitrogen [e.g., nitric oxide (NO), 
peroxynitrite (ONOO-)] species (Olson and Miller 2004; Akundi et al. 2005; Block et al. 
2007; Semple et al. 2010; Bazan 2012; Patro et al. 2016; Takahashi et al. 2016) (Fig. 
2.4). Other molecular mediators are also released including interferon (IFN) inducible 
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protein (IP-10) which promotes an inflammatory state (Frank-Cannon et al. 2009), 
excitatory neurotransmitters (glutamate), and complement factors (Akundi et al. 2005; 
Figuera-Losada et al. 2014; Patro et al. 2016).  
In addition to the above, their pattern of receptor expression is also altered as a result 
of cytoskeletal rearrangements (Norden et al. 2015), and their antigen presenting 
capacity is also increased upon activation, resulting from up-regulation of the major 
histocompatibility complex-II (MHC-II) antigen (Kreutzberg 1996; Carson 2006; 
Kettenmann et al. 2011; Gertig and Hanisch 2014). For instance, increase in MHC 
antigen allows microglia act as antigen-presenting cells to T-cells that will invade the 
brain during active infections (Aloisi 2001; Bazan 2012). The lipid mediator cascade is 
also activated, precipitating arachidonic acid (AA) release. Subsequently, the 
enzymes, lipoxygenases (5-LO and 15-LO) and cyclooxygenases (Cox-1 and Cox-2) 
readily oxygenate AA forming a sequence of pro-inflammatory eicosanoids [e.g., 
leukotrienes (LT), prostaglandins (PG), prostanoids, and others] (Akundi et al. 2005; 
Wang et al. 2005; Bazan 2012). Also, matrix metalloproteinases (MMPs) are activated 
resulting in increased BBB permeability, thus, allowing local infiltration of neutrophils 
and other leukocytes, which in-turn secrete more pro-inflammatory mediators, 
activating microglia further and  aggravating the inflammatory response (Bazan 2012). 
MMP-2 and MMP-9 seem to be the predominant culprits of this process (Agrawal et 
al. 2006; Webster and Crowe 2006).  
All these afore-mentioned responses to microglia activation are what goes on during 
acute inflammation (Bazan 2012) which in normal physiological state, is transient and 
somewhat short-lived, effective in getting rid of a host of CNS potential harmful 
substances. On elimination of the trigger or insult, the inflammation is resolved 
followed by a return to homeostasis (Bazan 2012) (Fig. 2.4). However, the 
dysregulation or microglia over-activation and the subsequent inflammation that 
persist when unresolved have neurotoxic effects that causes neurons and glial cells 
to decompose and die (Gao and Hong 2008; Frank-Cannon et al. 2009; Lull and Block 
2010; Bazan 2012; London et al. 2013) (Fig. 2.4). Thus, when activated microglia 
accumulate as a response to neuronal damage or from direct over-activity, this 
process is termed microgliosis (Block et al. 2007). In the end, neuroinflammation 
becomes a secondary pathological process associated with neurodegenerative 
diseases (Kim and de Vellis 2005; Frank-Cannon et al. 2009; Ransohoff and Perry 
2009; Glass et al. 2010; Gao and Hong 2008) (Fig. 2.4). 
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Figure 2.4  Microglia activation in neuroinflammation and neurodegeneration. 
Image modified and adapted from Bazan, 2012. See text for details. 
Activated microglia have been identified by numerous methods while their presence 
has also been established in a number of neurodegenerative diseases such as 
Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease (PD), Alzheimer’s disease 
(AD), Multiple Sclerosis (MS) (Gao and Hong 2008; Frank-Cannon et al. 2009; 
Sugama et al. 2009; Bazan 2012; Heppner et al. 2015; Chen et al. 2016), HIV- 
associated neurocognitive disorder (HAND) (Chen et al. 2017), stroke (Morioka et al. 
1993), Huntington disease (Möller 2010), and retinal degenerative diseases like AMD 
(Penfold et al. 2001; Langmann 2007; Xu et al. 2009; Bazan 2012). 
2.1.3.1 Microglia in Neovascular AMD 
Neovascular AMD (nAMD) (referred to as ‘exudative’ or ‘wet’ AMD) is an advanced 
stage of AMD accounting for about 15% of all AMD cases, but responsible for nearly 
90% of vision loss due to AMD cases (Chopdar et al. 2003; Noël et al. 2007).  
Neovascular AMD is characterised by pathologic CNV, the in-growth of neovessels 
from the choroid breaking through the Bruch’s membrane into the sub-RPE (retinal 
pigment epithelium) and or the sub-retinal space, leading to exudation, hemorrhage, 
pigment epithelial detachment, retinal edema, and fibrous scarring (Ambati et al. 2003; 
Grossniklaus and Green 2004; Lim et al. 2012) eventually leading to rapid and 
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permanent central vision loss (Bhutto and Lutty 2012; Yang et al. 2016). CNV is a 
complex process involving both angiogenesis and inflammation (Campa et al. 2010). 
While VEGF is the most important contributor to the angiogenesis in CNV (Bhutto and 
Lutty 2012), the role of PDGF also cannot be downplayed as angiogenesis involves 
the coordinated activity of both growth factors (Kudelka et al. 2013). The study by 
Benjamin et al., 1998, provided one of the first leads as to the important role VEGF 
and PDGF play in nAMD during post-natal retina remodelling examination. Since then, 
a number of pre-clinical studies have demonstrated the involvement of PDGFR 
signalling in nAMD. Jo et al., 2006, showed that the combination of anti-VEGF aptamer 
and APB5, a PDGFRβ blocking antibody showed lesser NV lesions in comparison to 
each of the monotherapies in laser-induced CNV mouse model. Similarly, using the 
same mouse model, Strittmatter et al., 2016, reported the formation of PDGFRβ+ 
scaffold before new vessels infiltrated this scaffold which formed the CNV lesions, 
while also observing that this scaffold limited the degree of neovascularization. Now, 
using both genetic and therapeutic approaches, authors showed that the targeting of 
proliferating PDGFRβ+ cells using both methods resulted in the potent inhibition of 
pericyte-like scaffold formation, with a resultant decrease in CNV. 
Accordingly, PDGF has been shown to be contribute to the fibrosis part of nAMD 
pathology (Kudelka et al. 2013). However, anti-VEGF mono therapies are still being 
used to manage patients presenting with nAMD. These therapies are not curative but 
only effective in preventing severe vision loss (Scott and Bressler 2013).  
While the vascular component that drives angiogenesis in CNV is involved in the 
development of nAMD, the extra-vascular component that drives the inflammatory 
process has also been implicated and has been fully elucidated, though, nAMD is said 
not be a classical inflammatory disorder (Cousins et al. 2004; Spaide 2006; Ding et al. 
2009). The vascular component is composed of circulating endothelial progenitor 
cells, endothelial cells, and pericytes while the invading extra-vascular cells are 
composed of inflammatory cells like lymphocytes, foreign body giant cells, 
macrophages, granulocytes, RPE cells, myofibroblasts, fibrocytes, and glial cells 
(Killingsworth 1995; Grossniklaus et al. 2002; Tsutsumi-Miyahara et al. 2004; 
Espinosa-Heidmann et al. 2005). Several histopathological studies have linked an  
increased presence of inflammatory cells to CNV regions (Penfold et al. 2001; McLeod 
et al. 2016).  
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Microglia which are the third population of glial cells are also the resident immune cells 
in the retina (Langmann 2007; Karlstetter et al. 2015). They find their way into the 
retina during embryological development (Ding et al. 2009). In the healthy adult retina, 
they reside within the plexiform layers, with their extremely branched morphology and 
small cell bodies where they are also involved in scanning the retinal environment with 
their branches (Karlstetter et al. 2015) (Fig. 2.5). They become activated by retinal 
injury and degeneration as in nAMD (Ding et al. 2009). These reactive microglia 
multiply, migrate to the injurious site, phagocytose debris, and release pro-
inflammatory chemokines, cytokines and neurotoxins (Langmann 2007) (Fig. 2.5).  
With respect to nAMD, microglia seen at the sub-retinal space has been shown to 
probably impact on CNV vascular density (Rathnasamy et al. 2019). Also, in the laser-
induced CNV animal model, the most recognised nAMD model  (Lambert et al. 2013), 
microglia were seen at future CNV sites before angiogenesis commenced (Liu et al. 
2013) and expressed a number of pro-angiogenic factors including VEGF, fibroblast 
growth factor 1 and 2 (FGF-1 and 2), PDGFB, and TGFβ-1 (Krause et al. 2014; Li et 
al. 2017) (Fig. 2.5) establishing their role in the induction of pathological angiogenesis 
(Rathnasamy et al. 2019). Besides, the expression of Il-6, ICAM-1 and Ccl2 were 
reduced upon treatment with an anti-inflammatory carotenoid, astaxanthin, which also 
subsequently reduced CNV volume (Izumi-Nagai et al. 2008). While the migration of 
microglial cells to the laser induced-damage site is not fully understood, Huang et al., 
2013, proposed that this might be through VEGF receptor activation, as its blockade 
was shown to inhibit microglia and macrophage infiltration while Rathnasamy et al., 
2019, opined that it might be through purinergic receptors expressed by the cells. 
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Figure 2.5  Retina microglia activity. 
Image modified and adapted from Akhtar-Schäfer et al. 2018. See text for details. 
Furthermore, in the retina of patients with AMD, accumulation of microglial cells were 
seen in the sub-retinal space especially at locations of retinal degeneration and CNV 
(Combadière et al. 2007). Additionally, human eyes affected with nAMD had increased 
levels of the chemo-attractants, Cxcl10 and Ccl11, that have the capacity to recruit 
immune cells (Mo et al. 2010). 
2.2 The Platelet-Derived Growth Factor (PDGF) ligands 
The PDGFs are amongst a family of peptide growth factors (that includes the VEGFs) 
that are related in structure and function (Fredriksson et al. 2004) and are highly 
conserved throughout evolution (Andrae et al. 2008). The PDGFs are made up of 
four polypeptide chains of A, B, C and D, encoded by separate genes and regulated 
independently (Hoch and Soriano 2003; Fredriksson et al. 2004; Raica and Cimpean 
2010; Chen et al. 2013; Demoulin and Essaghir 2014; Borkham-Kamphorst and 
Weiskirchen 2016; Papadopoulos and Lennartsson 2018). However, structural 
differences, as well as differences in proteolytic processing, separate the ligands into 
two sub-families (Hoch and Soriano 2003). PDGF-A and PDGF-B, referred to as the 
classical PDGFs were discovered in the 1970s (Betsholtz et al. 1986; Heldin et al. 
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1986) while PDGF-C and PDGF-D in 2000 and 2001 respectively (Li et al. 2000; 
Bergsten et al. 2001; Larochelle et al. 2001)(Fig. 2.6). 
 
Figure 2.6  The mammalian PDGFs. 
The classical PDGFs, PDGF-A and -B, have basic retention motifs which differ from 
the later discovered PDGFs, PDGF-C and -D with CUB domains. Image modified and 
adapted from Andrae et al. 2008. 
The four polypeptide chains form either homo- or hetero-dimers, linked together by 
disulphide bonds. Five dimeric isoforms have been characterised to date where 
PDGF-A and -B form both homodimers and heterodimer (PDGF-AA, PDGF-AB, 
PDGF-BB), while PDGF-C and -D form only homodimers (PDGF-CC and PDGF-DD) 
(Heldin and Westermark 1999; Heldin et al. 2002; Fredriksson et al. 2004; Kazlauskas 
2017). As a result, PDGF-AA or PDGF-BB can be produced by a cell if either of these 
two genes is primarily transcribed. However, if both genes are simultaneously 
transcribed, a combination of PDGF-AA, PDGF-BB and PDGF-AB will be formed. 
PDGF-C has not been reported to form a heterodimer with PDGF-A or PDGF-B (Li et 
al. 2000), a laudable reason might be that the PDGFC’s core domain is not relatively 
similar to that of PDGF-A and -B (Betsholtz et al. 2001).  On the other hand, PDGF-C 
and PDGF-D are closely related in structure but also a heterodimer of both isoforms 
is yet to be reported (Betsholtz et al. 2001). 
The PDGFs are known to be extremely stable. Protein denaturation by heat starts at 
42°C while heating up to 65°C completely inactivates many restriction enzymes 
(Kazlauskas 2017). However, the biological activity of PDGF-AB was unaffected, even 
at 100°C (Antoniades et al. 1979). The intra- and inter-disulphide bonds of the PDGFs 
which are necessary for their biological activity is said to be partly responsible for this 
extraordinary stability. Thus, in order of resistance to heat, PDGF-AB exhibits the 
highest resistance to high temperature, next to PDGFA and PDGFB, with more 
stability than PDGF-C and PDGF-D (Kazlauskas 2017). The PDGFs are functionally 
relevant at physiological temperature (i.e. 37°C); therefore, their extremely stable 
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nature remains incompletely understood (Kazlauskas 2017). In line with PDGFRs 
being able to bind both PDGFs and VEGFA (Ball et al. 2007; Pennock and Kazlauskas 
2012), Pennock and Kazlauskas, 2012, speculates that their extreme stability might 
be a reflection of their clear-cut structure, which therefore allows PDGFRs to 
differentiate between its ligand (that binds and activates) and VEGF, which merely 
binds but results neither in PDGF receptor dimerization nor efficient activation.  
2.2.1 Structure of the genes that encode the PDGFs 
The genomic structures of the PDGF genes are illustrated in figure 2.7. The four PDGF 
genes are similarly organised, especially the exons that code for the growth factor 
domain (GFD) which are involved in dimerization, receptor binding and activation 
(Fredriksson et al. 2004; Borkham-Kamphorst and Weiskirchen 2016) (Fig. 2.7). The 
PDGF genes (A to D) are located on chromosomes 7, 22, 4 and 11 in humans, and 
chromosomes 5, 15, 3 and 9 in mice, respectively (Dalla-Favera et al. 1982; Swan et 
al. 1982; Betsholtz et al. 1986; Uutela et al. 2001; Kazlauskas 2017).  
PDGF-A is synthesised as polypeptides of 196 and 211 amino acid residues owing to 
differential splicing of the transcript (Fig. 2.7) while PDGFB chain is 241 amino acids 
and PDGFC, and PDGFD chains are 345 and 370 amino acid residues in length 
respectively (Fredriksson et al. 2004). PDGF-A and -B are closely related structurally. 
There are seven exons in both Pdgfa and Pdgfb genes while exon one codes for the 
hydrophobic signal sequence, exons two and three code for the precursor sequences 
N-terminal of the GFD which all (exons one, two and three) undergo intracellular 
processing proteolytically in the trans-Golgi network prior to secretion (Fredriksson et 
al. 2004). Exons four and five, on the other hand, codes for the GFD, and exon six 
codes for the carboxyl-terminal (C-terminal) sequences which are processed 
proteolytically when the proteins mature and are released from the extracellular matrix 
(Fredriksson et al. 2004). Two different splice isoforms of the A-chain is expressed 
with or without the exon six-encoded sequence. Exon 7 in both of these genes, is 
primarily non-coding (Li and Eriksson 2003; Fredriksson et al. 2004). 
Human Pdgfc and Pdgfd genes are also structurally similar (Fredriksson et al. 2004) 
with approximately 50% amino acid sequence identity with each other in the 
PDGF/VEGF domain (GFD) while PDGFD shows 20-23% genomic sequence identity 
(with respect to exon numbers and sizes) with the classical PDGFs (PDGFA and 
PDGFB) and VEGFs in the core domains (GFD) (Bergsten et al. 2001; Fredriksson et 
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al. 2004) (Fig. 2.7). PDGFC is made up of six coding exons that codes for a 345 amino 
acid protein, while an extra exon is present in Pdgfd gene making it seven exons. In 
both genes, exon 1 codes for the signal peptide, while exons 2 and 3 codes for the 
110 amino acid CUB domain (Fredriksson et al. 2004; Lei and Kazlauskas 2008). Exon 
4 in the Pdgfc gene codes for the hinge region (of 70 amino acids) between the two 
structural domains in the growth factor while two exons, exons 4 and 5, codes for the 
equivalent region in Pdgfd gene (Li and Eriksson 2003; Fredriksson et al. 2004; Lei 
and Kazlauskas 2008). Thus, exons 5 and 6 codes for the 115 amino acid GFD in the 
Pdgfc gene, while exons 6 and 7 codes for the equivalent region in Pdgfd gene (Li and 
Eriksson 2003; Fredriksson et al. 2004; Lei and Kazlauskas 2008). In PDGFC, no 
alternatively spliced transcript has been identified, however, in PDGFD, an 
alternatively spliced mRNA that encodes the CUB domain and partly the GFD has 
been identified in mouse only (Zhuo et al. 2003). 
 
Figure 2.7  Structure of the genes that encode the PDGFs. 
The open boxes represent the exons with the base-pair length marked inside. The 
exons that encode the VEGF/PDGF domains are green while those that encode the 
CUB domains are in purple. The solid lines represent the introns with their respective 
lengths written on the top. The drawings of the introns and exons are not to scale. Also 
indicated are the start (ATG), and stop codons (STOP) together with the polypeptide 
length (amino acid residues written on top of the stop marks). Additionally, two stop 
codons are indicated for PDGFA due to alternative splicing while the arrows in PDGF-
C and PDGF-D indicate the recognised proteolytic cleavage sites. Image modified and 
adapted from Li and Eriksson, 2003. 
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As earlier mentioned, all four genes are structurally similar; however, there exist some 
differences.  
Firstly, PDGF-A and -B have short N-terminal extensions while both PDGF-C and 
PDGF-D, as part of their N-terminal extensions carry a distinct protein domain, the 
auto-inhibitory CUB domain (Complement subcomponents C1r/C1s, Urchin EGF-like 
protein and Bone morphogenic protein 1) (Li and Eriksson 2003; Fredriksson et al. 
2004; Andrae et al. 2008; Lei and Kazlauskas 2008). 
Secondly, in contrast to PDGF-A and PDGF-B, the CUB domains of PDGF-C and 
PDGF-D do not undergo intracellular proteolytic processing before secretion, but are 
maintained on them and secreted as latent factors (Betsholtz et al. 2001; Andrae et 
al. 2008) requiring extracellular proteolysis by proteases such as urokinase 
plasminogen activator (uPA), tissue plasminogen, matriptase or plasmin before 
receptor binding and activation can take place (Li et al. 2000; Fredriksson et al. 2004; 
Lei et al. 2008; Riehle et al. 2014). CUB domains are most commonly found in 
membrane-associated and extracellular proteins and are developmentally controlled. 
They are known to modulate extracellular binding in addition to mediating protein-
carbohydrate and protein-protein interactions (Bork and Beckmann 1993; Lei and 
Kazlauskas 2008). However, with PDGF-C and D, these domains tend to prevent 
activation of PDGFRs while with the VEGF family, the domains facilitate ligand and 
receptor interaction (Lei and Kazlauskas 2008). 
Thirdly, in the C-termini, the classical PDGFs have the basic sequences necessary for 
extracellular matrix binding while both PDGF-C and PDGF-D are devoid of these 
amino acid sequence extensions (Fredriksson et al. 2004) instead they have a C-
terminal PDGF/VEGF domain, that is separated by a hinge region, a region less 
conserved structurally in the range of 80 - 100 amino acid residues in length (Li and 
Eriksson 2003; Rönnstrand 2010). 
Lastly, the intron sizes between the classical and the later discovered PDGFs differ 
remarkably. While the genes that code for the classical PDGFs are approximately 
20 kb of genomic DNA, those that code for the later discovered PDGFS are 
approximately 200 kb of genomic DNA (Li and Eriksson 2003; Fredriksson et al. 2004). 
2.2.2 Expression of PDGFs in cells and tissues 
A variety of diverse cell population is known to express the PDGFs physiologically, 
where they locally act to mediate different cellular responses (Heldin and Westermark 
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1999; Andrae et al. 2008). In-vivo, expression levels are spatiotemporally regulated 
and show plasticity during developmental stages as well as in specific physiological 
hypertrophic responses (Andrae et al. 2008). Expression of PDGF in cultured cells is 
also known to be dynamic and respond to various stimuli, including thrombin (Daniel 
et al. 1986; Harlan et al. 1986), hypoxia (Kourembanas et al. 1997), cytokines, and 
growth factors, including PDGF itself (Heldin and Westermark 1999). 
A detailed expression pattern of each of the ligands is quite complex and have been 
reviewed in-depth (Heldin and Westermark 1999; Hoch and Soriano 2003). However, 
there is an overall expression pattern. PDGF-B expression is mostly seen in 
megakaryocytes, neurons, and vascular endothelial cells. A comprehensive analysis 
of PDGFB/Rβ expression in wild-type embryos and young pups showed that 
endothelium of growing arteries and sprouting, immature, capillary endothelium have 
the highest expression of PDGFB (Hellstrom et al. 1999). In tissues, highest 
expression has been seen in the placenta and heart with other organs expressing 
moderate levels (Fredriksson et al. 2004). PDGF-A and PDGF-C expression have 
been seen in muscles, epithelial cells, and neuronal progenitors with these 
expressions partially overlapping (Lindahl et al. 1997; Betsholtz 2003; Andrae et al. 
2008). In tissues, PDGF-A expression is highest in skeletal muscle, pancreas and 
heart (Fredriksson et al. 2004) while increases in PDGFA expression have also been 
seen in human uterine SMCs during the physiological hypertrophy of pregnancy 
(Mendoza et al. 1990). Expression of PDGFC is seen in most adult tissues in humans 
with the highest expression in the kidney, pancreas, and heart with lower levels in 
ovary and liver, however, no expression could be detected in spleen, colon or 
peripheral blood leukocytes (Fredriksson et al. 2004). PDGF-A and -C have also been 
seen to be co-expressed in the brain, heart, testis, kidney and liver (Fredriksson et al. 
2004). 
Expression of PDGFD has not been well characterised, but have been reported in 
most adult tissues in mouse, rat and human (Bergsten et al. 2001; Larochelle et al. 
2001). The expression has been reported in all three vascular layers (tunica adventitia, 
tunica media, and tunica intima - endothelium), in VSMCs, ECs and fibroblasts (Uutela 
et al. 2001; Chen et al. 2005; Andrae et al. 2008; Karvinen et al. 2009). Expression in 
fibroblasts is probably suggestive of autocrine signalling with PDGFRβ (Uutela et al. 
2001; Andrae et al. 2008). In tissues, expression was highest in the pancreas, ovary, 
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heart, and adrenal gland with none detected in skeletal muscle, lung nor in the brain 
(Larochelle et al. 2001; Fredriksson et al. 2004). 
In the healthy murine retina, expression of PDGF-A and -B have been seen in retinal 
ganglion cells/nerve fibre layer as well as in horizontal and amacrine cells (Cox et al. 
2003). Expression of PDGFA has also been reported in adult retinal vasculature 
(Robbins et al. 1994) although its expression seems to be restricted to retinal neurons 
during development (Mudhar et al. 1993). 
2.3 The PDGF receptors 
The PDGFs exert their biological activity by binding to two structurally similar but 
distinct cell-surface (transmembrane) receptor tyrosine kinases (RTKs), PDGFRα and 
PDGFRβ which both belong to the class III RTKs including c-FMS, c-KIT, and FLT3 
(receptors of CSF1, stem cell factor - SCF, and FLT3-ligand respectively) (Heldin and 
Westermark 1999; Blume-Jensen and Hunter 2001; Lemmon and Schlessinger 2010; 
Raica and Cimpean 2010; Rönnstrand 2010; Demoulin and Essaghir 2014; Borkham-
Kamphorst and Weiskirchen 2016). The RTKs catalyse the transfer of phosphate 
groups from ATP (phosphate donor) to tyrosine residues on protein substrates. In the 
human genome, of the 90 tyrosine kinases identified, 58 are receptor types, and 32 
are non-receptor types (Robinson et al. 2000). 
The PDGF receptors, alpha and beta, have molecular sizes of approximately 170 and 
180 kDa respectively following glycosylation (Yarden et al. 1986; Claesson-Welsh et 
al. 1989; Matsui et al. 1989). The genes encoding the PDGFR alpha and beta are 
located on chromosome 4 and 5 in humans (Yarden et al. 1986; Spritz et al. 1994) 
and 5 and 18 in mice (Kazlauskas 2017) respectively. These receptors are more 
distant in relation to VEGF and FGF receptors (Demoulin and Essaghir 2014). Though 
the PDGFRs are structurally similar, they differ in their expression patterns, ligand-
binding specificities, and physiological roles (Betsholtz et al. 2001; Ostman and Heldin 
2007; Rönnstrand 2010). 
These two receptor isoforms form dimers upon binding of the PDGF dimer and 
depending on the configuration of the ligand and the receptor expression pattern, three 
receptor combinations are possible: -αα, -ββ and -αβ  (Bishayee et al. 1989; Heldin et 
al. 1989; Seifert et al. 1989; Andrae et al. 2008) (Fig. 2.8).  
In theory and in general, based on cell culture experiments, multiple and complex 
PDGF-PDGFR interactions are possible (Fig. 2.8). 
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Figure 2.8  Simple illustration of the PDGF system. 
(Borkham-Kamphorst and Weiskirchen 2016). See text for details. 
PDGF-AA binds only to PDGFR-αα whereas PDGF-BB has the ability to bind both 
PDGFR-α and -β thereby making it the only PDGF ligand with the ability to bind to all 
of the three receptor combinations with high affinity (Hart et al. 1988; Fredriksson et 
al. 2004). PDGF-CC binds to PDGFR-αα and -αβ, but does not bind to PDGFR-ββ, 
thus resembling PDGF-AB (Li et al. 2000; Gilbertson et al. 2001). However, the 
physiological relevance of PDGFR-αβ heterodimer activation has not been established 
to date but studies report that this activation may be responsible for data that shows 
PDGF-CC to be more potent than PDGF-AA (Li and Eriksson 2003). In the chick 
embryo chorioallantoic membrane (CAM) and mouse corneal model of angiogenesis, 
PDGF-CC exhibited more potent angiogenic activity than PDGF-AA (Cao et al. 2002), 
likewise, amongst the tested ligands, PDGF-CC showed the highest potential as a 
mitogen on several mesenchymal cell lines (Gilbertson et al. 2001). The binding 
constant for PDGF-CC binding to PDGFR-αα is said to be similar with PDGF-AA and 
PDGF-BB (Li and Eriksson 2003). PDGF-DD binds to PDGFR-ββ with high affinity, 
but it is also able to bind to PDGFR-αβ but with relatively lower affinity as such it is 
being referred to as PDGFR-ββ specific (Bergsten et al. 2001; Larochelle et al. 2001). 
PDGF-D has been reportedly shown to bind PDGFRα, inducing receptor endocytosis, 
which decreases significantly PDGFRα availability. PDGF-D thus activates PDGFRα 
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specific Tyr754 and Tyr1018 phosphorylation and the adaptor protein that specifically 
associates with activated PDGFRα, CrkII. The recombinant PDGFRα-Fc chimera 
homodimer also binds to PDGF-D thereby preventing PDGF-D signalling (Borkham-
Kamphorst et al. 2015).  
Taken together, all the PDGF dimers except PDGF-DD (PDGF-AA, PDGF-BB, PDGF-
CC and PDGF-AB) can bind to PDGFRα, while PDGF-BB and PDGF-DD binds to 
PDGFRβ (Heldin and Lennartsson 2013; Demoulin and Essaghir 2014) . 
2.3.1 Structure of the PDGF receptors 
The structure of the PDGFR family is characteristic of the RTKs which consists of; a 
ligand binding domain extracellularly; a single transmembrane helix which transmits 
information from outside into the cell and intracellularly; a juxtamembrane segment 
(JM), that reduces tyrosine kinase domain basal activity, a split tyrosine kinase domain 
in the cytoplasmic region (which has a specific inserted sequence of around 100‐
amino acid residues with no resemblance to kinase domains) responding to 
extracellular cues, and undergoing phosphorylation to induce downstream signalling 
events and last, a carboxyl-terminal tail  (Heldin and Westermark 1999; Hoch and 
Soriano 2003; Hubbard 2004; Ostman and Heldin 2007; Andrae et al. 2008; Chen et 
al. 2013; Eger 2016; Kazlauskas 2017) (Fig. 2.9).  
The extracellular part of the receptors consists of five immunoglobulin-like domains 
(D1-D5) of which domains 2 and 3 are most important for ligand binding (Heidaran et 
al. 1990; Lokker et al. 1997; Miyazawa et al. 1998; Shim et al. 2010) while domains 4 
and 5 participate in receptor dimer stabilisation (Omura et al. 1997; Yang et al. 2008) 
(Fig. 2.9). Receptor dimer stabilisation is however important because the receptors 
can attain an orientation that facilitates their activation by trans auto-phosphorylation 
(Heldin and Lennartsson 2013). 
The single transmembrane helix present in each receptor probably functions to relay 
information from the D4 and D5 domains to the intracellular part. In both receptors, the 
linkers present between the transmembrane helix and the D5 domain are just 3-4 
amino acids in length which suggests that the two transmembrane helices from the 
dimerized receptors are not likely by geometry to form inter-helix interactions as a 
result of the D5 domains not being too close to clash into each other (Chen et al. 
2013). 
Between the transmembrane helix and the kinase domain is the juxtamembrane 
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segment, a polypeptide of approximately 40 amino acids in length which maintains the 
kinase domain in an auto-inhibited state until ligand binding activation (Chan et al. 
2003; Griffith et al. 2004; Walter et al. 2007). The JM segment contains several 
tyrosines conserved in all of the class III RTKs saddled with the responsibility for 
attaching the segment to the kinase domain. Most important is that phosphorylation of 
these conserved tyrosines results in constitutively activating PDGFRβ (Mori et al. 
1993). Chen et al. 2013, also noted that the addition of phosphate groups to these 
tyrosines likely prevents the JM segment from binding to the kinase groove, with the 
same tyrosines likely to be involved in the ligand-induced activation of the PDGFRs. 
Mol et al. 2003, also noted that trans auto-phosphorylation of these tyrosines could be 
responsible for kinase domain activation as seen with c-KIT. 
The tyrosine kinase domain is the effector domain in these receptors. Together with 
the phosphorylated tyrosines in the JM segment, the kinase domain of these receptors 
also harbor two major tyrosine auto-phosphorylation sites, one of which is Y751 in 
PDGFRβ, which is found precisely in the insert region within the kinase (Kazlauskas 
and Cooper 1989). These tyrosine phosphorylation thus provides docking sites for 
downstream signalling molecules (Kazlauskas and Cooper 1990; Escobedo et al. 
1991). 
At the C-terminus of the encoding sequences, both receptors possess a highly acidic 
region, rich in serine and threonine (Fig. 2.9). These sequences participate in 
ubiquitination and receptor down-regulation (Lennartsson et al. 2006). 
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Figure 2.9  Structure of PDGFRα and PDGFRβ. 
The different domains (D1-D5) and their compositions are shown. All numbers are for 
human PDGFRs. The two straight lines represent the lipid bilayer. Note that domains 
1 and 2 (D1 and D2) are an integral module while the intracellular kinase domain is a 
split domain having an insert between the N- and C-terminal lobes (Chen et al. 2013).  
2.3.2 Expression of PDGFRs 
While the pattern of expression of the two PDGFRs are not similar (Kazlauskas 2017), 
it is known to be dynamic and spatio-temporally regulated in-vivo as seen with the 
ligands (Andrae et al. 2008; Chen et al. 2013). Their expression has been detected in 
a large number of cell types (Heldin and Westermark 1999). The classical cells known 
to express PDGF, SMCs and fibroblasts, also express both alpha and beta receptors 
but in general higher levels of beta receptors are expressed. Some cells express only 
alpha receptor like the rat liver endothelial cells (Heldin et al. 1991), human platelets 
(Vassbotnlon et al. 1994), and O-2A glial precursor cells (Hart et al. 1989) while some 
others express only beta receptor like mouse capillary endothelial cells (Smits et al. 
1989). In addition, PDGFRα is expressed in lens epithelium (Reneker and Overbeek 
1996). Expression has also been seen in most mesenchyme cells with strong 
expression in subtypes of mesenchymal progenitors in skin, intestine, and lungs 
(Schatteman et al. 1992; Andrae et al. 2008). 
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Expression of PDGFRβ has been seen in mesenchyme, predominantly VSMCs and 
pericytes (Sorkin et al. 1993; Hellstrom et al. 1999; Andrae et al. 2008). PDGFR 
expression is generally low in mesenchymal cells in-vivo, however, expression is 
known to dramatically increase during inflammation and in culture and several factors 
have been reported to result in this expression induction, including TGFβ, FGF-2, 
estrogen, LPS, TNFα and IL-1α (Heldin and Westermark 1999). 
In the developing murine retina, expression of PDGFRα have been seen in astrocytes 
(Mudhar et al. 1993) with PDGFRβ in the microvascular pericytes (Benjamin et al. 
1998). Meanwhile, in the adult retina, expression of PDGFRα have been seen in the 
ganglion cell layer with PDGFRβ at the Müller cell end feet at the internal limiting 
membrane (Cox et al. 2003).  
2.3.3 Activation of the PDGFRs 
Although PDGFR activation independent of PDGF exist, which were first identified 
during pathological conditions, the best-known mechanism of PDGFR activation is the 
direct, PDGF-mediated form of activation (Kazlauskas 2017). 
2.3.3.1 Dimerization and auto-phosphorylation of Receptors 
The PDGF isoforms have two symmetric receptor binding epitopes each due to their 
dimeric nature. Hence, one molecule of PDGF simultaneously binds two receptor 
molecules bringing the two receptor promoters in nearness to each other (Duan et al. 
1991; Fretto et al. 1993; Herren et al. 1993; Heldin and Westermark 1999; Chen et al. 
2013). Hence, receptor dimer is formed which is non-covalently held together by the 
bivalent PDGF ligands (Betsholtz 2003; Heldin and Lennartsson 2013). Receptor 
dimerization and conformational changes results in destabilising the inhibitory 
interactions between the kinase and these three segments; the JM domain, the 
activation loop and the C-terminal tail (Rönnstrand 2010; Demoulin and Essaghir 
2014). Receptor dimerization is therefore crucial in PDGFR activation as it puts side 
by side the receptor’s intracellular parts allowing trans phosphorylation between the 
two receptors in the complex (Kelly et al. 1991; Heldin and Ostman 1996; Hoch and 
Soriano 2003; Chen et al. 2013; Kazlauskas 2017). 
In principle, auto-phosphorylation has two important functions: firstly, auto-
phosphorylation of tyrosines in the activation loop within the protein TK domain (i.e., 
Tyr849 in the PDGFRα and Tyr857 in the PDGFRβ) (Fantl et al. 1989; Kazlauskas 
and Cooper 1989; Kazlauskas et al. 1991; Rönnstrand 2010) results in kinase activity 
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stimulation, and secondly auto-phosphorylation of tyrosines positioned outside the 
kinase domains (i.e., in the JM, kinase insert, and carboxyl-terminal regions) provides 
docking sites for cytoplasmic downstream signalling molecules (Kazlauskas and 
Cooper 1989; Heldin et al. 2002; Betsholtz 2003; Heldin and Lennartsson 2013; 
Demoulin and Essaghir 2014), largely those having the Src homology 2 (SH2) domain 
(Choudhury et al. 1998; Heldin and Westermark 1999; Tallquist and Kazlauskas 
2004), but also those containing pleckstrin homology (PH) domains, recognising 
membrane phospholipids; SH3 domains recognising proline-rich regions; phospho-
tyrosine-binding (PTB) domains, recognising phosphorylated tyrosines; and 
Postsynaptic density protein (PSD95), Drosophila disc large tumor suppressor (DlgA), 
and Zonula occludens-1 protein (zo-1) (PDZ) domains, recognising C-terminal valine 
residue and specific upstream sequences (Pawson and Scott 1997; Pawson and Nash 
2003). However, most PDGFR effectors bind via SH2 domains to distinct sites on the 
phosphorylated receptors (Ostman and Heldin 2007; Andrae et al. 2008).  
So far, PDGFR-α and -β have a total of 11 and 13 tyrosine phosphorylation sites 
respectively out of which 10 and 11 sites respectively have been identified as auto-
phosphorylation sites (Heldin et al. 1998; Rönnstrand 2010). In PDGFRβ, Y934 is not 
auto-phosphorylation site, but phosphorylated by Src family kinases (Hansen et al. 
1996). Thus dimerized and activated PDGFRs associate with diverse families of SH2-
domain containing molecules initiating activation of diverse signalling pathways and 
around 10 different families have so far been identified (Heldin et al. 2002; Ostman 
and Heldin 2007; Heldin and Lennartsson 2013). The SH2-domain containing 
molecules tend to bind specifically, binding specificities of which are determined by 
the three to six amino acid residues (different SH2-domains have preferences that 
differ for these amino acids) lying downstream of the phosphorylated tyrosine residues 
(Songyang et al. 1996; Heldin et al. 2002; Heldin and Lennartsson 2013). Some of the 
SH-2 domain signalling molecules have in-built enzymatic activity [e.g., tyrosine 
kinases Src, Fer and Fes; the tyrosine phosphatase, SHP-2; phospholipase C-γ (PLC-
γ); PI3-kinase; and the GTPase‐activating protein (GAP) for Ras (RasGAP)] (Kim and 
Wong 1995; Heldin and Westermark 1999; Tallquist and Kazlauskas 2004; Ostman 
and Heldin 2007).  
Thus, activation of the corresponding enzymatic activities occur either by receptor 
binding or by receptor kinases phosphorylation. On the other hand, the enzymes are 
constitutively active and are only carried by the activated receptors into the plasma 
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membrane inner leaflet (Heldin and Lennartsson 2013). Others (SH-2 domain 
signalling molecules) are adaptor molecules that are devoid of intrinsic enzymatic 
activity but rather are links between the receptors and other effectors downstream 
(Ostman and Heldin 2007; Shah et al. 2010). Examples of these adaptor molecules 
include; Growth Factor Receptor Bound Protein 2 and 7 (Grb2 and 7), GRB2 
Associatfed Binding Protein 2 (Gab2), Crk, non-catalytic region of tyrosine 
kinase adaptor protein (Nck), Shc, and ALG-2-interacting protein X (Alix) (Yokote et 
al. 1996; Heldin et al. 1998). Grb2 complexes with the nucleotide exchange molecule, 
Sos1 (son of sevenless 1) (Grb2/Sos1 complex) and activates the small GTPase, Ras 
and the extracellular-signal-regulated kinases (ERK) MAPK pathway (Ostman and 
Heldin 2007; Andrae et al. 2008; Heldin and Lennartsson 2013). Nck and Crk activates 
JNK (Nishimura et al. 1993; Su et al. 1997). Alix binds aroufnd Tyr1021 region of the 
carboxyl-terminal tail and aids ubiquitin ligase (Cbl) binding (Lennartsson et al. 2006). 
PDGFRs, independent of auto-phosphorylation, also binds to signalling molecules or 
enhancers (e.g., the PDZ-domain protein, Na+/H+ exchanger regulatory factors, 
NHERF), which binds to the carboxyl-terminal tail end of the receptors, facilitating 
receptor signalling (Maudsley et al. 2000; Demoulin et al. 2003; James et al. 2004; 
Takahashi et al. 2006; Theisen et al. 2007). They are also able to activate transcription 
factors of the STAT family (Darnell 1997; Heldin and Westermark 1999; Ostman and 
Heldin 2007). Additionally, not only do the PDGFRs bind to N-cadherin (Theisen et al. 
2007) and the phosphatase, PTEN (phosphatase and tensin homologue) (Takahashi 
et al. 2006), they also associate with integrins (Assoian 1997; Frisch and Ruoslahti 
1997). Interaction of PDGFRs with integrins aids the localisation of these receptors 
and associating molecules at focal adhesions, which are sites where numerous 
signalling pathways are initiated and are connected (Clark and Brugge 1995). 
2.4 PDGFR-induced signalling pathways 
Potentially, a signalling pathway is initiated with the binding of each signalling molecule 
to the receptors following ligand binding (Heldin et al. 2002). PDGFRs thereby induce 
a number of well-characterised signalling pathways, e.g., MAPK, phosphatidyl-
inositol-3-kinase (PI3K), phospholipase C-γ (PLC-γ), JAK/STAT pathways and others 
that mediate several cellular and developmental responses such as cell survival, 
migration, proliferation, and ECM production (Andrae et al. 2008; Ostendorf et al. 
2012; Heldin and Lennartsson 2013; Borkham-Kamphorst and Weiskirchen 2016) 
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(Fig. 2.8). However, activation of the Ras-MAPK and the PI3K/Akt pathways are the 
two most characterised mechanisms through which cellular responses are being 
mediated by PDGFRs (Li et al. 2007). 
2.4.1 MAPK pathways 
MAP kinases pathways are important intracellular signalling pathways activated by 
PDGFs (Demoulin and Essaghir 2014; Eger 2016). MAP kinase family are proline 
(Pro)-targeted serine/threonine kinases (Turjanski et al. 2007; Roskoski 2012). They 
either undergo auto-phosphorylation i.e., phosphorylating their own dual serine and 
threonine residues or phosphorylate the ones located on their substrates, to either 
result in target activation or deactivation (Johnson and Lapadat 2002; Peti and Page 
2013).  
MAPKs are expressed ubiquitously and are highly conserved evolutionarily from 
plants, fungi, nematodes, insects to mammals (Widmann et al. 1999; Pimienta and 
Pascual 2007; Shaul and Seger 2007; Kyriakis and Avruch 2012; Peti and Page 2013). 
They participate in signal transduction from the cell surface to the cell interior and are 
responsive to enormous extracellular stimuli (Plotnikov et al. 2011; Roskoski 2012). 
They regulate numerous fundamental cellular processes whilst their dysregulation are 
also implicated in a number of diseased states (Dong et al. 2002; Wei and Liu 2002; 
Qi and Elion 2005; Liu et al. 2007; Pimienta and Pascual 2007; Raman et al. 2007; 
Shaul and Seger 2007; Turjanski et al. 2007; Arthur and Ley 2013). Induced cellular 
responses and implicated disease conditions are discussed under each of the 
individual pathways. 
Each MAPK pathway is made up of a three-tiered kinase cascade consisting of MAP 
kinase kinase kinase (MAPKKK, MAP3K, MEKK or MKKK), which is often activated 
by a MAP4K lying upstream. Downstream, MAP3K phosphorylates and activates the 
MAP kinase kinase (MAPKK, MAP2K, MEK or MKK), which in turn, activates the 
MAPK by dual phosphorylation of conserved threonine (Thr) and tyrosine (Tyr) 
residues present in the activation loop (denoted as T-X-Y) (Songyang et al. 1996; 
Canagarajah et al. 1997; Chen et al. 2001; Pearson et al. 2001; Wei and Liu 2002; 
Cargnello and Roux 2011; Plotnikov et al. 2011; Morrison 2012; Roskoski 2012; Lee 
et al. 2016) (Fig. 2.10). Once activation of the MAPK occurs, diverse substrates gets 
phosphorylated (including transcription factors, phosphatases, and protein kinases) 
both in the cytosol and nucleus resulting in changes in gene expression and protein 
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function that execute the corresponding biological responses (Turjanski et al. 2007; 
Plotnikov et al. 2011; Morrison 2012; Roskoski 2012) (Fig. 2.10). For the 
phosphorylation of nuclear targets, active MAPKs often translocate to the nucleus from 
the cytoplasm (Qi and Elion 2005; Plotnikov et al. 2011). In mammalian cells, at least 
14 MAP3Ks, 7 MAP2Ks, and 12 MAPKs have been recognised (Widmann et al. 1999). 
Dephosphorylation of MAPKs occur through the activity of dual specificity MAPK 
phosphatases (MKPs), serine/threonine phosphatases and tyrosine phosphatases 
that dephosphorylate both phospho-threonine and phospho-tyrosine residues on 
MAPKs (Sun et al. 1993; Keyse 2000; Liu et al. 2007; Pimienta and Pascual 2007; 
Zhang and Dong 2007). 
The MAPKs have been grouped into three main families based on their structure, 
activation motif, and function and these are ERKs, ERK1 - ERK8; JNKs/SAPK (C-Jun 
amino (NH3)-terminal kinases/stress activated protein kinase - JNK1, JNK2 and 
JNK3); and p38/SAPKs - p38α, p38β, p38γ and p38δ (Schaeffer and Weber 1999; 
Chen et al. 2001; Kyriakis and Avruch 2001; Wei and Liu 2002; Cui et al. 2007; Zhang 
and Dong 2007; Cargnello and Roux 2011) (Fig. 2.10). 
 
Figure 2.10  Simplified MAPK signalling cascade. 
Image modified and adapted from Morrison, 2012. See text for details. 
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2.4.1.1 ERK pathway 
The MAPK/ERK pathway is also generally denoted as the Ras-Raf-MEK-ERK 
pathway. The ERKs have been the best studied amongst the MAPK pathways 
(Turjanski et al. 2007). They have a TEY motif in the activation segment and are 
generally grouped into two: the classical ERKs, that primarily have a kinase domain 
(ERK1 and ERK2) and the larger ERKs (e.g., ERK5), that have to their kinase domain, 
a relatively more extended carboxyl-terminal sequence (Zhang and Dong 2007). 
ERK1/2, also referred to as p44 and p42 MAPK, respectively, were the initial MAPKs 
to be identified in mammals (Rossomando et al. 1989; Nakielny et al. 1992), with 83-
84% of sequence similarity, sharing almost all functions (Lloyd 2006; Turjanski et al. 
2007). Hence, referred to as ERK1/2 (Roskoski 2012). However, ERK2 remains the 
best characterised member of this group (Turjanski et al. 2007).  
Ras activation occurs in PDGF-stimulated cells and it is a key event in inducing signal 
transduction (Nånberg and Westermark 1993; Satoh et al. 1993; Heldin and 
Westermark 1999). PDGFRs interact with Ras-MAPK majorly through Grb2 and Shc 
adaptor proteins (Andrae et al. 2008). Grb2 is an adaptor molecule having one SH2 
domain and two SH3 domains. The SH3 domains of Grb2 allows it to form a complex 
with Sos1 (Schlessinger 1993; Andrae et al. 2008) while its SH2 domain can either 
directly bind to auto-phosphorylated (activated) PDGFRs, or indirectly bind through 
other components, such as SHP-2 or Shc. Following the binding of these other 
components to PDGFRs, they get phosphorylated on tyrosine residues and are 
recognised by the SH2 domain of Grb2 (Heldin and Westermark 1999; Demoulin and 
Essaghir 2014). Grb2 complexes with Sos1, a guanine nucleotide exchange factor 
(GEF) for Ras, Sos1 subsequently activates Ras [(by converting membrane-bound 
Ras from its inactive, GDP-bound form (Ras-GDP) to its transductionally active, GTP-
bound form - (RasGTP)] (Schlessinger 1993; Heldin and Westermark 1999; Andrae et 
al. 2008; Dance et al. 2008; Jurek et al. 2011). GTP hydrolysis, facilitated by guanine 
tri-phosphatase activator protein (GAP), thus terminates Ras signalling (Yoon and 
Seger 2006; Vigil et al. 2010).  
Upon activation, Ras recruits Raf-1, a serine/threonine kinase, to the plasma 
membrane from the cytoplasm for subsequent activation which involves two key steps 
(Wellbrock et al. 2004; Jurek et al. 2011). First, the auto-inhibition imposed on the 
catalytic domain of Raf-1 by its regulatory domain is eased (Cutler et al. 1998). 
Second, the catalytic domain undergo multiple phosphorylation and de-
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phosphorylation events which is necessary for elevation of Raf-1’s basal activity 
(Chong and Guan 2003). Raf-1 is the first kinase (entry point) in the three-tiered MAPK 
cascade, and once activated, it initiates MAPK cascade activation by phosphorylation 
and activation of MEK1/2 which subsequently activates MAP kinases ERK1/2 by the 
phosphorylation of tyrosine and threonine residues in the TEY sequence in the 
catalytic domain (Heldin et al. 1998; Heldin and Westermark 1999; Thomas and 
Huganir 2004; Qi and Elion 2005; Jurek et al. 2011) (Fig. 2.10). This process is 
facilitated by KSR, a scaffold protein that links the three levels of kinases to Ras (Qi 
and Elion 2005). ERK1/2 thus have several known substrates in all the cellular 
compartments, including the cytoskeleton, membranes, cytoplasm, and nucleus (Yoon 
and Seger 2006). Some of these targets include but are not limited to transcription 
factors, such as NF-kB, AP-1, and Myc, kinases, such as ribosomal protein S6 kinases 
(RSKs), and the RSK-related mitogen and stress-activated kinases (MSKs) that are 
localised to the nucleus, the cell survival regulator, Bcl-2 (B-cell lymphoma-2), cPL2, 
and paxillin (cytoskeletal scaffold protein) (Thomas and Huganir 2004; Qi and Elion 
2005; Turjanski et al. 2007).  
This cascade is therefore involved in the regulation of numerous processes including 
cell migration, adhesion, survival, metabolism, proliferation or differentiation 
(depending on the stimulant strength and duration), cell cycle progression, 
transcription, learning and memory in nerve cells (Marshall 1995; Pearson et al. 2001; 
Qi and Elion 2005; McKay and Morrison 2007; Shaul and Seger 2007; Roskoski 2012). 
2.4.1.2 JNK Pathway 
Initially, a 54-kDa MBP kinase from cycloheximide-treated rat livers was purified as a 
form of JNK/SAPK (Kyriakis and Avruch 1990). Before long, purification by affinity 
adsorption to a c-Jun fusion protein gave rise to 46 and 54 kDa JNK/SAPKs (Hibi et 
al. 1993). Their characteristic feature is the dual phosphorylation motif Thr-Pro-Tyr 
(TPY) within their activation loop (Turjanski et al. 2007; Morrison 2012). Initially 
recognised as a mediator of the c-Jun transcription factor, JNK earned its other name, 
SAPK (stress-activated protein kinase) from being identified as an environmental, 
intra- or extra-cellular stress mediator (such as DNA damage, heat, genotoxic, ionising 
radiation, osmotic, hypoxic or oxidative stress) (Kyriakis and Avruch 1990; Davis 1994; 
Kyriakis et al. 1994; Qi and Elion 2005; Johnson and Nakamura 2007; Roskoski 2012).  
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However, it was later shown that similar to other MAPKs, this cascade is activated by 
several other stimuli that are stress independent like growth factors such as PDGF 
and cytokines such as TNFα and IL-1β (Davis 2000; Weston and Davis 2002; Qi and 
Elion 2005; Roy et al. 2008). Upon activation, signals get transmitted from the stimuli 
or stress factor to Rho family small GTPases such as Rac1 and CDC42, which then 
activates the MAP3Ks either directly or through MAP4Ks (Qi and Elion 2005; Plotnikov 
et al. 2011). Alternatively, association of the MAP3Ks and MAP4Ks with the adaptor 
protein, TRAF can also lead to their direct activation (Bradley and Pober 2001). With 
several MAP4Ks (Dan et al. 2001) and MAP3Ks (Craig et al. 2008) recognised, each 
of them can pass on the cascade’s signal by binding to specific scaffold proteins under 
certain conditions [(e.g. JIPs (Whitmarsh 2006)] (Qi and Elion 2005). MAP3Ks for the 
JNK module include members of: the MEKK group, MEKK1 and MEKK4; the mixed 
lineage protein kinase group, MLK2 and MLK3; the apoptosis signal-regulating kinase 
group, ASK1; transforming growth factor-β activated kinase -1 (TAK1), and tumour 
progression locus 2 (Tpl2) (Davis 2000; Qi and Elion 2005; Weston and Davis 2007; 
Morrison 2012). Following activation of MAP3Ks, their signals are further transmitted 
by Thr and Ser residue phosphorylation in the activation loop, in turn activating the 
MAP2Ks (MKK4 and MKK7) (Qi and Elion 2005; Wang et al. 2007; Weston and Davis 
2007; Morrison 2012). Subsequently, the MAP2Ks activate the three MAPKs, 
JNK1/2/3, by directly phosphorylating the Tyr and Thr residues in the activation loop's 
Thr-Pro-Tyr motif (Weston and Davis 2007; Plotnikov et al. 2011) (Fig. 2.10).  
The JNK gene isoforms, JNK 1, 2 and 3 are a result of differential splicing of a single 
gene whilst JNK1 and 2 are ubiquitously expressed in several tissues, expression of 
JNK3 is specific to brain, testis and heart (Qi and Elion 2005; Roy et al. 2008). Thus, 
each JNK is expressed as a short and long form, 46 and 54 kDa respectively (Cui et 
al. 2007). These forms however, seem to differ in their binding and phosphorylation 
ability to different substrate proteins (Roy et al. 2008). This cascade activation, results 
in the JNKs and perhaps their putative MAPKAPKs, to phosphorylate several targets 
(including transcription factors) present mainly in the nucleus, but also in the cytoplasm 
(non-nuclear proteins) (Barr and Bogoyevitch 2001; Cui et al. 2007; Plotnikov et al. 
2011). Amongst their many substrates is c-Jun, to which JNK binds at the NH2-
terminal activation domain and phosphorylates it on Ser63 and Ser73 residues (Wei 
and Liu 2002; Roy et al. 2008). In addition to c-Jun, the following transcription factors 
can also be phosphorylated by JNK: c-fos, activating transcription factor 2 and 3 (ATF2 
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and 3), JunB, and JunD. Together with c-Jun, these transcription factors collectively 
make up the AP-1 transcription factor which is involved in regulating expression of 
numerous stress-responsive genes (Roy et al. 2008). Additionally, JNK 
phosphorylates DPC4, tumour protein p53 (TP53), nuclear factor of activated T-cells 
4 (NFAT4), c-Myc, SRF (Serum Response Factor) accessory protein 1a (Sap-1a), 
ETS Like-1 protein (Elk-1), Jun Dimerization Protein 2 (JDP2), and the Ets-related 
transcription factor, PEA3 (O’Hagan et al. 1996; Ip and Davis 1998; Widmann et al. 
1999; Bogoyevitch and Kobe 2006). MST1 (Bi et al. 2010) and MAPKAPK3 (Ludwig 
et al. 1996) have also been shown to be phosphorylated by JNKs, however, their 
functional properties as classical MAPKAPKs remains a subject of debate (Plotnikov 
et al. 2011).  
These phosphorylated substrates subsequently control the transcription of numerous 
genes which in turn mediate cellular processes such as immune responses, insulin 
signalling, neuronal activity, survival signalling, apoptosis, metabolism, cytokine 
production (Wei and Liu 2002; Dhanasekaran and Reddy 2008; Haeusgen et al. 2009; 
Huang et al. 2009; Rincón and Davis 2009) and several others (Whitmarsh 2007). 
Thus any dysregulation of this cascade can lead to numerous diseases. JNKs have 
been implicated in a number of neurodegenerative diseases, including but not limited 
to ALS, PD, AD (Kim and Choi 2010), inflammation (Zhang and Kaufman 2008), 
diabetes (Tanti and Jager 2009), and many types of cancers (Wagner and Nebreda 
2009). 
2.4.1.3 p38 MAPK pathway 
The discovery of p38α was borne out of three independent context. First, isolated as 
a 38-kDa tyrosine phosphoprotein present in LPS-treated cell extracts (Han et al. 
1993, 1994). Second, as a pyridinyl imidazole binding drug that blocked the 
biosynthesis of inflammatory cytokines like IL-1 and TNFα in LPS stimulated 
monocytes, as such, it was referred to as cytokine-suppressive anti-inflammatory 
drug-binding protein (CSBP) (Lee et al. 1994) and third, as MAPK activated protein 
kinase-2 (MAPKAP-2) reactivating kinase (Rouse et al. 1994). Furthermore, the other 
three splice variants [p38β (p38-2), p38γ (ERK6 or SAPK3), and p38δ (SAPK4)] 
encoding members of the p38 subfamily were identified by cloning strategies instead 
of biological approaches (Jiang et al. 1996; Lechner et al. 1996; Li et al. 1996; Goedert 
et al. 1997; Jiang et al. 1997; Kumar et al. 1997; Stein et al. 1997). Amongst the four 
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isoforms, p38α and p38β are ubiquitously expressed while p38γ and p38δ are 
expressed differentially depending on the type of tissue (Zarubin and Han 2005).  
A Thr-Gly-Tyr (TGY) dual phosphorylation motif in the activation loop is characteristic 
of all p38 kinases (Hanks and Hunter 1995; Plotnikov et al. 2011; Morrison 2012) while 
comparison of the sequences showed that each of the isoforms share approximately 
60% identity within the group but only 40-45% with other three members of the MAPK 
family (Zarubin and Han 2005). The p38 MAPKs respond to and are activated by 
several chemical and physical stresses including but not limited to ischemia, UV 
irradiation, hormones, heat and osmotic shock, certain mitogens like PDGF, protein 
synthesis inhibitors, LPS, inflammatory cytokines like TNFα and IL-1 (Wei and Liu 
2002; Qi and Elion 2005; Zarubin and Han 2005).  
Upon receptor activation or stress induction, signals get transmitted to the p38 
cascade via small GTPases, adaptor proteins, MAP4Ks and MAP3Ks identical to the 
ones that are involved in the JNK cascade (Plotnikov et al. 2011). However, the 
differences in activation between the p38 and JNK cascades are facilitated by specific 
scaffold proteins, compartmentalisation, and variable substrates (Morrison and Davis 
2003; Cuevas et al. 2007; Raman et al. 2007). Upon transmission of signals by MAP3K 
component cascade level, these signals result in the induction of phosphorylation and 
activation of the p38 cascade MAP2K components, mainly MKK3 and MKK6 (SKK3) 
(Qi and Elion 2005; Rubinfeld and Seger 2005; Zarubin and Han 2005; Raman et al. 
2007; Morrison 2012), but can also include MKK4 for p38-α and -γ (Whitmarsh and 
Davis 2007) under certain conditions. Several MAP3Ks are involved in the p38 
cascade, including MEKK1-MEKK4, DLK (MUK/ZPK), ASK1 (MAPKKK5), MLK2 and 
3, TAK1, TAO1/TAO2 and Tpl2 (Qi and Elion 2005; Zarubin and Han 2005; Raman et 
al. 2007; Morrison 2012). Following the transmission of signals to the MAP2Ks, these 
signals are further passed on to the four p38 isoforms (Fig. 2.10) and a few functional 
differentially spliced forms at the MAPK cascade level (32-54 kDa) (Plotnikov et al. 
2011). Alternatively, p38 activation can also be facilitated by auto-phosphorylation 
independent of MAP2K where activation can be induced either by phosphorylation of 
Tyr323 by ZAP-70 (Salvador et al. 2005), by association with analogues of lipidic 
phosphatidyl inositol (Gills et al. 2007), or by stimulated interaction with TAB1 (TAK1-
binding protein) adaptor proteins (Ge et al. 2002), subsequently catalysing an 
enhanced auto-phosphorylation of p38s on its activatory residues (Plotnikov et al. 
2011). Activation of the p38 MAPKs thus leads to activation of numerous substrates 
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amongst which are transcription factors, protein kinases and other types of substrates 
(Zarubin and Han 2005; Morrison 2012).  
Protein kinase substrates of p38 include: the MAPK-activated protein kinase 2 
(MAPKAPK2 or MK2) (Zarubin and Han 2005), its closely associated family member, 
MK3 (3pk) both of which activate  numerous targets including cAMP response 
element-binding protein (CREB), lymphocyte-specific protein 1 (LSP1), small heat 
shock protein 27 (HSP27), tyrosine hydroxylase (Zarubin and Han 2005). Other 
protein substrates are; MAPKAPK-5, MNK1, MNK2 (Fukunaga and Hunter 1997; 
Waskiewicz et al. 1997; Wei and Liu 2002; Plotnikov et al. 2011).  
Transcription factors substrate of P38 include; Sap-1a, high mobility group-box protein 
1 (HBP1), ATF-1/2/6, NFAT, p53, microphthalmia-associated transcription factor 1 
(MITF1), myocyte enhancer factor 2C and 2A (MEF2C and 2A), ELK1, C/EBPβ, DNA 
damage-inducible transcript 3 protein (DDIT3), NF-kB, and AP-1 (Wei and Liu 2002; 
Qi and Elion 2005; Zarubin and Han 2005). Other p38 substrates include; keratin 8, 
tau, Na+/H+ exchanger isoform-1 (NHE-1), cPLA2, and stathmin (p38δ) (Young et al. 
1993; Reynolds et al. 1997; Kusuhara et al. 1998; Parker et al. 1998; Feng et al. 1999).  
Dephosphorylation of the p38 MAPK cascade is triggered by many dual-specificity 
protein phosphatases while p38α and p38β can be dephosphorylated by several 
members of these proteins (Muda et al. 1996; Camps et al. 1998), p38γ and p38δ 
seem to resist all the identified MKP family members (Zarubin and Han 2005). 
However, MPK5/7 which dephosphorylates JNK also does same for p38, MPK2/4, 
which deactivates ERK also dephosphorylates p38 while MPK1 as a higher specificity 
for p38 (Owens and Keyse 2007; Salojin and Oravecz 2007). 
Activation of p38 MAPK therefore play significant roles in gene expression regulation, 
survival, proliferation, differentiation, development, stress responses, inflammation, 
senescence, apoptosis, and cell cycle regulation (Wei and Liu 2002; Zarubin and Han 
2005; Cuenda and Rousseau 2007; Maruyama et al. 2009; Cuadrado and Nebreda 
2010; Plotnikov et al. 2011; Roskoski 2012). Gene targeting experiments have also 
shown that p38 is indispensable for erythropoietin production and angiogenesis (Qi 
and Elion 2005; Roskoski 2012). Thus, the involvement of this cascade in all these 
essential processes implies that any cascade dysregulation would therefore have 
pathological consequences (Plotnikov et al. 2011) as seen in diabetes (Liu and Cao 
2009), in the induction and sustenance of neurodegenerative diseases (Kim and Choi 
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2010), in cancer (Loesch and Chen 2008), in cardiovascular diseases (Coulthard et 
al. 2009), and in asthma (Qi and Elion 2005). 
2.4.2 Phosphatidylinositol-3-kinase (PI3K) pathway  
The PI3K family is a large and complex family of intracellular lipid kinases that 
phosphorylate phosphatidylinositol and phosphoinositides in their 3' position (i.e., 
phosphorylating the 3-OH group) (Engelman et al. 2006; Vanhaesebroeck et al. 2012) 
(Fig. 2.11).  
 
Figure 2.11  Enzymatic activity of PI3K and SHP1/2 with their corresponding 
substrate. 
Phosphatidylinositol phosphates (PIPs) are made of membrane bound fatty acids and 
a glycerol backbone linked to a cytosolic, phosphorylated, inositol head group. PIP2 is 
phosphorylated at the 3' position by PI3K forming PIP3. The phosphatase, PTEN, can 
dephosphorylate PIP3 back to regenerate PIP2. In addition, SHIP1/2 can 
dephosphorylate PIP3 at the 5' position generating PtdIns(3,4)P2, another potential 
second messenger (Vivanco and Sawyers 2002). 
They are highly conserved evolutionarily amongst multicellular organisms (Engelman 
et al. 2006; Hemmings and Restuccia 2012; Fruman et al. 2017). Molecular cloning of 
the PI3Ks revealed that there are three members (Class I - III) in this family with 
multiple subunits and isoforms (Vivanco and Sawyers 2002), classified according to 
their substrate specificity, structural characteristics, lipid products, and sequence 
homology (Fruman et al. 1998; Katso et al. 2001; Cantley 2002).  
Class I PI3K is further subdivided into IA and IB on the basis of structural and functional 
differences (B Vanhaesebroeck et al. 1997). Class IA is activated by G protein-coupled 
receptors (GPCRs), RTKs like PDGFRs, and certain oncogenes like the small G 
protein RAS while Class IB are exclusively activated by GPCRs (Vivanco and Sawyers 
2002; Carracedo and Pandolfi 2008; Liu et al. 2009). The regulatory subunits of both 
sub-classes differ; p85α/p85β/p55γ (collectively referred to as p85) and 
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p101/p84/p87PIKAP for class IA and IB respectively (Bader et al. 2005; Engelman et 
al. 2006; Carracedo and Pandolfi 2008). Class I is characterised for generating 
predominantly the second messenger, phosphatidylinositol-3,4,5-trisphosphate 
[PI(3,4,5)P3], by phosphorylating phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2], 
the main in-vivo substrate (Katso et al. 2001; Vivanco and Sawyers 2002; Liu et al. 
2009). Class II PI3K which have three sub-classes, PI3KC2α, PI3KC2β, and PI3KC2γ, 
generates PI-3,4-P2 from PI-3P as wells as PI-3-P from PI and can be activated by 
cytokine receptors, RTKs, and integrins while Class III PI3K have only one single 
member, homologue of the yeast vacuolar protein sorting-associated protein 34 
(hVPS34) also referred to as PIK3C3 (Carracedo and Pandolfi 2008; Liu et al. 2009; 
Fruman et al. 2017).   
Of the three classes of enzymes, class I, activated by cell surface receptors, have 
been the most studied (Carracedo and Pandolfi 2008; Liu et al. 2009) and this review 
focuses on this class of PI3K enzymes. Members of this PI3K family (Class IA PI3Ks) 
are heterodimers that have a catalytic subunit, p110 [encoded by three genes (α, β 
and δ), which all have similar basic structure] and a regulatory subunit, p85 [also 
encoded by one of three genes (α, β and γ which all undergo differential splicing) 
(Vivanco and Sawyers 2002; Liu et al. 2009). The regulatory subunit, p85, codes for 
an adaptor-like protein containing two SH2 domains (binding to the motif pYXXM, 
where pY denotes a phosphorylated tyrosine residue) (Zhou et al. 1993; Vivanco and 
Sawyers 2002) and an inter-SH2 domain binding constitutively to the catalytic subunit, 
p110 (Vivanco and Sawyers 2002). This p85 regulatory subunit, facilitates binding and 
activation of the receptor as well as enzyme localisation (Liu et al. 2009). It also directly 
binds to two auto-phosphorylated tyrosine residues, conserved in both PDGFRs 
(Tyr740 and Tyr751 in PDGFRβ, both having a methionine at the +3 position) (Yu et 
al. 1991; Fantl et al. 1992; Kashishian et al. 1992; Kazlauskas et al. 1992; Cantley 
2002; Demoulin and Essaghir 2014). This binding therefore activates PI3K. The 
generation of this complex thus results in the membrane translocation and increased 
enzymatic activity of the p110 catalytic subunit, generating the product, PIP3 (Backer 
et al. 1992; Demoulin and Essaghir 2014). Kavanaugh et al., 1994, also showed that 
in addition to the aforementioned tyrosine phosphorylation sites, p85 regulatory 
subunit can also be phosphorylated at Tyr508 following binding to PDGFRβ.  
PI3K can also be activated by RTKs via Ras association and the resulting binding of 
GTPase to the Ras-binding domain (RBD) of PI3K (Engelman et al. 2006). By an 
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extensively studied mechanism which has been reviewed by Hanada et al., 2004, the 
lipid second messenger (PIP3) generation thus results in the activation of a cascade 
of effector kinases that starts with PDK1 (phosphoinositide-dependent kinase-1) 
activation which phosphorylates the serine/threonine kinase, Akt (protein kinase B, 
PKB) (Burgering and Coffer 1995; Franke et al. 1995; Klippel et al. 1997) (Fig. 2.12), 
the atypical protein kinase C isoforms (δ, ε, and ζ) (Nakanishi et al. 1993; Toker et al. 
1994; Akimoto et al. 1996; Moriya et al. 1996), and the p70 S6 kinase (Chung et al. 
1994; Cheatham et al. 1994). All these kinases thus contribute to PDGFR signalling 
(Heldin et al. 1998).  
 
Figure 2.12  Activation and regulation of Akt. 
Image modified and adapted from Hers et al., 2011. See text for details. 
Other effectors of PI3K include small GTPases of the Rho family (Hawkins et al. 1995), 
JNK (Lopez-Ilasaca et al. 1997), and the serine/threonine kinase, mammalian target 
of rapamycin (mTOR), that forms two cellular complexes, mTORC1 and mTORC2, 
having distinct subunit composition and substrate selectivity (Saxton and Sabatini 
2017). In comparison to other effectors, the Akt member family are more commonly 
activated downstream of receptor-induced PI3K activation and phosphorylation of Akt 
is often the prototype readout of PI3K class I activation (Fruman et al. 2017). As such, 
  
  Literature review 
41 
the PI3K/Akt pathway is regarded as the prototype PI3K signalling (Carracedo and 
Pandolfi 2008). 
Akt, expressed as three isoforms, Akt1, Akt2 and Akt3, are encoded by PKBα, PKBβ 
and PKBγ genes respectively (Scheid and Woodgett 2001; Vivanco and Sawyers 
2002). Expression of these three isoforms are broad while sharing the same structure 
consisting of an amino-terminal PH domain, a central serine/threonine catalytic 
domain, and a short carboxyl-terminal regulatory domain (Vivanco and Sawyers 2002; 
Liu et al. 2009). Activation of Akt thereby begins with its translocation to the plasma 
membrane, facilitated by docking of the PH domain (in the N-terminal region of Akt) to 
PIP3 (which has been generated on the plasma membrane’s inner leaflet in response 
to PI3K activation) on the membrane (Andjelković et al. 1997; Bellacosa et al. 1998; 
Liu et al. 2009). Subsequent conformational changes in Akt thus exposes two 
indispensable amino acid residues (Thr308 and Ser473) for phosphorylation (Alessi, 
Deak, et al. 1997; Heldin et al. 1998; Stephens et al. 1998). Full activation of Akt 
therefore requires phosphorylation of both Thr308 (in the activation loop by PDK1) and 
Ser473 (in the carboxyl-terminal hydrophobic motif by putative PDK2) (Fig. 2.12) 
(Alessi, James, et al. 1997; Stokoe et al. 1997; Stephens et al. 1998; Vanhaesebroeck 
and Alessi 2000). Several potential PDK2s have been recognised, including PKCβ2, 
ILK (integrin-linked kinase), ATm (ataxia telangiectasia mutated), DNA-dependent 
protein kinase (DNA-PK) and Akt itself (Scheid and Woodgett 2001; Feng et al. 2004); 
however, the source of PDK2 in most situation still remains the mTOR–rictor 
(rapamycin insensitive companion of mTOR) complex (mTORC2) (Sarbassov et al. 
2005). So once phosphorylation and activation of Akt occurs, it phosphorylates up to 
about 100 substrates, thus regulating various cellular functions (Hanada et al. 2004; 
Carracedo and Pandolfi 2008). 
First, by phosphorylating and inhibiting important pro-apoptotic proteins, such as 
caspase 9, mouse double minute 2 (MDM2), Bcl-2 associated agonist of cell death 
(BAD), and FOXOs (the forkhead box family of TFs which plays a vital role in PDGFR 
signalling), Akt is able to wield a strong anti-apoptotic effect, (Hanada et al. 2004; 
Carracedo and Pandolfi 2008). It is also able to regulate cell cycle and survival 
(through p21 and MDM2), and regulate metabolism (Hanada et al. 2004; Engelman et 
al. 2006). However, PDGF-mediated anti-apoptotic effect was shown by Romashkova 
and Makarov, 1999 to be reliant on Akt induced NF-kB activation [which binds and 
activates the IkB kinase (IKK)] but this finding was disputed by Rauch et al., 2000 and 
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Peppel et al., 2005 where they showed that PDGF-mediated NF-kB activation is 
insignificant in comparison to actual NF-kB stimuli such as TNFα. 
Second, Akt is able to activate proliferation of cells by p27 inactivation  (Fujita et al. 
2002) and inhibition of glycogen synthase kinase 3 (GSK3)-mediated Myc and cyclin 
D1 inhibition (Scheid and Woodgett 2001; Vivanco and Sawyers 2002; Manning and 
Cantley 2007). In addition, activated PI3K pathway can also regulate the following 
effects in response to PDGF; differentiation, polarity and motility, transcription, protein 
synthesis, vesicle trafficking, glucose homeostasis, promotion of actin reorganisation 
(Hu et al. 1995; Bart Vanhaesebroeck et al. 1997; Vivanco and Sawyers 2002; Bader 
et al. 2005; Engelman et al. 2006; Manning and Cantley 2007; Hemmings and 
Restuccia 2012).  
Numerous proteins have been recognised as negative regulators of PI3K activation 
intensity but the main regulator being, phosphatase PTEN (also referred to as 
MMAC1), that tightly regulates cellular level of PIP3 (Cantley and Neel 1999; Cully et 
al. 2006; Carracedo and Pandolfi 2008). Initially, the PTEN homologue deleted on 
chromosome TEN was identified as a candidate tumor suppressor mutated and lost in 
various cancers (Li and Sun 1997; Steck et al. 1997) until it was characterised as a 
lipid phosphatase that hydrolyses the phosphate group (transferred by PI3K) in the 3' 
position of phosphoinositides making it in control of PI3K signal termination (Maehama 
and Dixon 1998; Stambolic et al. 1998; Wu et al. 1998; Carracedo and Pandolfi 2008) 
(Fig. 2.12). NHERF (EBP50) and NHERF-2 adaptor proteins recruit PTEN to the 
PDGFR complexes (Takahashi et al. 2006) while binding via two PDZ domains to the 
C-terminus of the receptor (Maudsley et al. 2000), disrupting this complex thus induces 
PI3K signalling (Demoulin et al. 2003; Takahashi et al. 2006). Functionally, PTEN is 
able to antagonise PI3K’s activity via its built-in lipid phosphatase activity by reducing 
the cellular level of PIP3 via the conversion of PIP3 back to PIP2 (Vivanco and 
Sawyers 2002; Liu et al. 2009) (Fig. 2.12). PTEN levels are transcriptionally regulated 
by PI3K (Carracedo and Pandolfi 2008) as such any PTEN loss results in dysregulated 
PI3K signalling pathway, which can lead to cancer (Cully et al. 2006).  
Downstream of PI3K, Akt activation can also be negatively regulated by different 
identified proteins. While Thr308 is primarily dephosphorylated by protein 
phosphatase 2A (PP2A), Ser473 is dephosphorylated by PH domain leucine-rich 
repeat protein phosphatase (PHLPP1/2) (Fig. 2.12) (Andjelković et al. 1996; Bayascas 
and Alessi 2005; Gao et al. 2005; Brognard et al. 2007). Additionally, Tribbles 
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homologue 3, a pseudo-kinase, binds and inhibits Akt, causing insulin resistance (Du 
et al. 2003), while the carboxyl-terminal modulator protein, (CTMP) specifically binds 
to the carboxyl-terminal regulatory domain of PKBα at the plasma membrane, thus 
reducing the activity of PKBα by inhibiting Thr308 and Ser473 phosphorylation (Maira 
et al. 2001). As a result of the vital role of Akt in an array of fundamental cellular 
processes, dysregulation of its kinase, inevitably would be associated with numerous 
diseases including cancer and cancer susceptibility syndromes, insulin and non-
insulin dependent diabetes, neurological and cardiovascular diseases (Carracedo and 
Pandolfi 2008; Hers et al. 2011).  
2.5 Crosstalk between the signalling pathways 
In response to PDGF stimulation, a number of signalling pathways are initiated, some 
of which have been discussed. These signalling pathways are however not linear as 
extensive cross-talk occur between them (Eger 2016). For example, PI3K associates 
with Ras, forms a complex to mutually activate each other (Rodriguez-Viciana et al. 
1994; Hu et al. 1995; Klinghoffer et al. 1996). Additionally, Ras mediates some 
particular PI3K responses (Satoh et al. 1993; Hu et al. 1995). Besides, Ras also 
activates the small GTP binding proteins, Rac, Rho, and Cdc42 (Khosravi-Far et al. 
1995; Olson et al. 1995; Qiu et al. 1995, 1997). As a result, a given signal transduction 
pathway can display different degrees of importance for a particular response 
depending on the different signal transduction molecules present in different cells 
(Heldin et al. 1998). 
2.6 Modulation and regulation of PDGFR signalling  
Growth factor signalling, inevitably must be tightly regulated, as a result, PDGFR 
signalling is thoroughly regulated by feedback control mechanisms (Heldin et al. 1998; 
Andrae et al. 2008; Rönnstrand 2010; Borkham-Kamphorst and Weiskirchen 2016). 
One example is Ras-GAP, that negatively regulates Ras, also binds through its SH2 
domain to PDGFRβ (Fantl et al. 1992). Another example is deployed through cAMP 
synthesis induction. PDGF-stimulation results in an increase in intracellular levels of 
cAMP (Heldin et al. 1998), through a mechanism that involves phospholipase A2 
activation mediated by MAPK; ultimately, this results in arachidonic acid release, 
prostaglandin E2 synthesis by cyclo-oxygenase and subsequently adenylyl cyclase 
activation (Graves et al. 1996). The expression of cox enzyme in SMCs is thus a 
determining factor for which direction MAPK pathway activation goes, either leading 
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to stimulation or inhibition of proliferation (Bornfeldt et al. 1997). cAMP-dependent 
protein kinase activation thus inhibits growth in various cells by  inhibiting a number of 
pathways including; the eukaryotic initiation factor 4E (Graves et al. 1995); the MAPK 
(via Raf-1 inhibition or MAPK phosphatase-1 induction) (Heldin et al. 1998); cyclin 
expression and cyclin-dependent kinases (Gagelin et al. 1994; Kato et al. 1994); and 
the p70 S6 kinase (Graves et al. 1995; Monfar et al. 1995).  
Another remarkable feature in PDGFR signalling is the simultaneous occurrence of 
stimulatory and inhibitory signals, utmost response of which is dependent on the 
balance between these signals (Heldin et al. 1998; Borkham-Kamphorst and 
Weiskirchen 2016). An example is the simultaneous binding to activated PDGFRs of 
the Grb2/SOS1 complex (that activates Ras) and of RasGAP (that inactivates Ras) 
(Heldin et al. 1998; Heldin and Lennartsson 2013). 
2.6.1 Cbl mediated ubiquitination and degradation 
A major pathway for RTK protein expression regulation is via receptor ubiquitination, 
which targets them for degradation. Thus, ubiquitin E3 ligase, Cbl, is one of the most 
important ubiquitination regulator of the PDGFRs (Bonita et al. 1997; Miyake et al. 
1999). Upon PDGFR activation, diverse mechanisms recruit Cbl to the receptor and 
induces ubiquitination of the receptor which activates endocytosis (Joazeiro et al. 
1999; Lennartsson et al. 2006). Cbl thus interacts with RTKs either directly through 
the binding of its tyrosine kinase binding (TKB) domain to the receptor or indirectly via 
Grb2 adaptor protein. However, the direct binding via its TKB domain is the major path 
(Bonita et al. 1997) where it associates with activated PDGFRβ by binding to Tyr1021 
in the carboxyl-terminus of the receptor (Reddi et al. 2007).  
Cbl recruitment therefore results in its phosphorylation via Src family kinases and 
ubiquitination of lysine residues on target proteins, this ultimately labels the proteins 
for lysosomal degradation through the endosomal sorting complex (Haglund et al. 
2003). The tyrosine binding site for Cbl is also the docking site for PLCγ-1, which leads 
to competitive binding, as a result, cells lacking Cbl show increased PLCγ-1 activation 
and increased PDGF-induced chemotaxis (Rönnstrand 2010). Additionally, PDGFRβ 
mutants with reduced ability for ubiquitination were seen to have a longer half-life, a 
result of slower degradation (Mori et al. 1992). Cbl degradation is facilitated by the 
adaptor protein, Alix, which binds to the C-terminal domain of PDGFRβ, thus 
preventing receptor ubiquitination and stabilising it (Lennartsson et al. 2006). 
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2.6.2 Dephosphorylation of the PDGFR 
Given that tyrosine phosphorylation mediates essential diverse physiological 
responses, it must therefore be thoroughly controlled. Protein tyrosine phosphatases 
(PTPs) are key players that mediate this regulation. Most PTPs negatively regulate by 
dephosphorylating receptors and downstream targets, thus leading to signal 
termination. PTP’s are known to exhibit a certain level of specificity by recognising 
specific target sequences that vary between PTPs (Rönnstrand 2010). A number of 
PTP’s have thus been shown to be related to PDGFR signalling and these include; 
low-molecular weight PTP (LMW-PTP), PTEN, PTP1B, T-cell PTP, transmembrane 
tyrosine phosphatase CD45, density-enhanced phosphatase-1 (DEP-1, also called 
rPTP-h or CD148) and SHP-2 (also called PTP1D or Syp) (Mooney et al. 1992; Way 
and Mooneys 1993; Kang 2007). 
SHP-2, via its SH2 domain, binds to PDGFRβ, dephosphorylates it and its substrates 
(Lechleider et al. 1993; Heldin et al. 1998). T-cell PTP is expressed ubiquitously, 
regardless of its name (Rönnstrand 2010) and Y1021 in the PDGFRβ (docking site for 
PLCγ-1) was recognised as its target using phospho-specific antibodies directed 
against individual sites in the PDGFRβ and mouse embryonal fibroblasts carrying a 
targeted deletion of T-cell PTP (Persson et al. 2004; Heldin and Lennartsson 2013). 
As expected, cells deficient in T-cell PTP, showed an increase in PLCγ-1 
phosphorylation (Rönnstrand 2010). Overexpression of the LMW-PTP was also 
shown to inhibit phosphorylation of PDGFR and mitogenic stimulation (Berti et al. 
1994) while a mutated, catalytically inactive phosphatase complexes with activated 
PDGFR (Chiarugi et al. 1995). PTEN was shown to dephosphorylate activated 
PDGFR with a resultant decrease in PDGF-induced DNA-synthesis (Mahimainathan 
and Choudhury 2004). 
2.6.3 Receptor signalling regulation by serine/threonine phosphorylation 
Asides tyrosine dephosphorylation on RTKs and their respective degradation, 
serine/threonine phosphorylation is however another mechanism by which  a number 
of RTKs have been controlled (Rönnstrand 2010). PDGF-BB-induced PDGFRβ 
phosphorylation was studied and a sharp increase in serine phosphorylation was seen 
where this effect was blocked by casein kinase 1 inhibitor (CKI is a serine/threonine 
kinase) (Bioukar et al. 1999; Rönnstrand 2010). Another serine/threonine kinase 
known to regulate the kinase activity of PDGFRs is G-protein-coupled receptor kinase-
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2 (GRK2). PDGFRβ is phosphorylated at Ser1104 in the carboxyl-terminal end of the 
protein by GRK2 thus interfering with the binding of NHERF (Hildreth et al. 2004). 
Owing to NHERF’s ability to mediate PDGF-induced receptor dimerization, binding of 
GRK2 thus results in a decrease in PDGFRβ activation and downstream targets like 
Akt (Rönnstrand 2010). A-Raf is also another member belonging to the same family 
as the serine/threonine kinase, Raf-1. A-Raf occurs in a preformed complex with 
PDGFRβ, regulating the receptor’s activity (Mahon et al. 2005). Expression of a 
partially active mutant of A-Raf was shown to result in reduced PDGFRβ 
phosphorylation selectively at Y1021 and Y857, the site of interaction with PLCγ-1 and 
the activation loop site respectively (Rönnstrand 2010). 
2.6.4 Spatiotemporal cellular regulation of PDGFRs  
The synthesis of PDGFRs occur in the the endoplasmic reticulum from where they 
become heavily N- and O-glycosylated in the Golgi (Demoulin and Essaghir 2014). 
Following synthesis, they are not evenly distributed throughout the cell membrane, but 
rather have been found to be concentrated in different cell membrane structures such 
as lipid rafts, clathrin-coated pits, and caveolae (clear-cut membrane invaginations 
involved in endocytosis) (Liu et al. 1996; Demoulin and Essaghir 2014).  
Using image correlation spectroscopy, Wiseman et al., 1997, could also confirm the 
clustering of PDGFRs in the absence of ligand. Upon ligand binding, the ligand-
receptor complex become internalised in the endosomes in a manner dependent on a 
clathrin and dynamin through a process that also partially depends on the receptor’s 
kinase activity - of particular importance for this activity is auto-phosphorylation of 
Tyr579 in the JM (Sorkin et al. 1991; Mori et al. 1994), in addition to  the receptor-PI3K 
interaction (Joly et al. 1994). Signalling is continued in early endosomes (Wang et al. 
2004; Kawada et al. 2009; Muratoglu et al. 2010), until the ligand dissociates from the 
receptor (caused by a decrease in pH) (Heldin and Westermark 1999; Heldin and 
Lennartsson 2013) and the receptor is recycled back to the cell membrane in a PKC-
dependent manner (Heldin and Westermark 1999; Hellberg et al. 2009), or in the 
alternate, the ligand-receptor complex is degraded (Heldin and Westermark 1999). 
Though the recycling of PDGFRβ, but not PDGFRα, have been seen in TC-PTP 
(negatively regulates PDGFRβ phosphorylation) deficient cells (Persson et al. 2004; 
Karlsson et al. 2006), the latter pathway (of degradation), however seems to be 
predominant in the studied cell types (Heldin and Westermark 1999). Most of the 
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internalised PDGFRs undergo degradation by fusion of endosomes with multi-
vesicular bodies and lysosomes (lysosomal degradation) (Heldin et al. 1982; Sorkin et 
al. 1991; Mori et al. 1995; Heldin and Westermark 1999), or are cytoplasmically 
degraded in proteasomes, processes that are facilitated by poly-ubiquitination of the 
receptors (Heldin et al. 1982; Mori et al. 1992, 1995).  
Thus, activated receptors induced by ligand binding will be deactivated by degradation 
within half an hour to one hour after internalisation (Sorkin et al. 1993). Specifically, in 
this activated state, PDGFRα have been reported to have an half-life of approximately 
5 minutes (Rosenkranz et al. 2000) where the half-life of PDGFRβ is said to be 
seemingly 6 times longer (around 30 minutes) while in resting cells, half-lives range 
from approximately 2 hours for PDGFRβ to around 3 hours for PDGFRα (Coats et al. 
1994). 
2.7 Role of PDGFs in physiology and disease 
Clear insights into PDGF’s physiological functions have emerged from genetic studies 
in mice targeting both PDGFs and their receptors. An overview of mouse mutants and 
their phenotypes have been reviewed in Hoch and Soriano 2003; Betsholtz 2004.  
Overall, from these genetic studies, the PDGF/PDGFR system is important during 
embryogenesis, mostly in embryonic blood vessel growth, and organogenesis (Heldin 
and Westermark 1999; Demoulin and Essaghir 2014; Manzat Saplacan et al. 2017). 
The proof for this vital role during embryonic development stemmed from the discovery 
that that deletion or null mutation of either receptor is embryonically lethal (Boström et 
al. 1996; Soriano 1997; Betsholtz 2003; Tallquist and Kazlauskas 2004) where 
PDGFRα knockouts have shown the most severe phenotype (Soriano 1997; Betsholtz 
2003; Ding et al. 2004).  
Signalling through PDGFRα is thus required for the development of the intestinal villus, 
facial skeleton, lungs, astrocytes, and oligodendrocytes. It is also necessary for 
spermatogenesis, hair follicle morphogenesis, in the regulation of the development 
and maturation of non‐neuronal neural crest and chondrocytes (Fruttiger et al. 1999; 
Karlsson et al. 1999, 2000; Östman and Heldin 2001; Boström et al. 2002; Tallquist 
and Kazlauskas 2004; Rönnstrand 2010). 
Signalling through PDGFRβ is involved in recruiting pericyte to capillaries, maturation 
of white adipocytes, SMCs development in vessels, as well as mesangial cells 
development in the kidney (Levéen et al. 1994; Soriano 1994; Andrae et al. 2008; 
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Rönnstrand 2010). It also regulates interstitial fluid pressure, and can therefore control 
fluid transport from the vessels to surrounding tissues (Heuchel et al. 1999). 
In adults, the physiological function of PDGFR signalling is seen in tissue repair and 
wound healing via the stimulation of cells like SMCs, fibroblasts, and various 
inflammatory cells (Robson et al. 1992; LeGrand 1998; Heldin and Westermark 1999; 
Rönnstrand 2010). 
PDGF functions have thus been associated with or linked to a wide range of diseases 
that have been broadly classified into three; tumours, vascular diseases and fibrosis 
which have been reviewed extensively in Andrae et al. 2008. 
In tumours originating from PDGFR+ cells such as in glioblastomas and sarcomas 
(Hermanson et al. 1992; Smits et al. 1992). 
Vascular diseases like atherosclerosis and restenosis (Ross 1993; Rutherford et al. 
1997; Raines 2004), pulmonary hypertension (Humbert et al. 1998; Balasubramaniam 
et al. 2003; Schermuly et al. 2005), and in retinal vascular diseases such as 
proliferative vitreoretinopathy, proliferative diabetic retinopathy, and CNV (Akiyama et 
al. 2006; Jo et al. 2006). 
Fibrotic diseases like pulmonary fibrosis (both PDGFRα and PDGFRβ) (Yi et al. 1996; 
Hoyle et al. 1999), liver fibrosis (and its end stage cirrhosis) (PDGFRβ only) (Pinzani 
et al. 1994, 1996; Bonner 2004), dermal fibrosis (Bonner 2004; Distler et al. 2007), 
renal fibrosis (Johnson et al. 1992; Tang et al. 1996; Floege et al. 1999), and cardiac 
fibrosis (Pontén et al. 2005; Tuuminen et al. 2006). 
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CHAPTER THREE: MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Cells 
Table 3.1  Cell lines and primary cells 
Cell lines Origin 
BV-2 murine microglial cell line 
 
 
 
661W photoreceptor cell line 
Murine primary microglial cultures isolated from 
one week old C57BL/6 mice and infected with a 
v-raf/v-myc recombinant retrovirus (Blasi et al. 
1990) 
Prof. Muayyad Al-Ubaidi, University of Oklahoma 
Health Sciences Center, Oklahoma, USA 
Primary cells Origin 
Primary microglial cells Mixed glial cultures isolated from the brains of 1-
2 day old C57BL/6J mice (Spittau et al. 2013) 
 
3.1.2 Culture media 
Table 3.2  Reagents and culture media formula 
Cell culture reagents Manufacturer, Cat. No 
Antibiotic/Antimycotic Solution (100x), Stabilised Sigma-Aldrich, #A5955 
Dulbecco's Modified Eagle Medium - HG (DMEM-HG) Sigma-Aldrich, #D6429 
Dulbecco's Phosphate-Buffered Saline (DPBS) Gibco, #14190-094 
Fetal Calf Serum (FCS) Gibco, #10270-106 
Hank's Balanced salt Solution (HBSS) Gibco, #14025092 
L-Glutamine (200mM) Gibco, #25030081 
Penicillin/Streptomycin Gibco, #15140-122 
Roswell Park Memorial Institute (RPMI) 1640 medium Gibco, #21875034 
Trypsin/EDTA Sigma-Aldrich, #T3924 
β-mercaptoethanol 
Opti-MEM I 
Sigma-Aldrich, #M-7154 
Gibco, #31985-070 
Cells Media Formula 
BV-2  murine microglial cell line RPMI 1640 
  5 % FCS 
  1 % L-Glutamine 
  1 % Penicillin/Streptomycin 
  195 nM β-mercaptoethanol 
661W  photoreceptor-like cell line 
  
DMEM HG 
5 % FCS 
  1 % Penicillin/Streptomycin 
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3.1.3 Buffers and solutions 
Table 3.3  Recipes for buffers and solutions 
Buffer/Solution Formula Manufacturer, Cat. No 
1x PBS, pH 7.4 
137 mM Sodium chloride 
(NaCl) 
  
  
2.7 mM Potassium chloride 
(KCl) 
Amresco, #E404 
  
10 mM Disodium phosphate 
(Na2HPO4) 
1 tablet/100 ml ddH2O 
  
1.8 mM Monopotassium 
phosphate (KH2PO4) 
  
1x TBS-T 150 mM NaCl Merck, #106400 
  200 mM Tris Roth, #4855.3 
  0.1 % v/v Tween® 20 Merck, #822184 
Antibody solution 
(Western Blot) 
5 % w/v Bovine serum 
albumin (BSA) 
Roth, #3854.2 
  in 1x TBS-T see above 
Membrane blocking 
buffer 
5 % w/v non-fat milk powder  Roth, #T145.3 
  in 1x TBS-T see above 
RIPA buffer 50 mM Tris-HCl pH 7.4 see above 
  150 mM NaCl see above 
  1 % v/v NP-40 Calbiochem, #492016 
  
0.5 % w/v Sodium 
deoxycholate 
Sigma-Aldrich, #D6750 
  
0.1 % w/v Sodium dodecyl 
sulfate (SDS) 
Serva, #20765.03 
  
2mM 
Phenylmethanesulfonyl 
fluoride (PMSF) 
Applichem, #A0999 
  
Complete™ mini protease 
inhibitor  
Roche, #11836153001 
  
(±) 1 % Phosphatase 
inhibitor cocktail 
Cell Signalling 
Technology (CST), #5870 
Running buffer 192 mM Glycine AppliChem, #A1067 
  250 mM Tris see above 
  1 % Antibiotic/Antimycotic 
Primary microglial cells DMEM HG 
  10 % FCS 
  1 % Penicillin/Streptomycin 
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  0.1 % w/v SDS see above 
Transfer buffer 192 mM Glycine see above 
  250 mM Tris see above 
  20 % v/v Methanol Chemsolute, #1437.2511 
Stripping buffer, pH 2.2 15g Glycine see above 
  1g SDS see above 
  
10mL Tween® 20 
in 1L ddH2O 
see above 
 
Antibody solution 2.5 % Goat serum Abcam, #AB7481 
Immunocytochemistry 0.1 % v/v Triton X-100 Sigma-Aldrich, #T8787 
(ICC) in 1x PBS see above 
Blocking buffer (ICC) 10 % Goat serum see above 
  0.3 % v/v Triton X-100 see above 
  in 1x PBS see above 
Wash buffer, pH 7.2-7.4 0.05 % v/v Tween® 20 see above 
  in 1x DPBS see above 
Reagent diluent 
(filtered), pH 7.2-7.4  
1 % w/v BSA see above 
  in 1x DPBS see above 
Stop solution  96 % H2SO4 Roth, #4623 
 (2N H2SO4) in dd H2O (1: 18 dilution)   
 
3.1.4 SDS-Poly Acrylamide Gel Electrophoresis (PAGE) 
Table 3.4  Recipes for SDS-PAGE gels 
Gels Formula Manufacturer, Cat. No 
Resolving gel 8 % (or 15 %) v/v Acrylamide Roth, #A124.1 
  0.4 M Tris pH 8.8 see above 
  0.1 % w/v SDS see above 
  0.1 % w/v Ammonium persulfate (APS) Sigma-Aldrich, #A3678 
  0.01 % v/v TEMED Roth, #2367.1 
Stacking gel 5 % v/v Acrylamide see above 
  0.125 M Tris pH 6.8 see above 
  0.1 % w/v SDS see above 
  0.1 % w/v APS see above 
  0.005 % v/v TEMED see above 
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3.1.5 Kits 
Table 3.5  Commercially available kits 
Kit Manufacturer, Cat. No 
CellTiter 96® Cell Proliferation Assay Promega, #G4000 
Caspase-Glo® 3/7 Assay Promega, #G8090 
DCFDA Cellular ROS Detection Assay kit Abcam, #ab113851 
Mouse CCL2/JE/MCP-1 DuoSet® ELISA R&D SYSTEMS, #DY479-05 
NucleoSpin® RNA isolation kit Macherey-Nagel, #740955 
Pierce™ BCA Protein Assay kit ThermoFisher Scientific, #23225 
RevertAid RT Kit ThermoFisher Scientific, #K1691 
SignalFire™ Elite ECL Reagent CST, #12757 
Takyon™ No Rox Probe 2x MasterMix dTTP Eurogentec, #UF-NPMT-B0701 
Takyon™ No Rox SYBR® 2x MasterMix dTTP Eurogentec, #UF-NSMT-B0710 
 
3.1.6 Antibodies 
Table 3.6  Primary and secondary antibodies and stains 
Antibodies and stains Dilution Manufacturer, Cat. No 
Anti-PDGFB Rabbit polyclonal 
1:1000 (WB) 
1:100 (ICC) 
Abcam, #ab23914 
PDGF Receptor β (28E1) Rabbit 
monoclonal 
1:100 
Cell Signalling Technology, 
#3169 
Phospho-PDGF Receptor β 
(Tyr1009) (42F9) Rabbit 
monoclonal 
1:1000 
Cell Signalling Technology, 
#3124 
Anti-Iba1, Goat polyclonal 1:100 Abcam, #ab5076 
SAPK/JNK Antibody Rabbit 
Polyclonal 
1:1000 
Cell Signalling Technology, 
#9252 
Phospho-SAPK/JNK 
(Thr183/Tyr185) (81E11) Rabbit 
monoclonal 
1:1000 
Cell Signalling Technology, 
#4668 
Akt (pan) (C67E7) Rabbit 
monoclonal 
1:1000 
Cell Signalling Technology, 
#4691 
Phospho-Akt (Ser473) (D9E) XP® 
Rabbit monoclonal 
1:2000 
Cell Signalling Technology, 
#4060 
p44/42 MAPK (Erk1/2) (137F5) 
Rabbit monoclonal 
1:1000 
Cell Signalling Technology, 
#4695 
Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (D13.14.4E) XP® 
Rabbit monoclonal 
1:2000 
Cell Signalling Technology, 
#4370 
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p38 MAPK (D13E1) XP® Rabbit 
monoclonal 
1:1000 
Cell Signalling Technology, 
#8690 
Phospho-p38 MAPK 
(Thr180/Tyr182) (D3F9) XP® 
Rabbit monoclonal 
1:1000 
Cell Signalling Technology, 
#4511 
β-Actin (C4) Mouse monoclonal 1:500 
Santa Cruz Biotechnology, sc-
47778 
Alexa Fluor® 488 goat anti-rabbit 
IgG, polyclonal 
1:2000 
ThermoFisher Scientific, 
#A11008 
Alexa Fluor® 488 donkey anti-goat 
IgG, polyclonal 
1:1000 
ThermoFisher Scientific, 
#A11055 
goat anti-rabbit IgG-HRP, 
polyclonal 
1:4000 Agilent Dako, #P0448 
goat anti-mouse IgG-HRP, 
polyclonal 1:4000 
Agilent Dako, #P0447 
DAPI 0.1 µg/ml Invitrogen, #D1306 
Phalloidin-TRITC 0.1 µg/ml Sigma-Aldrich, #P1951 
 
3.1.7 Primers and probes 
Table 3.7  TaqMan (Probe-based) and SYBR® Green primers 
TaqMan primers 
Gene Forward primer (5' → 3') Reverse primer (5' → 3') UPL Probe # 
m Atp5b ggcacaatgcaggaaagg tcagcaggcacatagatagcc 77 
m Pdgfa gatgaggacctgggcttg gatcaactcccggggtatct 68 
m Pdgfb cggcctgtgactagaagtcc gagcttgaggcgtcttgg 32 
m Pdgfc tgtgtcccacgtaaagttacaaa tcagtgagtgacttatgcaatcc 109 
m Pdgfrα ttaagccggtcccaacct ctagacctggctgtgggttt 83 
m Pdgfrβ ggcttctgggtgaaggctat gcaggatggtcactcctcag 62 
m Ccl2 catccacgtgttggctca gatcatcttgctggtgaatgagt 62 
m Cox2 gatgctcttccgagctgtg ggattggaacagcaaggattt 45 
m Tnfα ctgtagcccacgtcgtagc ttgagatccatgccgttg 78 
m Nox1 cttgcaccgattgctttttat cattagatgggtgcatgacaa 3 
m Ccl3 tgcccttgctgttcttctct gtggaatcttccggctgtag 40 
m Ccl5 tgcagaggactctgagacagc gagtggtgtccgagccata 110 
m P2ry12 cccggagacactcatatcctt gtcccaggggagaaggtg 102 
m Cd36 ttgaaaagtctcggacattgag tcagatccgaacacagcgta 6 
m Trem2 tgggacctctccaccagtt gtggtgttgagggcttgg 18 
m Msr1 ctggacaaactggtccacct gtccccgatcacctttaaca 1 
m Scarb1 cttcatgacacccgaatcct caaacacccttgattcgttg 41 
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m Gpx1 gtttcccgtgcaatcagttc caggtcggacgtacttgagg 2 
m Gpx4 ccgtctgagccgcttactta gctgagaattcgtgcatgg 71 
m Gsr actatgacaacatccctactgtgg cccatacttatgaacagcttcgt 83 
m Catalase ccttcaagttggttaatgcaga caagtttttgatgccctggt 34 
m Sod1 caggacctcattttaatcctcac tgcccaggtctccaacat 49 
m Sod2 tgctctaatcaggacccattg gtagtaagcgtgctcccacac 3 
m Il-6 gatggatgctaccaaactggat ccaggtagctatggtactccaga 6 
m Il-1β agttgacggaccccaaaag agctggatgctctcatcagg 38 
SYBR® Green Primers 
Gene Forward primer (5' → 3') Reverse primer (5' → 3')   
m Actin aggaggagcaatgatcttg agacctgtacgccaacacag   
m Nox2 ggttccagtgcgtgttgct gcggtgtgcagtgctatcat   
 
3.1.8 siRNA sequences 
Table 3.8  ON-TARGERTplus SMARTpool siRNA sequences 
Gene Target sequence (5'-3') Antisense (5'-3') Cat. No 
Pdgfrα CCAGCGAGUUUAAUGUUUA UAAACAUUAAACUCGCUGG J-048730-05 
 AGGUACAGCUUAUGGAUUA UAAUCCAUAAGCUGCACCU J-048730-06 
  GAGACAGGUUCCAGUAGUU AACUACUGGAACCUGUCUC J-048730-07 
  UAUCGUGGCUGAAGGACAA UUGUCCUUCAGCCACGAUA J-048730-08 
Pdgfrβ CAGCGAGGUUUCACUGGUA UACCAGUGAAACCUCGCUG J-048218-05 
 GAACGACCAUGGCGAUGAG CUCAUCGCCAUGGUCGUUC J-048218-06 
  GGAAGCGUAUCUAUAUCUU AAGAUAUAGAUACGCUUGC J-048218-07 
  UAGAUUACGUGCCCAUGUU AACAUGGGCACGUAAUCUA J-048218-08 
 
3.1.9 General consumables 
Table 3.9  Consumables 
Consumables Manufacturer, Cat. No. 
Nitrocellulose membrane 0.45 µm Bio-Rad, #1620115 
1.5 ml micro tube Sarstedt, #72.690 
1.5 ml micro tube black Roth, #AA80.1 
12-well cell culture plates  Sarstedt, #83.3921 
15 ml reaction tube  Sarstedt, #62.554.502 
2 ml micro tube Sarstedt, #72.689 
30 µl Impact 384 tips Thermo Scientific, #7431 
50 ml reaction tube  Sarstedt, #62.554.254 
6-well cell culture plates  Sarstedt, #83.3920 
96-well microtitre plate  Sarstedt, #83.3924 
Biosphere R  filter tips 1000 µL  Sarstedt, #70.762.211 
Biosphere R  filter tips 2.5 µL  Sarstedt, #70.1130.212 
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Biosphere R  filter tips 200 µL  Sarstedt, #70.760.211 
Black clear-bottomed 96-well microtitre 
plates  
ThermoFischer Scientific, 
#611F96BK 
Cell Culture Dish, 100 x 20 mm Eppendorf®, #0030702115 
Cell scraper  Sarstedt, #83.1830 
Cover glasses 18x18mm  Th.Geyer, #7695023 
FrameStar® 384-well plates with seal 4titude, #4ti-0382 
Gloves  Dermagrip, #100176 
Nunc MaxiSorp® flat-bottom 96-well plates  ThermoFischer Scientific, #44-2404 
PCR stripes  Kisker Biotech, #G003-SF 
Steriflip-HV, 0.45 µm, PVDF, radio-sterilized Sigma-Aldrich, #SE1M003M00 
Superfrost Plus™ Microscope Slides 
ThermoFischer Scientific, 
#J1800AMNT 
T-75 culture flask  Sarstedt, #83.3911.002 
Vannas-Tübingen Spring Scissors Fine Science Tools, #15003-08 
White-walled 96-well microtiter plates  Costar, #3912 
 
3.1.10 Compounds, chemicals and reagents 
Table 3.10 Cytokines, compounds, chemicals and other reagents 
Cytokines, compounds and siRNAs Manufacturer, Cat. No. 
Recombinant human PDGF-AA PeproTech, #100-13A 
Recombinant human PDGF-AB PeproTech, #100-00AB 
Recombinant human PDGF-BB PeproTech, #100-14B 
Recombinant human PDGF-CC PeproTech, #100-00CC 
LPS from E. coli 0111:B4 Sigma-Aldrich, #L4391 
Anti-mouse CD140a (APA5), Functional Grade Invitrogen, #16-1401-82 
Anti-mouse CD140b (APB5), Functional Grade  Invitrogen, #16-1402-82 
Rat IgG2a kappa (eBR2a), Functional Grade Invitrogen, #16-4321-82 
U0126, MEK1 and MEK2 Inhibitor InvivoGen, #tlrl-u0126 
SP600125 PeproTech, #1295666 
LY294002, PI3K Inhibitor 
Mouse PDGFRα siRNA - SMARTpool, 5 nmol 
Mouse PDGFRβ siRNA - SMARTpool, 5 nmol 
Non-targeting pool 
InvivoGen, #tlrl-ly29 
Dharmacon, #L-048730-00-
0005 
Dharmacon, #L-048218-00-
0005 
Dharmacon, #D-001810-10-05 
Chemicals and reagents Manufacturer, Cat. No. 
5x siRNA Buffer Dharmacon, #B-002000-UB-100 
CellTracker™ CM-Dil Invitrogen, #C7001 
Dimethylsufoxide (DMSO) Serva, #20385.01 
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Ethanol 100% Applichem, #A3678 
Ethanol 70 % Applichem, #A2192 
Fluorescence Mounting Medium Dako, #S302380-2 
Isopropanol Merck, #100995 
Laemmli sample buffer  Bio-Rad, #161-0747 
Lipofectamine™ 3000 Transfection Reagent 
ThermoFisher Scientific, 
L3000015 
Methanol Chemosolution, #1437.2511 
PageRuler™ Plus Prestained Protein Ladder 
ThermoFisher Scientific, 
#26619 
PageRuler™ Prestained Protein Ladder 
ThermoFisher Scientific, 
#26616 
Poly-d-lysine Sigma-Aldrich, #P6407 
Micro particles based on polystyrene, dark blue, 
1µm 
Sigma-Aldrich, #51972-5ML-F 
RNase away Molecular Biopro., #70003 
Roti® HistoFix 4% Roth, #P087.4 
Substrate Reagent Pack R&D Systems®, #DY999 
 
3.1.11 Devices 
Table 3.11 Laboratory devices 
Devices Manufacturer 
Adventurer Pro balance Ohaus®  
ApoTome.2  Zeiss 
AxioCam MRC vert. A1 camera  Zeiss 
AxioCam MRm camera  Zeiss 
Centrifuge 5415 R  Eppendorf 
Centrifuge Mini Star  VWR International 
Explorer R Ex 124 balance  Ohaus®  
Galaxy 170S CO2 incubator New Brunswick Scientific 
Heraeus Labofuge 400 R  Thermo Scientific 
Imager.M2 microscope Zeiss 
Infinite® F200 Pro plate reader Tecan 
LightCycler® 480 Instrument II  Roche Applied Science 
Matrix™ Multichannel Pipette ThermoFisher Scientific 
Mini-Protean® Tetra System Bio-Rad 
MiniTrans-Blot® Cell Module Bio-Rad 
MSC-Advantage hood  Thermo Scientific 
MultiImageII Alpha Innotech 
NanoDrop 2000 Spectrophotometer  Thermo Scientific 
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Neubauer counting chamber  OptikLabor 
Orbital incubator S1500 Stuart®  
PCR workstation VWR International 
peQSTAR 2x cycler  peQlab 
See-saw rocker SSL4  Stuart®  
Thermomixer compact Eppendorf  
TW20 watherbath Julabo 
VisiLight® binocular VWR International 
Vortex-genie® Scientific Industries™ 
VWR Electrophoresis Power Source 250V VWR International 
 
3.1.12 Software 
Table 3.12 Software 
Software Manufacturer 
AlphaView FluorChem FC2 Cell Biosciences  
CSl Adobe Creative Suite  Adobe Systems 
GraphPad Prism version 7 GraphPad Software, Inc. 
ImageJ 1.50i  National Institutes of Health 
LightCycler® 480 software 1.5.1  Roche Applied Science 
Nanodrop2000/2000c software ThermoFisher Scientific 
Office Suite 2013 Microsoft Corporation 
Tecan i-control 1.9 PerkinElmer 
Zen 2012  Zeiss 
 
3.2 Methods 
3.2.1 Cell culture 
3.2.1.1 Maintenance and sub-culturing of cell lines 
Cell lines used in this study were murine BV-2 microglia and 661W photoreceptor cells. 
The cell lines were maintained appropriately in their respective media (Table 3.2) in T-
75 flasks at 37°C in a humidified atmosphere of 5% CO2. Cells were routinely sub-
cultured every 2 to 3 days depending on confluency.  BV-2 microglial cells were rinsed 
with 5ml sterile 1x DPBS and detached by gentle scraping in freshly pre-warmed 
media. 661W cells were detached by incubation with 5ml trypsin/EDTA (1x) at 37°C, 
5% CO2 for 5 minutes. Flasks were checked under the microscope to ensure cell layer 
dispersion before an equal volume of complete media was added to stop the trypsin 
reaction. The cell suspension was transferred to a 50ml falcon tube and centrifuged at 
1500 rpm for 5 minutes. Trypsin containing media was aspirated and cells re-
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suspended in fresh media. All cells were split at a 1:5 ratio and appropriate volume re-
suspended in flasks pre-filled with 10ml of complete media. Cells were maintained up 
to a maximum of 23 passages. 
3.2.1.2 Primary microglia cell culture 
Mixed glia cultures were prepared from 1-2 day old C57BL/6J pups as previously 
described by Spittau et al., 2013 with minor modifications. Briefly, pups were 
decapitated and isolated whole brains were rinsed in ice-cold HBSS twice. The brain 
surface were freed from blood vessels and meninges using fine forceps under the 
binocular microscope. Cleaned brains were enzymatically dissociated (by dicing into 
small pieces and immersion in a 2ml Eppendorf tube pre-filled with 1ml 1x 
trypsin/EDTA) for 15 minutes at 37°C in Eppendorf Thermomixer. Subsequently, an 
equal amount of ice-cold FCS previously supplemented with DNase at a final 
concentration of 0.5mg/ml were added. Brains were then mechanically dissociated 
with a 1000µl and then a 200µl pipette tip. Dissociated cells were centrifuged at 500 
RCF for 10 minutes, supernatants were discarded and cells re-suspended in 
appropriate media (Table 3.2). The cell suspension was transferred at a density of 2 
brains/T-75 flasks pre-coated with poly-D-lysine (1µg/cm2). The mixed glia culture was 
maintained at 37°C in a humidified atmosphere at 5% CO2. On the two successive 
days following isolation (i.e., DIV 2 and 3), cultures were washed twice with 1x DPBS 
and fresh complete medium was added. Microglial cells were then harvested from 
adherent astrocytes at around 10-14 days in-vitro, by shaking flasks at 250 rpm for 2-
3 hours at 37°C. The media containing microglial cells were collected in a 50ml falcon 
tube and centrifuged at 800 RCF or 10 minutes. Microglial cell purity was assessed by 
staining for ionized calcium-binding adaptor (Iba-1) protein, a microglia marker 
(Appendix fig. 1A). Harvested microglial cells were counted and seeded in 12-well 
culture plates for experiments.  
3.2.1.3 Cell seeding 
BV-2 cells were seeded either in 6-well culture plates at a density of 3x105 cells/well 
in 2ml media or in 12-well culture plates at a density of 2x105 cells/well in 1ml media 
unless otherwise indicated. Primary microglia cells were seeded in 12-well culture 
plates at a density of 2x105/well in 1ml media. Seeded cells were allowed to attach 
overnight, medium was changed prior to start of experiment and cells were treated 
according to the different experiments. 
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3.2.1.4 Cell treatment 
BV-2 cells: For the expression of PDGF ligands and their receptors, cells were treated 
with 50 and 100ng/ml LPS for 6 hours. For the pharmacological inhibition studies; in 
the first experiment, cells were treated with LPS 100ng/ml for 6 hours with or without 
30 minutes pre-treatment with 10µg/ml IgG, APA5 or APB5; in the second experiment, 
cells were treated with 50ng/ml recombinant human PDGF ligands for 3 hours with or 
without 1 hour pre-treatment with 10µg/ml APA5 or APB5.  
APA5 and APB5 are PDGFR blocking antibodies for Rα and Rβ respectively with IgG 
serving as the isotype control. APA5, APB5 and IgG were diluted in DPBS and the 
concentrations used were based on concentration testing. 
For western blot, in one experiment, cells were treated with 100ng/ml LPS in a time 
kinetic study (3, 6, 24 and 48 hours) while in separate experiments, cells were treated 
with 50ng/ml PDGF-BB also in a time kinetic study (5, 15, 30, 60, 120 and 180 
minutes).  
In the kinase pathway inhibition studies, cells were pre-treated with inhibitors specific 
for MEK (U0126, 10μM), JNK (SP600125, 10μM), and PI3K (LY294002, 10μM) for 1 
hour prior to 50ng/ml PDGF ligand treatment for 3 hours. The inhibitors were prepared 
(reconstituting in DMSO) according to product leaflet and stored in aliquots at -20°C 
where the final concentration of DMSO used on cells was less than 0.05%. The 
concentrations utilised for these small molecule kinase inhibitors were based on 
previously published data (Yao et al. 2009; Bethel-Brown et al. 2012) and cell 
cytotoxicity assay.  
For the indicated experiments, LPS was diluted in DPBS which served as the vehicle 
control. PDGF ligands were first reconstituted in water and further diluted in DPBS 
containing 0.1% BSA as carrier protein and this served as the vehicle control.  
661W cells: Cells were treated with microglia conditioned medium (MCM). Microglia 
conditioned medium was obtained from 24 hours of vehicle treated and 50ng/ml PDGF 
ligand treated BV-2 cells and were centrifuged at 4000 RCF for 10 minutes. 
Conditioned medium was carefully transferred and stored at -80°C until needed. 
Primary microglia cells: In one set of experiments, cells were treated with 50ng/ml 
recombinant PDGF ligands for 3 hours. In another set of experiment, cells were pre-
treated for 1 hour with kinase pathway inhibitors prior to 3 hours PDGF ligand 
treatment.  
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All experiments involving treatment of cells with recombinant PDGF ligands were done 
under serum-free conditions since the PDGF promoter is known to have serum 
response elements (Perez-Albuerne et al. 1993) and serum induces PDGF (Dhillon et 
al. 2007). 
3.2.2 MTT cell proliferation and or viability assay 
The MTT cell proliferation assay is a colorimetric assay measuring the rate of cell 
proliferation and conversely cell viability reduction when metabolic processes results 
in necrosis or apoptosis. It is based on the ability of mitochondrial dehydrogenase 
enzymes (Mosmann 1983) primarily succinate dehydrogenase to reduce the yellow 
water-soluble tetrazolium dye, 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) to its insoluble purple formazan (MTT-formazan) in metabolically active 
cells (Wang et al. 1996; Vajrabhaya and Korsuwannawong 2018). Because this 
reduction is only feasible in viable cells, the amount of purple formazan formed is 
proportional to the number of viable cells (Mosmann 1983). 
BV-2 microglial cells were seeded at a density of 10,000 cells/well in 100µl in 
transparent 96-well culture plates and allowed to attach overnight. Cytotoxic effects of 
increasing concentrations (1-30µg/ml) of APA5 and APB5 were evaluated for 48 hours 
(Appendix fig 2A and B). In separate experiments, cytotoxic effects of U0126, 
SP600125, and LY294002 at 10μM was also evaluated for 4 hours (Appendix fig. 2C). 
At the termination of experiments, 15µl of the dye solution was added to each well 
(avoiding skin or eyes contact as the dye solution is an irritant) and plates re-incubated 
at 37°C for 4 hours in a humidified 5% CO2 atmosphere. In each of the experiments, 
control wells (vehicle in culture medium without cells plus the tetrazolium reagent) 
were included in the set-up to test for chemical interference effect. Reaction was 
stopped by addition of 100µl solubilization solution/stop mix to each well, one hour 
after addition of solubilization solution/stop mix, plate was mixed to get a uniformly 
coloured solution while avoiding bubbles as this could cause interference with 
accurate recording of absorbance values. Absorbance measurements were taken with 
the Tecan Infinite® F200 pro microplate reader at a wavelength of 570nm and values 
of no-cell control were subtracted from all experimental wells to obtain corrected 
absorbance values. 
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3.2.3 Transcript analysis 
3.2.3.1 RNA Isolation 
Total RNA was extracted using the NucleoSpin® RNA Mini Kit according to the 
manufacturer’s instructions. At the termination of experiment and prior to addition of 
lysis buffer, culture medium was removed and the cells washed with 1x DPBS. Cells 
were thereafter lysed with 350µl of lysis buffer RA1 supplemented with 3.5µl of β-
mercaptoethanol as reducing agent. 
The lysis buffer inactivates RNases thus creating suitable binding conditions which 
favours adsorption of RNA to the silica membrane. Thereafter, rDNase solution is 
applied directly onto the silica membrane to remove contaminating DNA which also 
binds to the silica membrane. Subsequent washing steps with two different buffers 
aids to remove salts and other metabolites. 
In a final step, RNA is eluted from silica-based columns in 40µl RNase-free water and 
concentrations measured with 1µl using NanoDropTM spectrophotometer. Absorbance 
is proportional to the RNA concentration and nucleotides absorb ultraviolet light at 
260nm wavelength. Therefore, absorbance ratio at 260nm and 280nm is an 
assessment of the purity of DNA and RNA. Thus, a 260/280 ratio of approximately 2.0 
is accepted as “pure” for RNA samples and subsequently reverse transcribed. 
Samples were either reverse transcribed immediately or stored at -80°C until further 
use.  
3.2.3.2 Reverse transcription  
First-strand cDNA synthesis was performed with 0.1ng - 5µg of RNA in a 20µl final 
volume using the RevertAidTM H Minus First Strand cDNA synthesis kit. The resulting 
cDNA was diluted with nuclease-free water to a final concentration of 20ng/µl which 
was immediately used for quantitative PCR or stored at -20°C until further use. 
3.2.3.3 Quantitative PCR (qPCR) 
Quantitative amplifications of reverse transcribed (RT) cDNA were performed with the 
LightCycler® 480 Instrument II. The use of fluorescent signals affords the quantification 
of gene expression by the detection of the amplicon (PCR product) at every PCR cycle. 
In this study, TaqMan (also known as fluorogenic 5' nuclease assay) and SYBR® green 
I (SG) detection chemistries have been used for different genes.  
The TaqMan assay is based on the principle of the specific hybridisation of a dual-
labelled TaqMan (Holland et al. 1991) probe to the amplicon. At the 5' end of this 
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probe, is a fluorescent reporter dye while at the 3' end is a quencher dye and via 
complementary binding, the probe binds to the target sequence between the forward 
and the reverse primer at the initiation of reaction. The close proximity of the reporter 
and the quencher dye allows the suppression of the reporter fluorescence, thus, 
inhibiting signal. As the amplification primer is extended in the course of the reaction, 
the probe is cleaved by Taq polymerase, spatially separating the reporter and 
quencher dye, allowing reporter dye fluorescence detection. As the amount of target 
gene increases, the fluorescence intensity also increase and thus more probe 
cleavage (Butler 2012). The reaction component can be seen in Table 3.13. Incubation 
was done at 95°C to activate the polymerase and reaction was subjected to 40 
amplification cycles as in Table 3.14. Measurements were done in triplicates, run 
validity was confirmed with both positive and negative controls. 
Table 3.13 TaqMan qPCR components 
TaqMan Assay 
Reaction components Volume (µL) Conc. 
Template DNA (cDNA) 2.5 50 ng 
Forward primer 1 1 µM 
Reverse primer 1 1 µM 
Roche probe 0.125 125 nM 
2x Probe MasterMix 5 1x  
Nuclease-free ddH2O 0.375   
Total Mix/reaction 10   
 
Table 3.14 TaqMan qPCR program 
Program Name Temperature Time   
Initial denaturation 95 °C 5 minutes 1 cycle 
Cycling 
95 °C 15 seconds  
40 cycles 
60 °C 1 minute 
Cooling down 40 °C 20 seconds  1 cycle 
 
SYBR® Green I is a dsDNA-intercalating dye that binds the minor groove of dsDNA. 
Consequently, as PCR proceeds and amplification of target sequence is ongoing, 
every new copy of dsDNA produced is bound by the dye during the extension step 
and fluorescence intensity increases. Fluorescence intensity signal is therefore 
proportional to the amount of dsDNA in the reaction (Arya et al. 2005). Reaction 
components and qPCR program are presented in tables 3.15 and 3.16 respectively. 
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Table 3.15 SYBR® Green qPCR components 
SYBR® Green Assay 
Reaction components Volume (µL) Conc. 
Template DNA (cDNA) 2.5 50 ng 
Forward primer 1 0.5 µM 
Reverse primer 1 0.5 µM 
2x SYBR MasterMix 10 1x  
Nuclease-free ddH2O 5.5   
Total Mix/reaction 20   
 
Table 3.16 SYBR® Green qPCR program 
Program Name Temperature Time   
Pre-incubation 95 °C  5 minutes 1 cycle 
Amplification 
95 °C 10 seconds  
45 cycles 60 °C 10 seconds  
72 °C 10 seconds  
Melting curve 
95 °C 5 seconds  
1 cycle 65 °C 1 minute 
97 °C - 
Cooling 40 °C 30 seconds  1 cycle 
 
Data were normalised using Ct (Cp) values of the endogenous control. ATP synthase 
subunit- β (Atp5b) was used as endogenous control for TaqMan assay while actin was 
used as the endogenous control of SYBR® Green assay. The LightCycler® 480 
software 1.5.1 was used to run absolute quantification/2nd derivative max and 
advanced relative quantification analysis (which automatically calculates fold change 
in expression based on the 2-ΔΔCT method by Livak and Schmittgen, 2001 for both 
assays. In addition, Melt Curve genotyping analysis was run for SYBR® Green assay.  
3.2.4 Small interfering (siRNA)-mediated gene silencing 
siRNAs are short (approximately 21-25 nucleotides), non-coding double-stranded 
RNAs (dsRNA) that facilitate gene silencing through complementary targeting of the 
mRNA to be degraded. On the 3' end of each strand (sense/passenger and 
antisense/guide strand), siRNAs have  an overhang of 2 nucleotides (Gavrilov and 
Saltzman 2012). Because siRNAs are directly introduced into cells, the dicer (which 
cuts long pieces of dsRNA into the siRNAs) mechanics have already been by-passed 
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(Whitehead et al. 2009). Once in the cell’s cytoplasm, siRNAs get integrated into a 
multi-protein complex called RNA-induced silencing complex (RISC) having 
argonaute-2 as the main protein that executes the process of gene silencing  
(Hammond et al. 2001). Argonate-2 unwinds the dsRNA, with the passenger strand 
being cleaved off leaving the guide strand (i.e., strand with more stability at 5'-end) in 
the complex, which is now the activated RISC (Matranga et al. 2005). The antisense 
strand of the siRNA now guides and positions the RISC complex on the target mRNA 
and with the aid of argonate-2, the target mRNA is degraded resulting in gene silencing 
(Ameres et al. 2007). The active RISC-siRNA complex is then recycled for subsequent 
mRNA degradation further propagating the process of gene silencing (Whitehead et 
al. 2009). 
In this study, ON-TARGETplus SMART pool siRNAs were used. These siRNAs 
combine four different siRNA sequences per gene (Table 3.8) to reduce off target 
effects. siRNAs targeted against mouse PDGFRα and PDGFRβ were used while the 
non-targeting negative control pool served as control siRNA. A 20µM stock solution of 
these siRNAs were prepared from a lyophilized vial of 5nM by reconstituting in 250µl 
of 1x siRNA buffer (diluted from a 5x stock solution with RNase free water). The 20µM 
stock solution of siRNAs were aliquoted (in volumes of single use to avoid freeze and 
thaw degradation) and stored at -20°C until use.  
BV-2 microglial cells were seeded in 12-well culture plates as previously described 
above (section 3.2.1.3). Transfection was done as previously described by Rosner et 
al., 2010. Briefly, one hour before transfection, cells were washed with 0.5ml of pre-
warmed 1x DPBS, thereafter, 900µl of Opti-MEM I reduced serum medium was added 
and re-incubated. siRNA/lipid complexes were prepared by combining 3µl of 
lipofectamine 3000 transfection reagent with 100µl of Opti-MEM I medium for 5 
minutes at room temperature. 2.5µl of siRNA duplex was then added into the mixture 
to a final concentration of 50nM. The siRNA/lipid mixture was then incubated at room 
temperature for 20 minutes after which the combined mixture was added to cells in a 
dropwise manner and incubated at 37°C at 5% CO2. After 6 hours of transfection, 
medium was changed to transfection medium (medium without antibiotics) and 
transfection continued for a total of 48 hours. In one experiment, medium was changed 
to fresh transfection medium and 48 hours post transfection, cells were treated with 
100ng/ml LPS for 6 hours (supernatant used for ELISA while cells were lysed for RNA 
isolation as described in section 3.2.3.1). In separate experiment, medium was 
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changed to fresh serum-free transfection medium and 48 hours post transfection, cells 
were treated with 50ng/ml PDGF-BB for 3 hours (gene expression) or 24 hours 
(protein expression - ELISA). 
3.2.5 Protein analysis 
3.2.5.1 Protein isolation and quantification 
BV-2 microglial cells were seeded in 6-well culture plates (section 3.2.1.3) and treated 
in a time kinetic study as described above (section 3.2.1.4). At the termination of 
experiment, cells were washed once with ice-cold 1x DPBS and lysed in 50µl ice-cold 
RIPA buffer supplemented with protease inhibitor cocktail and phosphatase inhibitor 
(for phospho-proteins). Following an incubation period of 30 minutes on ice, samples 
were transferred into chilled 1.5ml PCR tubes and centrifuged (centrifuge previously 
cooled to 4°C) at maximum RCF at 4°C for 15 minutes. Supernatant containing protein 
was carefully transferred into chilled tubes and stored at -80°C until further use. All 
steps were performed on ice to avoid protein degradation.  
Protein concentration present in samples were determined using the PierceTM 
Bicinchoninic Acid (BCA) protein assay kit according to the manufacturer’s protocol. 
The principle of BCA assay is based on the reduction of Cu2+ to Cu+ by proteins in an 
alkaline medium which results in a purple colour formation from green by BCA. This 
purple colouration is a result of chelation of two molecules of BCA with one molecule 
of cuprous ion. Thus, the colour change is proportional to protein concentration. 
Briefly, Bovine Serum Albumin (BSA) protein standard, provided in the kit at a 
concentration of 2mg/ml was serially diluted with water to 1.5, 1.0, 0.75, 0.5, 0.25, 
0.125 and 0.025mg/ml while the protein samples were diluted 1:20 also with water. 
25µl of each standard or unknown samples were then pipetted in triplicates into a 96-
well culture plate after which 200µl of working reagent (50 parts of reagent A mixed 
with 1 part of reagent B) was added to each well containing standard and samples. 
The plate was mixed thoroughly on a plate shaker for 30 seconds and incubated at 
37°C for 30 minutes. The plate was allowed to cool to room temperature and 
absorbance measured at 570nm with Tecan Infinite® F200 pro microplate reader. 
Absorbance values of the standard (BSA) were plotted against known concentrations 
to generate a standard curve from where concentrations of unknown samples were 
interpolated.  
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3.2.5.2 Western Blot 
Protein samples were denatured at 95°C for 5 minutes following the addition of 1x 
Laemmli sample buffer (diluted from 4x with β-meracptoethanol) to the samples. 20µg 
of protein were separated using 8 or 15% (depending on the molecular size of 
analysed protein) SDS-PAGE with PageRuler™ (Plus) Prestained Protein Ladder at 
100V for 2 hours. Subsequently, proteins were transferred onto a 0.45µm 
nitrocellulose membrane at 70V for 1-2 hours. Following successful protein transfer, 
membranes were blocked in membrane blocking buffer for 1 hour to prevent non-
specific binding. Thereafter, membranes were washed in 1x TBS-T buffer for 15 
minutes at three intervals of 5 minutes each. Subsequently, membranes were 
incubated with diluted primary antibody at 4°C overnight on a roller. All primary 
antibodies used here were diluted in antibody solution for WB except for PDGFB and 
β-actin antibody that were diluted in membrane blocking buffer. The following day, 
membranes were washed in 1x TBST buffer as previously described, thereafter 
incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies 
(against the respective primary antibody) for 2 hours at room temperature on a roller. 
Membranes were developed with SignalFire™ Elite ECL Reagent and protein bands 
visualised and imaged with the MultiImage II system.  
For detection of phosphorylated and total proteins, the phosphorylated proteins were 
probed first after which membranes were stripped off the phospho-protein using mild 
stripping in a series of steps. First, membranes were incubated in stripping buffer twice 
for 10 minutes each, discarding the buffer each time. Second, membranes were 
washed in 1x PBS twice for 10 minutes each and last, membranes were washed in 1x 
TBS-T twice for 5 minutes each. Efficiency of stripping was checked by incubating the 
membrane in the chemiluminescent detection (SignalFire™ Elite ECL) reagent and 
visualisation with the imager. Following successful stripping, membranes were rinsed 
severally with stripping buffer before blocking and continuation with the remaining 
steps for incubation in primary antibody for the total protein. Blocking, washing and 
stripping steps were all done at room temperature on a see-saw rocker to ensure even 
distribution of solutions. Band intensities were quantified using Image J 1.47 software. 
3.2.5.3 Immunocytochemistry  
BV-2 microglial cells were seeded on cover slips in 6-well plates at a density of 1x105 
cells/well in 2ml media and allowed to attach overnight. Cells were treated with 50 and 
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100ng/ml LPS for 24 hours. At the termination of experiment, medium was aspirated, 
cells washed with 1x PBS, thereafter fixed with 4% HistoFix for 10 minutes. 
Subsequently, cells were washed with 1x PBS for 15 minutes at 5 minutes interval 
discarding the PBS each time. Following the third wash, cells were incubated in 
blocking buffer for 30 minutes followed by washing steps as previous. Thereafter, cells 
were incubated in primary antibody (diluted in antibody solution for ICC) at 4°C 
overnight on a see-saw rocker. On the second day, washing steps were repeated as 
previous, and cells were further incubated in secondary antibody (diluted in 1x PBS) 
for 30 minutes. From secondary antibody incubation onwards, cells were protected 
from light. This step was followed by washing steps as previous. Thereafter, cell nuclei 
were stained with 0.1µg/ml DAPI (diluted in 1x PBS) for 5 minutes, washing steps were 
again repeated as previous and cover slips mounted on microscope glass slides with 
Dako fluorescence mounting medium. Fixation, washing, blocking, secondary 
incubation, and nuclei staining steps were all done at room temperature on a see-saw 
rocker to ensure even distribution of solutions. Cover slips were allowed to dry and 
fluorescence photomicrographs were taken with an AxioImager.M2 plus ApoTome2 
microscope. 
3.2.5.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
BV-2 microglial cells were seeded in 12-well culture plates for siRNA experiments as 
described above. At the termination of experiments, culture medium was collected 
from treated cells into 2 ml reaction tubes, centrifuged (centrifuge previously cooled to 
4°C) at 1500 rpm at 4°C for 10 minutes. Supernatants were carefully transferred into 
chilled 2ml reaction tubes and stored at -80°C until used for measurement of CCL2 
protein with ELISA kit according to manufacturer’s instruction.  
Capture antibody was reconstituted in 0.5ml 1x DPBS, detection antibody in 1ml 
reagent diluent, and standard in 0.5ml reagent diluent which were all aliquoted in 
volumes of single use and stored at -20°C. Thereafter, each well of a 96-well ELISA 
microplate was coated with reconstituted 100µl capture antibody (further diluted in 1x 
DPBS to the working concentration of 200ng/ml), plate was sealed with an adhesive 
strip and incubated overnight at room temperature. Following day, wells were 
aspirated and washed with 400µl wash buffer for a total of three washes ensuring 
complete removal of liquid by inverting the plate and blotting against clean paper 
towels. Subsequently, plates were blocked by adding 300µl reagent diluent to each 
  
  Materials and methods 
68 
well and incubated at room temperature for 1-2 hours. During this time period, 
standard and samples were prepared accordingly. A two-fold serial dilution (diluted in 
reagent diluent) of the reconstituted standard was prepared from a starting 
concentration of 250pg/ml to the lowest concentration of 3.91pg/ml (a 7-point standard 
curve). Samples were equally diluted in reagent diluent from 1:50 to 1:100 dilution. 
After the indicated period of plate blocking, aspiration/wash steps were repeated as 
previously mentioned. Thereafter, 100µl of each standard and samples were pipetted 
to each well in duplicates, covered with an adhesive strip and incubated for 2 hours at 
room temperature. Following standard/sample addition, aspiration/wash steps were 
repeated as previous and 100µl of reconstituted detection antibody (further diluted in 
reagent diluent to the working concentration of 50ng/ml) was added to each well, plate 
was covered with a new adhesive strip and incubated for another 2 hours at room 
temperature. Aspiration/wash steps were repeated followed by addition of 100µl of 
Streptavidin-HRP (40-fold dilution in reagent diluent) to each well, plate was covered 
and incubated for 20 minutes at room temperature avoiding direct light contact. Again, 
aspiration/wash steps were repeated followed by addition of 100µl of substrate 
solution (1:1 mixture of A and B) to each well, plate was covered and incubated for 
another 20 minutes at room temperature while again avoiding direct light contact 
(green colouration visible). Reaction was terminated by adding 50µl of stop solution 
(2N H2SO4) to each well (colour change with visible yellow colour in sight). The plate 
was gently mixed and resulting colour change was read at a wavelength of 450nm 
with the Tecan Infinite® F200 pro microplate reader. However, to correct for optical 
imperfections in the plate, readings were also taken at 540nm and values from these 
readings were subtracted from readings at 450nm. Absorbance values of the 
standards were plotted against their known concentrations generating a standard 
curve from where concentrations of samples were interpolated. 
3.2.6 Microglia functional assays 
3.2.6.1 Morphology assay 
BV-2 microglial cells were seeded on cover slips in 6-well plates at a density of 1x105 
cells/well in 2ml media and allowed to attach overnight. Cells were treated with 
50ng/ml recombinant PDGF ligands and vehicle control for 3 hours. At the termination 
of experiment, cells were washed once with 1x PBS for 5 minutes. Thereafter, cells 
were fixed with 4% HistoFix, washed thrice with 1x PBS for 5 minutes each and 
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permeabilized in PBS containing 0.1%v/v Triton X-100 for 5 minutes. Previous 
washing steps were repeated. Next, filamentous actin (F-actin) was fluorescently 
labeled with 1µg/ml phalloidin-TRITC (diluted in 1x PBS) for one hour under exclusion 
from light followed by washing steps as previously described. Cell nuclei were stained 
with 0.1µg/ml DAPI (diluted in 1x PBS) for 10 minutes in the dark, and cover slips 
mounted on microscope glass slides with Dako fluorescence mounting medium. All 
steps from the termination of experiments to nuclei staining were done on a see-saw 
rocker (to ensure even distribution of solutions) at room temperature. Cover slips were 
allowed to dry and photomicrographs were taken with an AxioImager.M2 plus 
ApoTome2 microscope. 
3.2.6.2 Migration (Wound healing) assay 
BV-2 microglial cells were seeded at a density of 1x106 cells/well in 2ml media and 
incubated until 100% confluent with daily medium renewal and finally changing to 
serum-free medium prior to the experimental day. On experimental day, cells were 
linearly scratched with a sterile 100μl pipette tip, afterwards the medium was aspirated 
and cells washed twice with medium to remove floating cells. At this point, time ‘0’ 
hour pictures were taken at pre-marked areas after which medium was replaced with 
that containing vehicle and 50ng/ml recombinant PDGF ligands. Migration into the 
open scar was monitored with photomicrographs taken at 3 and 6 hours with an 
AxioVert.A1 inverted microscope (Nikon, Tokyo, Japan). The unpopulated area at 
these time points were measured using the MRI wound healing tool of ImageJ 
software. The values of the scratch area at the different time points (3 and 6 hours) 
were subtracted from the scratch area at time ‘0’ to get the repopulated area (after 3 
and 6 hours). Results are presented as percentage area coverage of scratch area at 
time ‘0’ hour to the repopulated area at time ‘6’ hours. 
3.2.6.3 Phagocytosis assay 
Microglia phagocytic capacity were determined using two different established 
methods, the latex beads method (to mimic exogenous particles) and the apoptotic 
material method (to mimic apoptotic debris). Polystyrene latex beads and 661W 
photoreceptor cell debris were used as substrates for microglia to engulf. BV-2 
microglial cells were seeded in 6-well culture plates as described above (section 
3.2.1.3). While cells were seeded directly into culture plates for the first assay, they 
were seeded on cover slips for the second assay. 
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Polystyrene latex beads: Cells were pre-treated for 2 hours with 50ng/ml 
recombinant PDGF ligands and vehicle control before 4μl polystyrene latex bead 
solution was added to the wells. Cells were further incubated for a period of 3 hours. 
At the termination of the experiment, five independent photomicrographs were taken 
per well using an AxioVert.A1 inverted microscope. The average number of total cells 
per field and the average number of cells which had phagocytosed 10 or more latex 
beads were calculated. Phagocytic capacity was then determined in percentage as 
the average number of cells which had phagocytosed 10 or more latex beads of the 
average number of total cells per field. 
Apoptotic material: Apoptosis was induced in 661W photoreceptor cells by serum 
deprivation for two to three weeks. Dead cells were harvested into 50ml falcon tubes, 
centrifuged at 10,000 RCF for 10 minutes to collect cell pellet which was either stored 
at -80°C until use or immediately labelled with the fluorescent lipophilic dye, 
CellTracker™ CM-Dil. 400µl-stained apoptotic 661W cell suspension were added for 
6 hours to cells pre-treated for 3 hours with 50ng/ml recombinant PDGF ligands and 
vehicle control. At the termination of experiment, cells were thoroughly washed with 
1x PBS to get rid of the remaining extracellular 661W debris. Cells were fixed with 4% 
HistoFix. Thereafter, nuclei were stained with 0.1µg/ml DAPI (diluted in 1x PBS) for 10 
minutes in the dark at room temperature, and cover slips mounted on microscope 
glass slides with Dako fluorescence mounting medium. Cover slips were allowed to 
dry and fluorescence micrographs were taken with an AxioImager.M2 plus ApoTome2 
microscope ensuring constant exposure times for all groups. The ratio of 
phagocytosed photoreceptor debris (background-corrected red signal) relative to the 
total microglial cell number (background corrected DAPI signal) was determined using 
Image J software and values expressed as percentages. 
3.2.6.4 Cellular Reactive Oxygen Species (ROS) generation assay 
The 2',7'-dichlorofluorescein diacetate (DCFDA)-cellular ROS detection assay kit was 
used to measure intracellular ROS production. Hydroxyl, peroxyl and other ROS 
activity within the cell is measured by the cell-permeable fluorogenic dye DCFDA 
which is able to diffuse into the cell to get acetylated by cellular esterases into a non-
fluorescent compound. Intracellular ROS then oxidises this non-fluorescent compound 
into a highly fluorescent compound, 2',7'- dichlorofluorescein (DCF), which is then 
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detected at a maximum excitation and emission spectra of 495nm and 529nm 
respectively.  
BV-2 microglial cells were seeded in phenol free media at a density of 2.5x104 
cells/well in 100µl media in black, clear-bottom(ed) 96-well culture plates and allowed 
to attach overnight. Phenol-free media was used in order to reduce background 
fluorescence. Appropriate volumes needed for the following solutions were freshly 
prepared; 1x buffer solution prepared from a 10x buffer with double-distilled water, 
20µM DCFDA prepared from a 20mM stock with 1x buffer solution, 1x supplemented 
buffer prepared by adding 2ml FBS (not included in the kit) to 18ml of 1x buffer, 50µM 
Tert-Butyl Hydrogen Peroxide (TBHP) prepared from a 55mM stock with 1x 
supplemented buffer.  
Cells were stained with 100µl of 20µM DCFDA at 37°C for 45 minutes followed by 
washing with 1x buffer and treatment in separate wells with 100µl of: 50ng/ml 
recombinant PDGF ligands, vehicle control, 50µM TBHP (positive control) and 1x 
supplemented buffer (control for TBHP) for 3 hours at 37°C. Blank wells with non-
stained cells were included to determine background fluorescence. Intracellular 
production of ROS was then measured by fluorescence detection of DCF in a 
microplate reader - Tecan Infinite® F200 pro reader at an excitation and emission 
wavelength of 485nm and 535nm respectively. Background values were subsequently 
subtracted from all measurements. 
3.2.6.5 661W photoreceptor apoptosis assay 
The Caspase-Glo® 3/7 assay was used to measure caspase activity (an indication of 
apoptotic cell death) in 661W cells treated with MCM in order to investigate microglia 
neurotoxicity. The assay provides a pro-luminescent caspase-3/7 substrate which 
contains the tetrapeptide sequence, DEVD, combined with luciferase and a cell-lysis 
agent. When the Caspase-Glo® 3/7 reagent is directly added to assay wells, this 
causes cell lysis followed by caspase cleavage of the DEVD substrate, and 
subsequently, the generation of luminescence. The luminescence amount is therefore 
proportional to the amount of caspase activity within the sample. 
661W cells were seeded at a density of 10,000 cells/well in 100µl of serum-free media 
in white-walled 96-well luminometer culture plates and allowed to attach overnight. 
Following day, media was aspirated and cells were re-incubated for 48 hours either in 
their own serum-free medium or with serum-free microglia conditioned medium as 
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described above (section 3.2.1.4). The Caspase-Glo® 3/7 reagent was then prepared 
by adding all of the Caspase-Glo® buffer to the Caspase-Glo® 3/7 substrate (both 
provided in the kit) ensuring complete mixture. 100µl of the Caspase-Glo® 3/7 reagent 
was then added to each well and incubated at room temperature for 1 hour. Included 
in the experimental set-up, were blank reactions (vehicle in culture medium without 
cells plus Caspase-Glo® 3/7 reagent), to determine background luminescence 
associated with the Caspase-Glo® 3/7 reagent and the cell culture system and 
negative control reactions (vehicle-treated cells plus Caspase-Glo® 3/7 reagent), to 
determine basal caspase activity of the 661W cells. Following incubation with the 
Caspase-Glo® 3/7 reagent, the generated luminescence was measured using the 
Tecan Infinite® F200 pro microplate reader. Background luminescence values were 
subtracted from all experimental values and the amount of luminescence expressed 
as Relative Light Units (RLU) which is proportional to the amount of caspase activity 
(apoptotic cell death) in 661W cells. 
3.2.7 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 7 (GraphPad 
Software Inc., San Diego, CA). Depending on the experimental set up, statistical 
significance was determined using either unpaired Student’s T-test (for two groups) or 
one-way ANOVA (for multiple group) followed by Dunnet’s, Tukey’s, or Sidak’s 
multiple comparisons test and p ≤ 0.05 was considered statistically significant. Data 
are expressed as mean ± standard deviation (SD) unless otherwise stated.  
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CHAPTER FOUR: RESULTS 
4.1 Expression of PDGFs and their receptors in murine microglial cells 
Expression of PDGF ligands and their receptors were studied in BV-2 microglial cells 
first using qPCR (Fig. 4.1). In LPS-activated BV-2 microglial cells, where activation 
was confirmed by upregulation of Tnfα gene (Fig. 4.1A), mRNA expression levels of 
Pdgfb (Fig. 4.1E) and Pdgfrβ (Fig. 4.1C) were significantly upregulated while 
expression of Pdgfc (Fig. 4.1F) was significantly downregulated. mRNA levels of Pdgfa 
(Fig. 4.1D) and Pdgfrα (Fig. 4.1B) were not significantly altered while expression of 
Pdgfd could not be detected. 
 
Figure 4.1  Expression of PDGF ligands and their receptors in BV-2 microglial 
cells. 
Quantitative PCR data of gene expression levels of Tnfα (A), Pdgfrα (B), Pdgfrβ (C), 
Pdgfa (D), Pdgfb (E) and Pdgfc (F). Data are presented as mean ± SD of three 
independent experiments measured in duplicates (N=6). **p≤ 0.01, ***p≤ 0.001, ****p≤ 
0.0001 compared to control (PBS), one-way AVOVA with Tukey’s multiple comparison 
test. 
To confirm whether increased gene expression levels of Pdgfb (Fig. 4.1E) and Pdgfrβ 
(Fig. 4.1C) translated into increased protein levels, western blot analysis of BV-2 
microglial cells exposed to LPS in a time kinetic study (3 - 48hrs) and immunostaining 
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of cells exposed to LPS for 24 hours was done. Fluorescence immunostaining of both 
PDGF-BB (observed throughout the whole cell, cytoplasm and nucleus) (Fig. 4.2A) 
and PDGFRβ (observed as punctate staining in the cytoplasm and predominantly in 
the perinuclear region of the cells) (Fig. 4.3A) showed significant increased expression 
with 100ng/ml LPS after 24 hours (Fig. 4.2B and 4.3B) while WB analysis of both 
PDGF-BB (Fig. 4.2C) and phospho-PDGFRβ (Fig. 4.3C) proteins showed significant 
increased expression at 24 and 48 hours respectively. 
 
Figure 4.2  LPS induced protein expression of PDGF-BB in BV-2 microglial 
cells 
(A) Representative immunostaining of PDGF-BB protein (Red), nuclei stained with 
DAPI (blue) and (B) Quantification of fluorescence intensity from six immunostainings 
per group done in duplicates of three experiments, *p≤ 0.05 compared to control 
(PBS), one-way AVOVA with Tukey’s multiple comparison test. (C) Representative 
western blot of PDGF-BB protein and densitometric analysis from five immunoblots, 
**p≤ 0.01 compared to control (PBS), one-way AVOVA with Dunnett’s multiple 
comparison test. All data are presented as mean ± SD. 
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Figure 4.3  LPS induced PDGFRβ and p-PDGFRβ expression in BV-2 microglial 
cells. 
(A) Representative immunostaining of PDGFRβ protein (Red), nuclei stained with 
DAPI (blue) and (B) Quantification of fluorescence intensity from two 
immunostainings, *p≤ 0.05 compared to control (PBS), One-way AVOVA with Tukey’s 
multiple comparison test. (C) Representative western blot of phosphorylated PDGFRβ 
protein and densitometric analysis from two immunoblots, *p≤ 0.05 compared to 
control (PBS), one-way AVOVA with Dunnett’s multiple comparison test. All data are 
presented as mean ± SD. 
4.2 Effect of PDGF on microglia functional properties 
BV-2 microglial cells were treated with human recombinant PDGF ligands and their 
effects on microglia functional properties: morphology, migration, phagocytosis, 
inflammatory response, ROS release and neurotoxicity were studied. 
4.2.1 PDGF induced an amoeboid-like phenotype in microglia 
Treatment of BV-2 microglial cells with 50ng/ml recombinant human PDGF ligands for 
3 hours induced an amoeboid-like phenotype in microglia (Fig. 4.4A). Following 
exposure to PDGF ligands, microglial cells showed clear morphological differences in 
all the treatment groups compared to the control group. In control-treated group, 
microglial cells displayed a ramified morphology characterised by elongated 
processes while in all of the treatment groups, all cells were induced towards an 
amoeboid morphology with large cell bodies indicative of an activated state (Fig. 4.4A). 
The induced activation of BV-2 microglial cells by PDGF was accompanied by 
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concomitant decrease in mRNA levels of the microglia homeostatic gene, P2ry12 (P2Y 
purinoceptor-12) (Fig. 4.4B). P2ry12 gene is one of the ‘sensome’ genes used by 
microglia processes to sense changes within their environment and facilitate tissue 
homeostasis (Haynes et al. 2006; Hickman et al. 2013; Fourgeaud et al. 2016) thus a 
change in microglia homeostasis results in downregulation of these genes (Hickman 
et al. 2013). Results show that all the PDGF ligands significantly decreased the 
expression of the P2ry12 gene (Fig. 4.4B). 
 
 
Figure 4.4  PDGF induced an amoeboid-like phenotype in BV-2 microglial 
cells. 
(A) Representative images of phalloidin-TRITC stained BV-2 microglial cells treated 
with recombinant PDGF ligands. (B) Quantitative PCR data of expression level of the 
microglia homeostatic gene, P2ry12 in the presence of PDGF. Data are presented as 
mean ± SD of at least two independent experiments measured in duplicates (N=4-8). 
***p≤ 0.001, ****p≤ 0.0001 compared control, one-way AVOVA with Dunnett’s multiple 
comparison test. Control - 0.1% BSA in DPBS. 
4.2.2 Effect of PDGF on microglial cell migration  
To investigate the effect of PDGF on microglial cell migration, a wound healing 
(scratch) assay was performed where a ‘wound’ in form of a scratch was introduced 
onto a confluent layer of BV-2 microglial cells and migration into the open scar was 
monitored following treatment with 50ng/ml recombinant human PDGF ligands over 
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the indicated time period. As shown in figure 4.5A and B, PDGF ligands did not 
significantly affect BV-2 microglial cell migration compared to control after 6 hours of 
ligand treatment. However, the pro-migratory related genes, Ccl3 and Ccl5 (Fig. 4.5C 
and D) including Ccl2 (Fig. 4.7A) were significantly upregulated after 3 hours of ligand 
treatment. 
 
Figure 4.5  Effect of PDGF on BV-2 microglial cell migration and pro-migratory 
genes.  
(A) Representative micrograph of scratch migration assay in BV-2 microglial cells 
treated with recombinant PDGF ligands. Scale bar-200µm (B) Quantification of 
surface area coverage from six micrographs taken per group from three experiments 
in duplicates (N=6). No significant differences seen between treatment and control 
group. (C and D) Quantitative PCR data of expression levels of pro-migratory genes, 
Ccl3 and Ccl5 in the presence of PDGF (N=7-11 of at least three independent 
experiments). All data are presented as mean ± SD, **p≤ 0.01, ***p≤ 0.001, ****p≤ 
0.0001 compared to control, one-way AVOVA with Dunnett’s multiple comparison test. 
Control - 0.1% BSA in DPBS. 
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4.2.3 Effect of PDGF on microglia phagocytic capacity 
Microglia are characterised by their ability to phagocytose extracellular protein 
aggregates, pathogens, and apoptotic cell debris (R. Fu et al. 2014) as part of their 
housekeeping functions. Thus, to mimic exogenous particles and apoptotic cell debris, 
polystyrene micro particles latex beads and CM-Dil-stained apoptotic 661W 
photoreceptor fragments were used as substrates for BV-2 microglial cells to engulf 
while the phagocytic capacity following 3 hours of treatment with 50ng/ml 
recombinant human PDGF was assessed. In the latex bead assay, treatment with 
the PDGFs did not significantly affect phagocytic capacity of BV-2 microglial cells 
(Fig. 4.6A and B). Similar results were also observed in the cellular debris assay 
(Appendix fig. 3A and B). In addition, treatment with 50ng/ml PDGF-BB did not 
significantly affect the expression of phagocytosis related genes, cluster of 
differentiation 36 (Cd36) (Fig. 4.6C), triggering receptor expressed on myeloid cells 2 
(Trem2) (Fig. 4.6D), and the scavenger receptors, macrophage scavenger receptor 1 
(Msr1) (Fig. 4.6E), and scavenger receptor class B member 1 (Scarb1) (Fig. 4.6F). 
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Figure 4.6  Effect of PDGF on BV-2 microglia phagocytic capacity. 
(A) Representative micrograph of polystyrene latex bead phagocytosis assay in BV-2 
microglial cells treated with recombinant PDGF ligands. Scale bar-20µm (B) 
Quantification from two experiments in duplicates (N=4). Percentage phagocytosis 
index measured as average number of cells (from 5 fields) that phagocytosed ≥ 10 
latex beads relative to the average total number of cells (from 5 fields) x 100. No 
significant differences were seen between treatment and control group, one-way 
AVOVA with Dunnett’s multiple comparison test. (C-F) Quantitative PCR data of 
expression levels of phagocytosis related genes; Cd36, Trem2, Msr1 and Scarb1 in 
the presence of PDGF-BB, N=4 of two independent experiments in duplicates. No 
significant differences were seen between PDGF-BB treated control group, unpaired 
t-test. All data are presented as mean ± SD. Control - 0.1% BSA in DPBS. 
4.2.4 PDGF induced an inflammatory response in microglia 
The effect of PDGF ligands on inflammatory response in microglial cells were 
assessed as reactive microglia are known to induce the expression of pro-
inflammatory genes. To this end, BV-2 microglial cells were treated with 50ng/ml 
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human recombinant PDGF ligands for 3 hours and transcript levels of pro-
inflammatory genes were assessed by qPCR. All the PDGF ligands significantly 
upregulated the expression of Ccl2, Cox-2 (PDGF target genes) and Tnfα genes (Fig. 
4.7A, B and C respectively). 
To further confirm results from BV-2 microglial cells, primary microglial cells were used 
as they are more physiologically relevant owing to their phenotypic similarities to 
microglia in-vivo (Stansley et al. 2012). To this end, isolated primary microglial cells 
were also treated with 50ng/ml human recombinant PDGF ligands for 3 hours and the 
same set of pro-inflammatory genes were assessed by qPCR. In primary microglial 
cells, all the PDGF ligands significantly upregulated Ccl2, Cox-2 and Tnfα genes (Fig. 
4.7D, E and F respectively) as seen in BV-2 microglial cells. In addition, significant 
differences were seen in Tnfα response between PDGF-AA and PDGF-CC and 
PDGF-AB and PDGF-CC (Fig. 4.7F) which was however not seen in BV-2 microglial 
cells. 
 
Figure 4.7  PDGFs upregulated expression of pro-inflammatory genes in BV-2 
and primary microglial cells. 
Quantitative PCR data of gene expression levels of Ccl2 (A, D), Cox-2 (B, E) and Tnfα 
(C, F) in BV-2 and primary microglial cells respectively. BV-2 microglial cells: N ≥ 9; 
primary microglial cells: N=4 (two independent experiment in duplicate). All data are 
presented as mean ± SD. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001 compared to 
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control; #p≤ 0.05, one-way AVOVA with Tukey’s multiple comparison test. Control - 
0.1% BSA in DPBS. 
4.2.5 PDGF decreased intracellular ROS levels 
Not only do microglial cells release pro-inflammatory cytokines when activated, they 
also release neurotoxic factors like toxic oxygen radicals e.g., ROS (Akundi et al. 2005; 
Block et al. 2007; Bazan 2012; Patro et al. 2016; Takahashi et al. 2016). To this end, 
the effects of 50ng/ml human recombinant PDGF ligands on the release of cellular 
ROS was investigated. Using the DCFDA ROS assay kit, PDGF-BB and -CC 
significantly decreased total ROS levels while no significant effects were seen with 
PDGF-AA and –AB compared to control although the trend shows an overall decrease 
in ROS levels with all the PDGF ligands after 3 hours of treatment (Fig. 4.8A).To 
understand the molecular mechanisms involved in PDGF-mediated decrease of 
microglia ROS levels, firstly, transcript levels of NADPH oxidases (NOXs) including 
the dual oxidases (DUOX1 and 2) were assessed as these are the major ROS 
generating enzymes (Kang 2007; X.-J. Fu et al. 2014; Sun et al. 2016). While the 
expression of Nox1 and Nox2 genes were significantly upregulated (Fig. 4.8B and C), 
expression of Nox4, Duox1 and Duox2 genes could not be detected in BV-2 microglial 
cells. Also, neither Nox3 nor Nox5 transcript levels were assessed for in this study 
because Nox3 is localised to the inner ear and Nox5 is absent in mice (Bedard and 
Krause 2007). 
 
Figure 4.8  PDGF decreased intracellular ROS levels while inducing 
expression of NADPH oxidases. 
(A) DCF fluorescence measurement in BV-2 microglial cells treated with recombinant 
PDGF ligands (N=9-10). (B and C) Quantitative PCR data of gene expression levels 
of ROS generating enzymes, Nox1 and Nox2 in the presence of PDGF ligands (N=8-
13). All data are presented as mean ± SD. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, compared 
to control, one-way AVOVA with Dunnett’s multiple comparison test. Control - 0.1% 
BSA in DPBS; 485/535nm - excitation/emission wavelength respectively. 
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Secondly, the involvement of the anti-oxidant system was investigated by assessing 
the expression levels of the anti-oxidant genes, glutathione peroxidase 1 (Gpx1), 
glutathione peroxidase 4 (Gpx4), glutathione reductase (Gsr), Catalase, superoxide 
dismutase 1 and 2 (Sod1 and Sod2) in the presence of PDGF ligands (Fig. 4.9A-F). 
Of all these antioxidant genes, only the expression of Sod2 gene (Fig. 4.9F) was 
significantly upregulated by all four ligands while expression of Gsr gene (Fig. 4.9C) 
was upregulated by only PDGF-BB. 
 
Figure 4.9  Effect of PDGF-treated BV-2 microglial cells on anti-oxidant genes. 
Quantitative PCR data of expression levels of anti-oxidant genes: Gpx1 (A), Gpx4 (B), 
Catalase (D) and Sod1 (E), N=4 of two independent experiments measured in 
duplicates. No significant differences were seen between treated and vehicle control, 
unpaired t-test; Gsr (C) and Sod2 (F), N=4-8. **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001 
compared to vehicle control, one-way AVOVA with Dunnett’s multiple comparison test. 
All data are presented as mean ± SD, vehicle control - 0.1% BSA in DPBS. 
4.2.6 Effect of microglia neurotoxicity on neuronal cells 
To further test the effect of microglia neurotoxicity, 661W photoreceptor cells were 
cultured in conditioned medium from PDGF-treated BV-2 microglial cells for 48 hours 
and caspase-related apoptotic cell death was measured. 661W photoreceptor cells 
cultured in microglia supernatants from vehicle treated cells showed significantly 
  
  Results 
83 
higher caspase 3/7 activity when compared to control (baseline) while 661W cells 
cultured in microglia supernatants from PDGF-ligand treated cells showed decreased 
caspase 3/7 activity with significant differences seen with PDGF-AA, -AB and -CC 
when compared to vehicle treated cells (Fig. 4.10). This result is suggestive of the 
notion that PDGF limits microglial production of neurotoxic molecules.  
 
Figure 4.10 PDGF decreased apoptosis-related caspase 3/7 activity in 
photoreceptor cells. 
Caspase 3/7 activity in 661W photoreceptor cells at baseline (control - untreated cells) 
and incubation with BV-2 microglia conditioned medium from vehicle (red bar, denoted 
as -) and PDGF-treated cells. Data are presented as mean ± SD, N=11-12. *p≤ 0.05, 
***p≤ 0.001, ****p≤ 0.0001 compared to vehicle treated. One-way AVOVA with Sidak’s 
multiple comparison test. Vehicle - 0.1% BSA in DPBS; RLU - Relative Light Units. 
4.3 Expression of PDGF receptor-β but not receptor-α is induced upon 
microglia activation 
Because PDGF effects are mediated by binding to their cognate receptors, α and β, 
the next step was to investigate the effect of PDGF induced microglia activation on the 
receptors. All the PDGF ligands significantly upregulated expression of β-receptor but 
not α-receptor in both BV-2 and primary microglial cells (Fig. 4.11A and B 
respectively). This result is however similar to that seen with LPS activation of 
microglial cells where β-receptor but not α-receptor was also upregulated (Fig. 4.1C 
and B respectively). 
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Figure 4.11 PDGF ligands upregulated receptor-β but not receptor-α in both 
BV-2 and primary microglial cells. 
Quantitative PCR data of gene expression levels of Pdgfrα (grey) and Pdgfrβ (black) 
in (A) BV-2 and (B) primary microglial cells respectively. BV-2 microglial cells: N=9-16 
(of at least 4 independent experiments performed either in duplicates/triplicates); 
Primary microglial cells: N=4 (two independent experiment performed in duplicates). 
All data are presented as mean ± SD. **p≤ 0.01, ****p≤ 0.0001 compared to control. 
One-way AVOVA with Dunnett’s multiple comparison test. Control - 0.1% BSA in 
DPBS. 
4.4 Antibody blockade of microglial PDGFRβ reduced LPS and PDGF 
induced inflammatory responses 
Having determined the relative expression of PDGF receptors and the effect of both 
LPS and PDGF treatment on their expressions in both BV-2 and primary microglial 
cells, next was to determine the role each receptor played in the induction of 
inflammatory responses. To this end, rat mAbs, APA5 and APB5 were used as 
pharmacological blockers for receptor α and β respectively. 
Firstly, BV-2 microglial cells were pre-treated with 10µg/ml APA5 and APB5 
respectively for 30 minutes followed by 100ng/ml LPS treatment for 6 hours. Antibody 
blockade of microglial PDGF receptor-β but not receptor-α significantly attenuated 
LPS induced Tnfα, Il-6 and Il-1β gene expression (Fig. 4.12A-C).  
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Figure 4.12 Antibody blockade of microglial PDGFRβ reduced LPS-induced 
inflammatory responses. 
Quantitative PCR data of gene expression levels of Tnfα (A), Il-6 (B), and Il-1β (C). 
Data are presented as mean ± SD of two independent experiments measured in 
triplicates (N=5-6). *p≤ 0.05, **p≤ 0.01, ****p≤ 0.0001, One-way AVOVA with Sidak’s 
multiple comparison test. 
Secondly, BV-2 microglial cells were pre-treated with10µg/ml APA5 and APB5 
respectively for 1 hour followed by 50ng/ml PDGF-BB treatment. Similarly, antibody 
blockade of microglial PDGF receptor β but not receptor α significantly attenuated 
PDGF-BB induced Ccl2 target gene expression (Fig. 4.13) 
 
Figure 4.13 Antibody blockade of microglial PDGFRβ reduced PDGF-BB-
induced Ccl2 target gene expression. 
Quantitative PCR data of expression levels of Ccl2 gene induced by PDGF-BB and 
attenuated by antibody blockade of PDGF receptor β. Data are presented as mean ± 
SD of two independent experiments measured in duplicates (N=4). **p≤ 0.01, ****p≤ 
0.0001 compared to PDGF-BB group (red bar), one-way AVOVA with Sidak’s multiple 
comparison test. 
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4.5 Effect of PDGF receptor siRNA-mediated gene silencing on LPS and 
PDGF induced inflammatory responses 
To further corroborate the findings from the pharmacological blockade of PDGF 
receptor-α and -β, BV-2 microglial cells were transfected with PDGFRα, PDGFRβ and 
non-targeting scrambled control (scram.) siRNA respectively followed by LPS and 
PDGF-BB treatment in separate experiments. Transfection of BV-2 microglial cells 
with these siRNAs for 48 hours resulted in significant knockdown with efficiencies of 
70 and 51%  for receptor-α (Fig. 4.14A) and -β (Fig. 4.14B) respectively with a 
significant compensatory effect of 20% on receptor-β when receptor-α was knocked 
down (Fig. 4.14C) (compared with non-targeting scrambled control) as demonstrated 
by qPCR.  
In one experiment, cells were transfected with these siRNAs for 48 hours followed by 
treatment with 100ng/ml LPS for 6 hours. While supernatants were used for protein 
expression (ELISA), cells were lysed in RNA lysis buffer and processed for gene 
expression. LPS-mediated induction of Il-1β (Fig. 4.14D) and Ccl2 (Fig. 4.14E) gene 
expression was attenuated in cells transfected with PDGFRβ siRNA when compared 
to non-targeting scrambled control, however, there was a significant increase in Il-1β 
gene expression (Fig. 4.14D) upon Pdgfrα gene knockdown while no significant effect 
was seen in CCL2 protein expression (Fig. 4.14F) when both receptors were knocked 
down. 
In a separate experiment, cells were transfected for 48 hours as described above 
followed by treatment with 50ng/ml PDGF-BB for 3 hours (gene expression) and 24 
hours for protein expression (ELISA). PDGF-mediated induction of Tnfα gene 
expression (Fig. 4.14G) was attenuated when both receptor-α and -β were knocked 
down while gene expression of Ccl2 (Fig. 4.14H) was only attenuated when receptor-
β but not -α was knocked down with no significant effect observed in CCL2 protein 
expression (Fig. 4.14I) either in PDGF-BB treatment or in receptor knockdown. Taken 
together, these results implicates the involvement of both PDGF receptors in LPS- and 
PDGF-mediated microglia inflammatory response.  
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Figure 4.14 siRNA-mediated gene silencing of Pdgfrβ attenuated LPS and 
PDGF-BB induced inflammatory responses in BV-2 microglial cells. 
Quantitative PCR data of gene expression levels of (A) Pdgfrα, (B) Pdgfrβ, and (C) 
Pdgfrα when receptor-β was knocked down, and Pdgfrβ when receptor-α was knocked 
down following 48 hours of transfection with 50nM of the respective siRNAs. *p≤ 0.05, 
***p≤ 0.001, ****p≤ 0.0001 compared to scram, unpaired t-test. (D-F) Gene expression 
levels of Il-1β, Ccl2 and protein expression of CCL2 respectively following 48 hours of 
receptor-α and -β knockdown plus 6 hours LPS treatment. *p≤ 0.05, **p≤ 0.01, ***p≤ 
0.001, ****p≤ 0.0001 compared to ‘scram. + LPS group’ (red bar), ###p≤ 0.001, one-
way AVOVA with Sidak’s multiple comparison test. (G-I) Gene expression levels of 
Tnfα, Ccl2 and protein expression of CCL2 respectively following 48 hours of receptor 
α and β knockdown plus 3 and 24 hours of PDGF-BB treatment for gene and protein 
expression respectively. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001 compared to 
‘scram. + PDGF-BB group’ (red bar), one-way AVOVA with Sidak’s multiple 
comparison test. All data are presented as mean ± SD of two independent experiments 
measured in triplicates (N=6).  
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4.6 PDGF mediated microglial inflammatory response involves MAPK and 
PI3K/Akt cell signalling pathways 
Having determined the induction of microglia inflammatory response mediated by 
PDGF, next, was to investigate the intracellular signal transduction pathways involved 
in this process. Since PDGF is a known mitogen, the involvement of MAPKs and 
PI3K/Akt signalling pathways were investigated.  
First, BV-2 microglial cells were treated with 50ng/ml recombinant PDGF-BB protein 
and phosphorylation of MAPKs (p38, ERK 1/2, and JNK) and Akt were assessed by 
western blot (figure 4.15A). Treatment of BV-2 microglial cells with PDGF-BB resulted 
in a time-dependent increase in phosphorylation of ERK 1/2, JNK, and Akt but not p38 
with significant increases seen in phosphorylation of ERK 1/2, JNK and AKT from 15, 
120 and 5 minutes respectively compared to vehicle-treated cells (C, D, and E 
respectively).  
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Figure 4.15 PDGF mediated inflammatory response involves MAPK and 
PI3K/Akt cell signalling pathways. 
(A) Representative western blot of time-dependent effect of PDGF-BB on total and 
phosphorylated P38, ERK, JNK, and Akt. (B-E) Densitometric analysis from two 
immunoblots, *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001 compared to control (-). 
One-way AVOVA with Dunnett’s multiple comparison test. Data are presented as 
mean ± SD. Control - 0.1% BSA in DPBS. 
Second, the functional implication of the MAPKs and PI3K/Akt signalling in PDGF-
mediated microglia inflammatory response was investigated. BV-2 microglial cells 
were pre-treated with inhibitors specific for the respective signalling pathways for 1 
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hour followed by treatment with 50ng/ml recombinant PDGF ligands for 3 hours and 
subsequently gene expression of Tnfα and PDGF-target genes (early response gene), 
Ccl2 and Cox-2 were assessed for. Treatment of BV-2 microglial cells with MAPK and 
PI3K inhibitors resulted in significant attenuation of PDGF-mediated induction of pro-
inflammatory gene Ccl2, Cox-2 and Tnfα expression levels however inhibition of PI3K 
did not attenuate PDGF-mediated induction of Tnfα gene expression with all PDGF 
ligands except PDGF-BB (C). Similar effects with the inhibitors were seen in primary 
microglial cells with PDGF-BB mediated induction of Cox-2 and Tnfα gene however 
inhibition of JNK signalling did not attenuate PDGF-BB mediated induction of Cox-2 
gene (Appendix fig 1B and C). 
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Figure 4.16 PDGF-mediated induction of inflammatory mediators is inhibited 
by MEK1/2, JNK and PI3K inhibitors 
(A-D) Quantitative PCR data of gene expression levels of Ccl2, Cox-2 and Tnfα in 
PDGF-AA, -AB, -BB and -CC treated BV-2 microglial cells pre-treated with inhibitors 
for MEK1/2 inhibitor - U0126, PI3K - LY294002, and JNK - SP600125. Data are 
presented as mean ± SD of two to three independent experiments measured in 
duplicates and triplicates (N=6-7). **p≤ 0.01, ****p≤ 0.0001 compared PDGF-treated 
group (red bar). One-way AVOVA with Sidak’s multiple comparison test.  
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CHAPTER FIVE: DISCUSSION 
Several cellular and molecular processes are implicated in neurodegenerative events 
including protein aggregate accumulation, oxidative responses, triggering of 
apoptosis, and impaired mitochondrial function (Höglund and Salter 2013). However, 
neuroinflammation also correlates with the initiation and development of both acute 
and chronic neurodegenerative diseases (Frank-Cannon et al. 2009; Amor et al. 2010; 
Heneka et al. 2014). Although acute neuroinflammatory responses are relatively 
transient and in general beneficial to the CNS by getting rid of a host of potential CNS 
harmful substances thereby contributing to tissue homeostasis. However, unresolved 
acute inflammation becomes chronic and pathologic with neurotoxic effects causing 
serious neuronal damage, which interferes with CNS homeostasis thus causing an 
imbalance between restorative and pro-inflammatory responses (Streit et al. 2004; 
Bazan 2012; McManus and Heneka 2017). This pathological neuroinflammation 
associated with neurodegeneration is predominantly orchestrated by microglia, the 
resident immune cells of the CNS (Bazan 2012; Cianciulli et al. 2020). Hence, 
microglia activation is a hallmark common to neurodegenerative diseases.  
Thus, in the quest for understanding microglia activation and how it influences 
pathologic angiogenesis, this present study focused on investigating the direct 
association and interaction between microglia and the PDGF/PDGFR system with 
respect to microglia-mediated neuroinflammatory responses. 
5.1 BV-2 cell line and primary cells as models for microglia cultures 
In order to study the biology of microglia and its role in neuroinflammation, primary 
microglial cultures and quite a number of immortalised microglial cell lines generated 
from mice (N9, BV2, and EOC), rats (HAPI), and humans (HMO6 and HMC3) have 
been established (Sarkar et al. 2018). However, despite the evident differences that 
have been reported between microglia in-vivo and in-vitro (Carson et al. 2008), these 
in-vitro cultures are still beneficial in studying microglia properties like activation state, 
motility, the ability to release numerous factors, characterisation of molecular 
pathways involved in their activation, as well as other important components 
characterising microglia, for which efficient examination in-vivo might not suffice 
(Gresa-Arribas et al. 2012; Stansley et al. 2012). Despite the similarities between 
these culture models, there exists distinct differences that must however be taken into 
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consideration when a neurodegenerative research model is to be utilised (Stansley et 
al. 2012).  
Primary microglia cultures, mostly generated from neonatal cortex of mouse or rats 
(Giulian and Baker 1986) (though the utilisation of adult animals is now prevalent in 
more studies) (Butovsky et al. 2014) show more phenotypic similarities to in-vivo cells 
(Stansley et al. 2012). Following characterisation, these cells were seen to be 
consistently positive for non-specific esterases, negative for galactocerebroside 
(GalC, an oligodendrocyte marker); glial fibrillary acidic protein (GFAP, an astrocyte 
marker); and peroxidase activity (neutrophils); all of which are characteristic of 
microglial cells  (Giulian and Baker 1986). While the measurement of these proteins 
and cell markers in primary microglia is beneficial, in addition to several other 
advantages reviewed by Timmerman et al., 2018, the cost, considerable amount of 
time needed for its preparation, low cell number yield and the limited proliferation 
capacity, makes its use probably not highly favoured in comparison to other microglial 
cells lines with shorter preparation time but comparable cell properties (Stansley et al. 
2012; Sarkar et al. 2018).  
With these, immortalised cell lines mentioned above were generated by infecting 
primary cells with a retrovirus (Stansley et al. 2012; Timmerman et al. 2018). BV2 and 
N9 microglial cell lines, of mouse origin, are the two of these type that are most 
commonly used (Stansley et al. 2012). Of these two mouse cell lines, BV-2 is the best 
characterised and most used culture model appearing in approximately 75% of 
publications as reported by Sarkar et al., 2018. The BV-2 cell line was generated by 
transduction of primary microglia isolated from neonates with the v-raf/v-myc carrying 
J2 retrovirus (Blasi et al. 1990). Characterisation of these cells, showed that they 
express MAC1 and MAC2 macrophage markers but are negative for the antigen, 
MAC-3. In similar vein to primary microglia, these cells were negative for GalC, and 
GFAP, oligodendrocyte and astrocyte marker respectively, and lacked peroxidase 
activity while being 90% positive for non-specific esterases (Bignami et al. 1972; 
Timmerman et al. 2018). 
BV-2 cell line has been used in many neuroinflammatory and neurodegenerative 
studies including those studies on PD and AD (Gao et al. 2013; Griciuc et al. 2013; 
Velagapudi et al. 2018). They also respond very well to LPS as seen with numerous 
studies to mention a few (Stansley et al. 2012; Boza-Serrano et al. 2014; Dai et al. 
2015) which was also seen in this study by the expression of a number of pro-
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inflammatory cytokines including but not limited to Ccl2, Cox-2, Tnfα, Il-6 etc. While 
BV-2 cells are not in morphology or activation state similar to primary microglia, their 
ease of use and the disadvantages of primary microglia usage makes BV-2 cells an 
attractive choice. In light of this, while majority of the experiments in this study were 
done with BV-2 cells, the key experiments were confirmed with primary microglial cells 
(isolated from neonatal mice) as proof of concept. Primary microglial cells used in this 
study were stained for Iba-1 protein to assess microglia purity. Iba-1 is an actin-binding 
cytoplasmic protein primarily expressed by monocytic lineage cells including microglia 
in the brain (Imai et al. 1996) and extensively utilised as a microglia marker during 
immunostainings (Ahmed et al. 2007). 
5.2 Effect of BV-2 microglia activation on the expression of PDGF ligands and 
their receptors 
In the current study, BV-2 microglial cells expressed both PDGF receptors, alpha and 
beta and all of the PDGF ligands but PDGFD. Microglia expression of the PDGF 
isoforms, PDGF-A, -B and -C are however consistent with expression results seen in 
a brain radiation necrosis study, where they investigated the roles of PDGF factors 
and their receptors (Miyata et al. 2014). In this study, authors show microglia (amongst 
other cells) expression of all PDGFs in undamaged brain tissue and at the peri-necrotic 
area. While the expression of the PDGFD isoform could not be detected in BV-2 
microglial cells, these authors show microglial expression of the PDGF-D isoform in 
microglia in their study. This difference could however be attributed to differences 
between rodent and human microglia as reported by Smith and Dragunow, 2014 and 
Streit et al., 2014.  
LPS, a confirmed activator of microglial cells, binds to TLR4 and leads to rapid 
activation of various intracellular signalling pathways thus inducing the expression of 
a broad spectrum of endogenous mediators including pro-inflammatory cytokines like 
TNFα; interleukins like IL-6 and IL-1β (Alexander and Rietschel 2001). In this current 
study, following LPS stimulation, an induction of TNFα expression was seen 
confirming microglia activation while significant increases in gene expression of 
PDGFB and PDGFRβ was seen. Also, a significant decrease in expression of PDGFC 
was seen while the expression of PDGFA and PDGFRα were not significantly altered. 
Furthermore, increased expression of both PDGFB and its receptor-β were sustained 
at protein level as seen by significant increases in expression of both proteins using 
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two independent approaches, ICC and WB. Decreased PDGFC expression seems to 
be contrary to expected results given that the PDGF-PDGFR signalling play critical 
role in and induces inflammation (Olson and Soriano 2011; Miyata et al. 2014) as well 
as contributing to a number of inflammatory associated diseases like asthma (Kardas 
et al. 2020), renal interstitial fibrosis (Eitner et al. 2008), and atherosclerosis (He et al. 
2015) to mention a few. 
The co-expression of both PDGF ligands and receptors seen in microglial cells in this 
study is suggestive of autocrine signalling mechanisms. Such autocrine PDGFR 
signalling have been seen in neural progenitor cells, regulating proliferation 
(Erlandsson et al. 2006), in lens epithelium, contributing to lens development through 
the co-expression of PDGFA and PDGFRα (Andrae et al. 2008) and particularly in 
tumour cells where it contributes to their growth and survival (Maxwell et al. 1990; 
Lokker et al. 2002). 
5.3 Effect of PDGF on microglia functional properties 
Microglia is known to be involved in a number of physiological roles, as it relates with 
this study, in surveillance and monitoring with their dynamic processes (Hickman et al. 
2018), migration to sites of injury or neuronal death to phagocytose dying or dead cells 
or other forms of debris (Fuhrmann et al. 2010; Lull and Block 2010; Krasemann et al. 
2017), in regulating host defense against infectious pathogens (Hickman et al. 2018). 
Thus, any functional irregularity causes an imbalance initiating the onset of 
neurodegeneration (Hickman et al. 2018).  
Here, the effect of ligand mediated PDGF receptor activation in microglia were 
assessed on these functional properties in order to characteristically understand 
microglia-PDGFR system interaction. Firstly, results show that PDGF ligands induced 
an amoeboid-like phenotype in BV-2 microglial cells indicating a change in microglia 
homeostasis. Consistent with this finding, a downregulation of the P2ry12 gene was 
seen. P2ry12 is a member of the purinergic receptors, and one of the ‘sensome’ genes 
used by microglia processes to sense changes within their environment and facilitate 
tissue homeostasis (Inoue 2002; Haynes et al. 2006; Hickman et al. 2013; Fourgeaud 
et al. 2016), thus a change in microglia homeostasis results in downregulation of these 
genes (Hickman et al. 2013) as seen in this study. Furthermore, PDGF ligands did not 
significantly affect microglia migration though pro-migratory genes Ccl2, Ccl3 and Ccl5 
were significantly upregulated which should have translated to the needed response. 
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A possible explanation for this could be that PDGF is not a strong stimulant for BV-2 
microglial cells compared to LPS evidently seen by fold changes in pro-inflammatory 
gene expression between PDGF and LPS. Another plausible reason could be that 
PDGF cellular responses have been reported to be independent of gene expression 
and protein synthesis (Andrae et al. 2008).  
Microglia phagocytic activity has been reported to increase upon inflammation in-vivo 
(Sierra et al. 2010; Karlstetter et al. 2014). However, in this study, PDGF ligands did 
not significantly affect microglia phagocytic capacity while phagocytosis related genes, 
Cd36, Trem2, scavenger receptors: Msr1 and Scarb1 were also not significantly 
changed. These chemokines/chemoattractant and phagocytosis related genes are 
amongst the genes involved in house-keeping functions (Hickman et al. 2018). TREM2 
is particularly indispensable for apoptotic cell membrane phagocytosis by microglia 
(Neumann and Takahashi 2007). 
5.4 PDGF induced an inflammatory response in microglia 
During activation, microglial cells release pro-inflammatory mediators that drive 
immune/inflammatory responses (Alexander and Rietschel 2001). As mentioned 
earlier, while these acute neuroinflammatory responses are in general beneficial to the 
CNS, chronic neuroinflammatory responses thus have neurotoxic effects (Czeh et al. 
2011; Bazan 2012).  
Here, the effects of PDGF ligands on inflammatory responses in microglia was 
investigated by assessing pro-inflammatory gene expression. In BV-2 microglial cells, 
all the PDGF ligands used significantly upregulated the expression of pro-inflammatory 
mediators after 3 hours including the expression of Tnfα, the chemokines, Ccl2, Ccl3 
and Ccl5, and the pro-inflammatory enzyme, Cox-2. Ccl2 and Cox-2 (PTGS2) are 
regarded as PDGF target genes (Wu et al. 2008). To further confirm results from BV-
2 microglial cells, primary microglial cells were used as they are more physiologically 
relevant owing to their phenotypic similarities to microglia in-vivo (Stansley et al. 2012). 
Similar results were also seen in primary microglial cells. 
Not only is this result consistent with the numerous studies as mentioned above of 
increased pro-inflammatory gene expression during microglia activation, it is also 
consistent with the results of PDGF induced Ccl2 expression in fibroblast and SMCs  
(Freter et al. 1996; Poon et al. 1996; He et al. 2015) as well as in astrocytes (Bethel-
Brown et al. 2012). 
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5.5 Effect of PDGF-mediated decrease in intracellular ROS levels in 
microglia 
Not only do microglial cells release pro-inflammatory cytokines in the course of being 
activated, they also release neurotoxic factors like ROS (Akundi et al. 2005; Block et 
al. 2007; Bazan 2012; Patro et al. 2016; Takahashi et al. 2016). On the other hand, 
ROS involvement in PDGFR-signalling has been well established since it was firstly 
observed by Sundaresan et al., 1995 where authors reported the induction of 
intracellular ROS levels in VSMCs  by PDGF. Since then, numerous studies have 
looked at ROS involvement in PDGFR-signalling in different cell types (lens epithelial 
cells, VSMCs, fibroblasts) and have reported that PDGF induces ROS production via 
NADPH oxidases (Marumo et al. 1997; Suh et al. 1999; Kreuzer et al. 2003; Chao-
Wei Chen et al. 2004; Spadoni et al. 2015).  
Here, the effect of PDGF ligands on intracellular ROS production in BV-2 microglial 
cells was investigated. However, contrary to the above referenced studies, PDGF 
ligands, specifically, PDGF-BB and -CC decreased total ROS levels in BV-2 microglial 
cells. Thus, to understand the molecular mechanisms involved herein, gene 
expression levels of the Nox/Duox enzymes were assessed. The Nox/Duox enzymes 
(having seven members, Nox-1 to Nox-5, Duox-1 and Duox-2) are the only enzyme 
system that generates ROS in a controlled manner (Kang 2007; X.-J. Fu et al. 2014; 
Sun et al. 2016; Haslund-Vinding et al. 2017). Though, a number of reports (some of 
which have been referenced above) have implicated these enzymes as the probable 
source of ROS in PDGF-stimulated systems, the mitochondria may also produce ROS 
specifically O2- as by-products of the electron transport chain (ETC) complex I and III 
(Reczek and Chandel 2015; Haslund-Vinding et al. 2017). Of the seven Nox/Duox 
family, only Nox1 and Nox2 gene expression could be detected in BV-2 microglial cells 
while expression of Nox3 and Nox5 genes were not assessed for in this study as 
expression of Nox3 is localised to the inner ear and Nox5 is absent in mice (Bedard 
and Krause 2007). Although the expression of Nox4 has been reported in microglia 
(Haslund-Vinding et al. 2017), it could not be detected in BV-2 microglial cells in this 
present study.  
Here, the expression of Nox1 and Nox2 genes were significantly upregulated following 
PDGF stimulation. First, the induced expression of Nox1 is consistent with reports of 
Suh et al., 1999, of Nox1 being a mitogenic oxidase involved in PDGF induced ROS 
while the expression of Nox2 is also consistent with literature where it is often referred 
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to as phagocytic Nox (Panday et al. 2015) with high expression levels in rodent as well 
as human microglia (Sorce et al. 2014). Likewise, the PDGF induced upregulation of 
Nox2 gene expression seen in this study is in tandem with results of Spadoni et al., 
2015 where induced gene expression of Nox2 enzyme was also seen in skin 
fibroblasts following PDGF stimulation. However, this induced Nox1 and Nox2 gene 
expression levels did not impact on increased ROS production by the PDGF ligands 
in this study, instead, a decrease in ROS levels were seen with PDGF-BB and -CC 
which is consistent with results of Krieger-Brauer and Kather, 1995, where PDGF-BB 
also inhibited NADPH-dependent H2O2 release in 3T3-L1 pre-adipocyte cells. 
However, since the temporal and spatial regulation of enzymes that generate ROS 
and the cellular antioxidant enzymes are responsible for the transient burst observed 
in receptor-dependent intracellular ROS release (Kang 2007), the involvement of the 
anti-oxidant system was investigated by assessing the expression levels of the 
different anti-oxidant enzymes. Of the antioxidant genes assessed, the expression of 
only glutathione reductase (Gsr) and superoxide dismutase 2 (Sod2) were significantly 
upregulated upon PDGF stimulation. While only PDGF-BB significantly upregulated 
the expression of Gsr gene, all four ligands used significantly upregulated Sod2 gene 
expression. Gsr catalyses the reduction of the oxidised form of glutathione (GSSG) to 
the reduced form (GSH) during Gpx-catalysed ROS detoxification when GSH is 
oxidised to GSSG (Hirrlinger et al. 2000). 
While three isoforms of SODs are known to exist (Miller 2012), only SOD1 (cytosolic 
Cu/Zn-SOD), and SOD2 (mitochondrial Mn-SOD) were assessed for in this study as 
SOD3 (extracellular, EC-SOD) is the predominant antioxidant enzyme present 
extracellularly (Marklund 1984). The dismutation of the highly reactive superoxide 
anion (O2-) into oxygen and the less reactive specie, H2O2 is catalysed by SOD (Kim 
et al. 2015). 
In this study, a significant upregulation of mitochondrial SOD2 but not cytoplasmic 
SOD1 was seen upon PDGF stimulation, an implication that mitochondrial ROS might 
be in play as SOD2 is known to specifically catalyse the dismutation of the superoxide 
anion generated as a by-product of the mitochondrial ETC (Fukai and Ushio-Fukai 
2011), more so that the mitochondrial ETC has been implicated as another source of 
cytosolic ROS (Reczek and Chandel 2015; Haslund-Vinding et al. 2017). However, 
further studies need to be done to confirm the specific contribution of mitochondrial 
ROS in PDGF stimulated BV-2 microglial cells. 
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Overall, an upregulation of the anti-oxidant enzymes seen here seems to be a parallel 
defence response to ongoing cellular oxidative stress (Hirrlinger et al. 2000), in an 
attempt to regulate and maintain the physiological balance with oxidants. However, 
the shift in balance in favour of the anti-oxidant genes overwhelming that of oxidative 
response might be responsible for the overall decrease in cellular ROS levels seen 
with PDGF ligands in this study. 
5.6 Effect of microglia neurotoxicity on neuronal cells 
Phagocytosis of dying or damaged cells have been used to describe reactive microglia 
(Kraft and Harry 2011; Bazan 2012; Perry and Holmes 2014; Patro et al. 2016), in 
addition, Gupta et al., 2003 have shown that in patients with retinal degenerative 
diseases such as AMD and retinitis pigmentosa (RP), reactive microglia have been 
detected in impaired photoreceptors. Not only have these cells been seen to 
phagocytose apoptotic rod cells in a RP mouse model, they also ingested rod cells 
that were stressed but still living which were negative for apoptotic markers (Zhao et 
al. 2015). As such, Karlstetter et al., 2015, opined that the activation of microglia in the 
retina cannot just be viewed as a bystander effect as it contributes actively to the 
apoptosis of photoreceptor cells during retinal degeneration.  
On this basis, the effect of microglial neurotoxicity on 661W photoreceptor cells were 
investigated using cultured conditioned medium from PDGF-treated BV-2 microglial 
cells while measuring caspase-related 661W apoptotic cell death. In this study, PDGF 
ligands were seen to have decreased microglial neurotoxicity on 661W photoreceptor 
cells suggestive that PDGF probably limits microglial production of neurotoxic 
molecules.  
5.7 Role of PDGF receptors and downstream signalling pathway in 
microglia inflammatory responses 
In an effort to determine the role and or contribution of each of the PDGFRs, 
expression of both receptors were investigated in PDGF ligand induced inflammatory 
responses in microglia. Significant upregulation of gene expression levels of β-
receptor but not α-receptor in both BV-2 and primary microglial cells respectively 
suggested an involvement of the β-receptor in PDGF mediated inflammatory 
responses in microglia. This induced gene expression of β-receptor but not α-receptor 
is similar with earlier result in this study where LPS also induced the expression of the 
β- but not the α-receptor further substantiating the involvement of the β-receptor. 
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However, using both pharmacological and genetic approaches, the relative 
contribution of each receptor in these responses could be better understood. Results 
show that antibody blockade of microglial PDGFRβ with APB5 but not blockade of 
PDGFRα with APA5 significantly decreased LPS induced inflammatory responses 
(Tnfα, Il-6 and Il-1β) and PDGF-BB induced chemoattractant gene, Ccl2. This 
decrease in inflammatory responses seen with the pharmacological blockade of 
receptor-β but not receptor-α is however consistent with previous results that have 
been seen in inflammatory associated disease mouse model. Firstly, Hideto et al., 
2001, showed that using the same monoclonal antibody blockers, APA5 and APB5, 
the functional blockade of PDGF receptor-β but not of receptor-α blocked the 
accumulation of VSMCs in fibrous cap lesions in mice deficient in Apolipoprotein E. 
Secondly, Kishi et al., 2018, have also shown that using the same specific blocking 
antibodies, blockade of PDGF receptor-β but not of receptor-α lessened the pulmonary 
fibrosis induced by bleomycin in mice.  
Consistently, siRNA-mediated gene silencing of Pdgfrβ significantly decreased both 
LPS-induced (Il-1β and Ccl2) and PDGF-BB induced (Tnfα and Ccl2) inflammatory 
responses although gene silencing of Pdgfrα also significantly decreased LPS induced 
Ccl2 and PDGF-BB induced Tnfα gene expression while increasing LPS induced Il-1β 
expression. Attenuation of PDGF-BB mediated induction of Ccl2 gene expression 
seen in this present study is in accordance with the result of Bethel-Brown et al., 2012, 
where it was reported that PDGFRβ engagement is important for increase in MCP-1 
(Ccl2) expression induced by PDGF in human astrocytic cells. In this study, authors 
report that PDGFRβ gene silencing attenuated the increased Ccl2 gene expression, 
an effect not seen in non-siRNA controls cells. The reduction in responses seen with 
Pdgfrα gene silencing were not as pronounced as that seen with silencing of Pdgfrβ 
gene as significant differences were seen between these two responses in LPS 
induced expression of chemo-attractant gene, Ccl2.  
Taken together, these results implicate both PDGF receptor-α and -β in LPS and 
PDGF induced inflammatory responses in BV-2 microglial cells, as such the relative 
contribution of each of the receptors in these responses could not be substantiated, 
perhaps, a third approach would be needed. 
Despite that the relative contribution of each receptor could not be delineated, results 
from the pharmacological inhibition cannot be completely overlooked as the most and 
highly specific way to block or inhibit PDGFR signalling is by inhibition extracellularly 
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either with antibodies (as was done in this present study with monoclonal antibodies) 
or with dominant-negative ligands (Andrae et al. 2008; Chen et al. 2013). This 
approach of extracellular targeting of PDGFRs have been successfully used in studies 
that served as a foundation for several other pre-clinical and clinical studies. Jo et al., 
2006, one of the very first studies, tested the combination of PDGFRβ-blocking 
antibody (APB5) and anti-VEGF DNA aptamer in a corneal and choroidal 
neovascularization model and found that this combination in comparison with anti-
VEGFA monotherapy was more effective in regressing vessels at sites of new vessel 
growth. Similarly, Strittmatter et al., 2016, showed that the blockade of pericyte 
function in a mouse model of AMD with neutralising PDGFRβ-antibodies caused a 
reduction in CNV. 
While siRNA-mediated gene silencing is a highly robust technique to research a cell’s 
loss-of-function effect, this technique is limited by its unspecificity and off-target effects 
are a common occurrence (Lin et al. 2005). Such off-target effects might be 
responsible for the significant upregulation seen with Il-1β gene expression upon 
PDGFRα gene silencing as this result seems to deviate from the trend when compared 
to other pro-inflammatory cytokines. More so that the expression of the Pdgfrα gene 
was not significantly affected upon microglia activation either with LPS or with the 
PDGF ligands. Off-target effects of gene knock-down has been reported to involve 
several mechanisms which includes; the use of high siRNA concentrations causing a 
total up- or down-regulation of genes (Persengiev et al. 2004; Semizarov et al. 2004), 
the degradation of mRNA caused by partial sequence complementation (Jackson et 
al. 2003) and miRNA-like translational inhibition (Saxena et al. 2003; Zeng et al. 2003; 
Scacheri et al. 2004). 
PDGFs, via their two receptors, alpha and beta, trigger a number of intracellular 
signalling pathways (Andrae et al. 2008; Ostendorf et al. 2012; Heldin and 
Lennartsson 2013), however, activation of the MAPK and the PI3K/Akt pathway are 
the two most characterised pathways through which cellular responses are being 
mediated (Li et al. 2007). In this study, the ERK, JNK, and p38 MAPK and the PI3K/Akt 
pathways were evaluated for their involvement in PDGF-mediated inflammatory 
responses in BV-2 microglial cells. First, results show significant increases in 
phosphorylation of Akt, ERK, JNK but not P38 upon PDGF-BB stimulation in a time-
dependent manner. Second, the functional relevance of the phosphorylated proteins 
were investigated. Using small molecule kinase inhibitors, the PDGF-mediated 
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induction of pro-inflammatory cytokines were significantly attenuated thus clearly 
defining a role for ERK, JNK MAPKs and PI3K/Akt signalling pathway.  
Phosphorylation of the MAPKs and Akt mediated by PDGF-BB and the subsequent 
blocking of these pathways which attenuated PDGF-mediated inflammatory 
responses is in accordance with similar results that have been reported in other cell 
types including astrocytes, and SMCs (Bethel-Brown et al. 2012; Zhang et al. 2015) 
to mention a few. 
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CHAPTER SIX: CONCLUSION AND PERSPECTIVE 
PDGFR signalling plays a fundamental regulatory role in microglia where these results 
provide the first evidence of the direct association and interaction between them. Most 
of the studies involving PDGFR signalling have been done in smooth muscle cells and 
fibroblasts. 
Results presented herein is indicative of PDGFR autocrine signalling in microglia as 
seen by the expression of both ligands and receptors. Ligand-mediated activation of 
PDGFR induced an activation state in microglia as seen by morphological changes 
accompanied by the release of pro-inflammatory mediators. However, whether this 
activation state is sufficient to sustain a prolonged inflammatory response is unknown 
as results from other functional assays that define “microglia activation” such as an 
increase in ROS and neurotoxicity were utterly opposite.  
While the complex interplay between several signalling pathways in microglia is of 
utmost importance, their individual roles cannot be downplayed. As such, a detailed 
characterisation of PDGFR signalling in microglia is therefore warranted beyond in-
vitro studies. This characterisation will adequately address its role during microglia 
homeostatic and activation state. It will also provide useful information in pathological 
conditions like nAMD, where the involvement of both systems has been implicated. 
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APPENDIX 
 
 
Appendix figure 1 Primary microglial cells. 
(A) Immunostaining for Iba1 protein (Green), nuclei stained with DAPI (blue). (B and 
C) Quantitative PCR data of gene expression levels of Cox-2 and Tnfα in PDGF-BB 
treated cells pre-treated with inhibitors for MEK1/2 inhibitor - U0126, PI3K - LY294002, 
and JNK - SP600125. Data are presented as mean ± SD of two independent 
experiments measured in duplicates (N=4). **p≤ 0.01, ****p≤ 0.0001 compared to 
PDGF-BB treated group (red bar). One-way AVOVA with Sidak’s multiple comparison 
test.  
 
 
Appendix figure 2 MTT cell viability assay in BV-2 microglial cells. 
Percentage cell viability of BV-2 microglial cells following; (A and B) 48 hours treatment with 
increasing concentrations of PDGFR-α and -β blocking antibodies, APA5 and APB5 
respectively. Data are presented as mean ± SD of three independent experiments 
measured in triplicates (N=9). C - control: untreated cells, V - vehicle: DPBS (C) 4 
hours treatment with kinase inhibitors. Data are presented as mean ± SD of two to three 
independent experiments measured in triplicates (N=6-9). C - control: untreated cells, 
V - vehicle: 0.03% DMSO, U0 - U0126 (MEK1/2 inhibitor), LY - LY294002 (PI3K 
inhibitor) and SP - SP600125 (JNK inhibitor).  
No significant differences were seen between the treatment and control group (red 
bar). One-way AVOVA with Dunnett’s multiple comparison test. 
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Appendix figure 3 Effect of PDGF on BV-2 microglia phagocytic capacity. 
(A) Representative micrograph of CM-Dil-stained apoptotic 661W photoreceptor 
debri phagocytosed by control and PDGF-treated BV-2 microglial cells. 661W debri 
(Orange), microglial cell nuclei stained with DAPI (blue). (B) Quantification from two 
experiments in duplicates (N=4). The ratio of phagocytosed 661W photoreceptor 
debris (background-corrected red signal) relative to the total microglial cell number 
(background corrected DAPI signal) was determined using Image J software and 
values expressed as percentages. No significant differences were seen between 
treatment and control group, one-way AVOVA with Dunnett’s multiple comparison test. 
Control - 0.1% BSA in DPBS. 
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